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Abstract 
Regulatory T cells (Treg) are critical to the maintenance of immune tolerance, partly by 
controlling the unwanted activation of effector T cells (Teff) and thereby enhancing the 
resolution of autoimmune and allergic inflammation. Recent data suggest that Treg can 
specialize to better control different types of inflammation by using transcriptional 
machinery which controls differentiation and function of Teff. This thesis addresses 
questions related to the efficacious use of Treg, notably their ability to adopt distinct 
phenotypic profiles under different inflammatory contexts and their need to recognize 
antigen in the inflamed organ. 
 
Two differentially mediated mouse disease models were used in this project, namely 
Th1/Th17-mediated experimental autoimmune encephalomyelitis (EAE) as a model of 
multiple sclerosis and Th2-mediated allergic airways inflammation (AAI) as a model of 
asthma. A new model of rMOG-induced AAI was developd to specifically answer the 
questions on the importance of cell phenotype versus antigen-reactivity for the effective 
Treg-mediated suppression. It was demonstrated that Treg from the inflamed CNS in 
EAE had an upregulated expression of Th1 master regulator T-bet and Th1-associated 
chemokine receptor CXCR3, whereas Treg derived from the inflamed lung in AAI had 
an increased expression of Th2 master regulator GATA-3, lacked expression of T-bet 
and displayed decreased levels of CXCR3. This specialized and activated phenotype was 
restricted to tissue-derived Treg. The importance of appropriate Treg phenotype for 
effective suppression was suggested by the observed inability of CNS-derived Treg to 
inhibit AAI. A different Treg subset, TGF-β induced Treg (iTreg), was shown to express 
high levels of T-bet and CXCR3, but not GATA-3 upon induction in vitro. iTreg 
effectively suppressed both Th1 and Th2 types of inflammation and the antigen-
reactivity was key to this.  
 
This thesis demonstrates that Treg are capable of acquiring a distinct phenotype 
corresponding with a CD4+ T cell response driving inflammatory disease and identifies 
antigen-reactivity as key to the efficacious suppression of inflammation. It also 
highlights substantial phenotypic differences betwen iTreg and naturally-occurring Treg 
which could be associated with different modes of suppression.  
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Immune regulation is essential to prevent excessive and unwanted immune responses 
directed at self- or innocuous antigens, and to promote a natural resolution of 
inflammation. Breakdown in immune tolerance and impaired regulation can lead to 
autoimmune and allergic diseases such as multiple sclerosis (MS) and asthma. Both 
MS and asthma are complex chronic inflammatory diseases believed to be 
coordinated by CD4+ T cells. MS is a demyelinating autoimmune disease of the 
central nervous system (CNS) mediated by myelin-reactive T helper (Th)1 and Th17 
cells (Sospedra and Martin, 2005). Asthma is a lung inflammatory disease mediated 
by Th2-driven IgE responses to otherwise harmless allergens which results in airway 
remodelling (Wills-Karp, 1999). Pathogenesis in both diseases is multifactorial, with 
complex interactions of genetic and environmental links.  
 
Foxp3+ regulatory T cells (Treg) have been demonstrated to effectively suppress 
CD4+ T cell responses via a variety of mechanisms (Shevach, 2009). Their 
importance is highlighted by the fact that a natural mutation in the foxp3 gene leads 
to autoimmune lymphoproliferative disorders in both mice and humans (Bennett et 
al., 2001, Brunkow et al., 2001). Evidence of impaired Treg function in MS and 
asthma patients has led to the investigation of this cell population in the context of 
animal models of human disease: experimental autoimmune encephalomyelitis 
(EAE) which is a model of MS and allergic airways inflammation (AAI) which is a 
model of allergic asthma. In both models pathogenic CD4+ T cell responses have 
been demonstrated to be regulated by Treg (Kohm et al., 2002, Kearley et al., 2005) 
and protective effects of Treg on disease severity suggested their potential use in 
immunotherapy.  
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This thesis addresses questions related to the efficacious use of Treg, notably their 
ability to adopt distinct phenotypic profiles under different inflammatory contexts 
and their need to recognize antigen in the inflamed organ. 
 
1.1. Basic T cells biology 
Lymphocytes develop in the bone marrow from pluripotent hematopoietic stem cells 
that by division produce two types of stem cells: common lymphoid progenitor and 
common myeloid progenitor. Common lymphoid progenitor gives rise to T cells, B 
cells and natural killer (NK) cells which further differentiate at distinct sites. 
Progenitor cells that generate T cells migrate from the bone marrow to thymus which 
provides a specialised microenvironment for their maturation (Petrie and Zuniga-
Pflucker, 2007).  
 
1.1.1. Generation in thymus 
There are two separate T cell lineages that are genrated in thymus and these are 
defined by their differential expression of an αβ T cell receptor (TCR) or a γδ TCR 
(Ciofani and Zuniga-Pflucker, 2010). During maturation, T cells pass through several 
stages of development, the earliest being the double-negative (DN, CD4-CD8-) stage 
subdivided into DN1, DN2, DN3a and DN3b stages. During the progression from the 
DN1 to DN3a stage, β-, γ- and δ-chain rearrangements occur and by the DN3b stage 
a decision is made whether a thymocyte becomes an αβ T cell or a γδ T cell (Burtrum 
et al., 1996, Livak et al., 1999). At all stages cells receive rescue or apoptosis signals 
which drive further maturation or terminate cell fate. Thymocytes that successfully 
rearranged γδ chains become mature γδ T cells, whereas thymocytes that 
successfully rearranged VDJ segments of a β-chain become double-positive (DP, 
CD4+CD8+) and start rearrangement of an α-chain. Once a functional α-chain is 
produced and paired with β-chain, DP thymocytes undergo selection for their ab lity 
to recognize peptide-MHC complexes that yields mature CD4+ or CD8+ single-
positive (SP) T cells.   
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1.1.2. Positive selection 
Once an αβ TCR is successfully rearranged, the processes of positive and negative 
selection are used to shape the mature TCR repertoire. DP thymocytes interact with 
thymic cortical epithelial cells (cTEC) that express elf-peptides in a major 
histocompatibility complex (MHC)-restricted manner. The specificity of TCR 
determines whether a DP thymocyte will engage with the MHC class I-presented 
peptide and hence become a CD8+ T cell, or with the MHC class II- presented 
peptide to become a CD4+ T cell (Kisielow et al., 1988, Scott et al., 1989). Only 
thymocytes that recognize self-peptides in a relevant MHC context receive survival 
signals and proceed to the next stage of selection (Jameson et al., 1995).   
 
1.1.3. Negative selection 
Random rearrangements of α- and β-chains provide not only a great diversity in the 
TCR repertoire but also a danger of generating potentially harmful autoreactive T 
cells. In a process of negative selection, CD4+ and CD8+ SP T cells move from the 
cortex into the medulla and interact with medullary TEC (mTEC) and bone marrow-
derived antigen presenting cells (APC) such dendritic cells and macrophages (Zoller, 
1991). If the TCR reacts strongly with self-peptide-MHC complex on an mTEC or 
APC, a T cell is deleted (Zal et al., 1994, Douek et al., 1996). This ensures that all T 
cells that react strongly to self-peptides are removed from a general T cell cohort. 
Once SP T cells have passed through both selection processes and are fully matured, 
they enter the blood system and are carried to the peripheral (secondary) lymphoid 
tissues.  
 
Both positive and negative selection are critical in generating T cells that respond in 
an MHC-restricted manner and are depleted of strongly autoreactive cells before 
entering the periphery. This is the basis of central tolerance which will be discussed 
in more detail later on in this chapter.  
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1.2. Development of immune responses 
Pathogens can enter the body by many different routes and to provide protection 
from infections, antigens are constantly being sampled by antigen presenting cells 
and carried to the secondary lymphoid tissues. Mature T cells exit the thymus and 
recirculate continuously between the peripheral lymphoid organs and blood until 
they encounter their cognate antigen. This interaction is facilitated in the secondary 
lymphoid organs which integrate both innate and adaptive immune system 
components and enable an adaptive immune response t be initiated.  
 
1.2.1. Innate immune system 
The innate immune system forms not only a second line of defence against pathogens 
(the first being epithelium) but also plays a critial role in initiating the adaptive 
immune response. Innate immune system includes mast cells, neutrophils, 
eosinophils, basophils, phagocytic cells such as macrophages and complement 
proteins. The cellular components are all derived from a common myeloid progenitor 
stem cell and mature in the bone marrow. Mast cells, ba ophils and eosinophils are 
large secretory cells that upon activation release granules containing toxic and pro-
inflammatory molecules such as histamine, cytokines and cationic proteins 
(O'Donnell et al., 1983, Welle, 1997). These cells are very important in defence 
against extracellular parasites but can also orchestrat  unwanted allergic responses 
(Stone et al., 2010).     
 
Macrophages and neutrophils are professional phagocytic cells able to phagocytose 
and kill extracellular pathogens. Macrophages act in tissue as sentinel cells sampling 
the environment for pathogens. Once they are activated by danger signals, they 
increase their rate of phagocytosis and secrete cytokines which attract neutrophils 
from blood (Silva, 2010). Neutrophils are short-lived and can efficiently kill 
pathogens by phagocytosis and production of antimicrob al products (Nathan, 2006). 
The process of phagocytosis is greatly facilitated by complement proteins and 
antibodies which opsonize the pathogen and bind to phagocytes via Fc/complement-
receptors on the cell surface (Carroll, 2004).  
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Another important function of macrophages but also of dendritic cells (DC) is to 
bring the innate and adaptive immune system together by acting as APC. Both 
macrophages and DCs have the ability to process protein antigens and present the 
resulting peptides in an MHC-restricted manner and provide co-stimulation to 
activate naïve T cells. Moreover, they play an important role in decision making on 
the type of immune response that is elicited (Kaiko et al., 2008).    
 
The rapid response of the innate immune system provides many advantages to 
protection from common pathogens. However, more tuned and specific immune 
responses are needed along with immunological memory to combat the diverse range 
of continuously evolving pathogens, and this is where the adaptive immune system 
comes into play.   
 
1.2.2. Adaptive immune system 
The cells of the adaptive immune system, T cells and B cells, are generated to 
specifically recognize a wide range of pathogens with a potential αβ TCR diversity 
of 1015 (Davis and Bjorkman, 1988). Appropriate and efficient activation of T cells 
and B cells requires highly organized secondary lymphoid structures. Mature 
antigen-inexperienced T cells (naïve T cells) enter secondary lymphoid organs such 
as lymph nodes via the high endothelial venules. Within a lymph node T cells 
accumulate in T cell zones, situated in the cortex, where they encounter antigens 
presented by APC. The transient binding of naïve T cells to APC enables them to 
sample peptide-MHC complexes on the surface of APC (Bousso, 2008, Ingulli et al., 
2002). The majority of T cells do not encounter their cognate antigen, move into the 
medulla and leave the lymph node via efferent lymphatic vessel before returning to 
the circulation. If, however, a naïve T cell recognizes its antigen, a signalling cascade 
is activated which eventually leads to T cell activation and expansion (Stoll et al., 
2002, Miller et al., 2004). 
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1.2.3. T cell activation 
Bretscher and Cohn originally suggested a 2-signal model for lymphocyte activation: 
the first being a recognition of a cognate antigen and the second a co-stimulation 
(Bretscher and Cohn, 1970). This explained how a lymphocyte is activated in an 
antigen-specific way and can discriminate between slf and non-self. Since then 
detailed studies into CD4+ T cell activation led to the redefinition of this model to 
include 3 signals: 1) activation through the TCR that recognizes the peptide-MHC 
complex on the surface of the APC, 2) co-stimulation through the accessory 
molecules on the surface of the T cell and APC and 3) cytokine signalling. However 
for this to occur, APC has to become activated and this is defined as signal 0.  
 
1.2.3.1. Signal 0: DC activation 
Although both macrophages and DC can present antigen o T cells, DC are most 
efficient at presenting exogenous antigens and activating naïve T cells (Steinman, 
1991, de Jong et al., 2006). Immature DC frequently reside within peripheral tissues 
where they continuously take up foreign material. In the presence of danger signals, 
they become activated and migrate to the draining lymph nodes where they initiate T 
cell activation (Guermonprez et al., 2002). Danger signals include pathogen-
associated molecular patterns (PAMPs) such as bacterial lipopolysaccharides (LPS) 
or viral-derived dsRNA (Bianchi, 2007) but also components released from necrotic 
cells, lysates such as uric acid (Shi et al., 2003). These are sensed by the DC via a 
wide variety of cell surface receptors, for example, pattern recognition receptors 
(PRR) including Toll-like receptors (Takeuchi and Akira, 2010).  
 
1.2.3.2. Antigen processing and presentation 
There are two main antigen processing pathways: 1) MHC class I-processing 
pathway which delivers peptides originating from the cytosol of the cell, occurs in all 
nucleated cells and the final product is recognized by CD8+ T cells, and 2) MHC 
class II-processing pathway which delivers peptides originating from endocytosed 
material, occurs only in APC and the peptide-MHC complex is recognized by CD4+ 
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T cells (Vyas et al., 2008). MHC class II-processing pathway will be discussed 
briefly as it is critical to the activation of naïve CD4+ T cells.  
 
Antigen taken up by the APC enters endosomes which become acidified as they 
progress towards the endoplasmic reticulum of the cell. They fuse with lysozomes 
containing proteases which cleave the protein into peptides. The vesicle then fuses 
with another vesicle pre-loaded with MHC class II molecule. The binding groove of 
the MHC class II molecule is occupied with an invariant chain that prevents 
inappropriate peptide-binding. It is cleaved by proteases upon fusion leaving only a 
small fragment bound to the MHC groove (CLIP). The removal of CLIP and the 
peptide loading is catalysed by a specialised MHC class II-like molecule called 
HLA-DO (H-20 in mice). The peptide-MHC II complex in next delivered to the cell 
surface.  
 
1.2.3.3. Signal 1: TCR engagement and signalling 
TCR is a heterodimer of an α-chain and β-chain linked by a disulphide bond. Each 
consists of an extracellular domain containing variable (V) regions responsible for 
antigen binding and a short intracellular domain. αβ heterodimers are associated with 
CD3 which is a complex of four signalling chains (two ε, γ and δ) and a homodimer 
of ξ signalling chains. Each CD3 chain has a cytoplasmic ta l containing one 
immunoreceptor tyrosine-based activation motif (ITAM) and each ξ chain has 3 
ITAMS (Kuhns et al., 2006). The TCR complex is thought to consist of two αβ 
heterodimers and 6 accessory chains and is associated wi h a CD4 or a CD8 co-
receptor which binds to the invariant site of the MHC class II or MHC class I, 
respectively, and is required for stable peptide-MHC-TCR binding (Yin et al., 2012).    
 
TCR engagement with the peptide-MHC complex leads to the clustering of the TCR 
complex and the co-receptors on the cell surface forming an immunological synapse 
(Grakoui et al., 1999). Activated Src-family protein kinases, Lck and Fyn, 
phosphorylate ITAMs on the CD3 and ξ chains allowing tyrosine kinase ZAP-70 to 
bind to the phosphorylated ITAMs on ξ chains. Activation of ZAP-70 initiates a 
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cascade of signalling events eventually leading to the activation of transcription 
factors NFκB, NFAT and AP-1 which induce cell proliferation and differentiation 
(Nakayama and Yamashita, 2010).   
 
1.2.3.4. Signal 2: Co-stimulation 
For naïve T cells to be activated, in addition to TCR engagement with the peptide-
MHC complex, there is a requirement for the co-stimulatory signals. TCR ligation in 
the absence of co-stimulation leads to the state of unresponsiveness, known as anergy 
(Schwartz, 2003).   
 
One of the best characterised co-stimulatory molecules is CD28 which is 
constitutively expressed on both naïve and activated T cells (Gross et al., 1992). 
CD28 is a receptor that binds to CD80 (B7.1) or CD86 (B7.2) expressed on the 
surface of APC and is upregulated upon APC activation (signal 0) (Freeman et al., 
1991). In naïve T cells signalling through CD28 reduces the threshold for T cell 
activation (Viola and Lanzavecchia, 1996) and promotes T cell survival (Sperling et 
al., 1996), whereas in previously activated T cells, it promotes IL-2 and effector 
cytokine production, cell proliferation and survival (Thompson et al., 1989, Boise et 
al., 1995). Other co-stimulatory molecules include CD40/CD40L, OX40/OX40L and 
ICOS/ICOSL (Sharpe and Freeman, 2002).  
 
A number of co-inhibitory signals also exist and are c itical for keeping T cells in 
check. These include molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) 
and programmed death-1 (PD-1) which are upregulated upon T cell activation. 
CTLA-4 competes for the same ligands as CD28 (Linsley et al., 1992) with higher 
affinity and its binding significantly impairs IL-2 production and T cell proliferation 
(Krummel and Allison, 1995). PD-1 has two differentially expressed ligands (PDL-1 
and PDL-2) and was shown to be important for negative regulation of cell 
proliferation and cytokine production (Freeman et al., 2000).  
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1.2.3.5. Signal 3: Cytokines 
The third signal, which is not required for T cell activation but is critical during the 
activation process and affects T cell differentiation, comes from cytokines produced 
by the APC. Upon encountering an antigen in the presence of danger signals such as 
PAMPs, APC are activated and can produce a wide range of cytokines which dictate 
what type of effector T cell (Teff) response will be elicited (Kapsenberg, 2003). 
Cytokines bind to their cell surface receptors on T cells and induce intracellular 
signalling which results in the activation of specific signal transducer and activator of 
transcription (STAT) proteins (Adamson et al., 2009). Activation of different STATs 
promotes expression of distinct genes directing an activated T cell (Th0) towards 
different differentiation pathways such a Th1, Th2 or Th17 (O'Shea and Paul, 2010) 
which are discussed later in section 1.4.  
 
In a summary, signals 0, 1 and 2 ensure that only T cells recognizing specific 
pathogen-derived antigens are activated (and negativ ly regulated when needed) and 
signal 3 tunes the response to the type of invading pathogen (Figure 1.1). However, T 
cells recognizing self- or innocuous antigens can still be activated in the periphery 
and therefore various mechanisms of maintaining tolerance have evolved.  
        
Figure 1.1 Signals required for CD4+ T cell activation. 
 
CD4+ T cells require 4 signals for activation and differentiation. Signal 0: activation 
of APC by danger signals such as pathogen-associated molecular patterns (PAMPs). 
Signal 1: TCR engagement by peptide-MHC complex. Signal 2: co-stimulation. 
Signal 3: cytokine signalling which is not required for T cell activation but is critical 
for T cell differentiation.   
APC Naïve T cell 
Signal 0  
PAMPs 
Signal 1  
Peptide-MHC  TCR 
CD80/86 
  Signal 2  
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1.3. Maintaining tolerance 
Tolerance is required to prevent autoimmune diseases nd chronic inflammation, and 
it can be maintained at 2 main levels: 1) central (in thymus) during maturation of 
naïve lymphocytes and 2) peripheral (in secondary lymphoid organs or tissues) when 
T cells that escaped central deletion are activated in the presence of self-reactive or 
innocuous antigens.    
 
1.3.1. Central tolerance 
Negative selection that occurs in thymus during maturation of lymphocytes is called 
central tolerance. As described before, T cells that bind to self-peptide-MHC 
complexes too strongly undergo apoptosis. The main and unique cell type that 
instructs T cells in this process is called medullary thymic epithelial cell (mTEC) 
which in addition to presenting ubiquitously express d self-antigens, can also present 
tissue-specific antigens (TSA) (Derbinski et al., 2001). This promiscuous (ectopic) 
gene expression was discovered to be driven by Autoimmune regulator (Aire) (Liston 
et al., 2003), the gene that is responsible for a clinical disorder called autoimmune 
polyendocrinopathy syndrome type I (APS1) (Nagamine et al., 1997). Ectopic gene 
expression allows for T cells highly reactive to self-antigens not normally expressed 
in thymus to be deleted before they enter peripheral pool of naïve T cells. However, 
this mechanism is not fail-proof and not all peptides are presented efficiently by 
mTEC and hence self-reactive T cells can escape thymic deletion (Anderton and 
Wraith, 2002). This has been demonstrated to be true for encephalitogenic Ac1-9 
peptide of myelin basic protein (MBP) which was shown to be expressed in thymus, 
however, this did not lead to deletion of T cells that can recognize it (Liu et al., 
1995).  
 
The existence of self-reactive T cells in the periphery is one of the reasons for the 
requirement of a second level of tolerance induction called peripheral tolerance.  
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1.3.2. Peripheral tolerance 
Harmful immune reactions can not only be mediated by self-reactive T cells that 
escaped central tolerance, but can also occur due to the degeneracy of TCR 
recognition (Reiser et al., 2003). The ability of the TCR to recognize more than one 
antigen provides more robust protection against a wide variety of pathogens, 
however, it also means that a T cell can cross-react with a self-antigen. This is the 
basis of the molecular mimicry theory which suggests that self-antigens can contain 
similar epitopes to those found in pathogen-derived antigens and self-reactive T cells 
can therefore be initially activated during infection, ultimately leading to 
autoimmune response (Oldstone, 1987). Inducing tolerance is also very important for 
T cells recognizing innocuous antigens. Cells at the mucosal surfaces such as in the 
lung and the gut are in constant contact with harmless antigens and peripheral 
tolerance prevents a state of chronic inflammation. There are three main mechanisms 
of peripheral tolerance and these include death, adapt tion and regulation (Ryan et 
al., 2007).  
 
1.3.2.1. Death  
High affinity TCR-bearing T cells that escape negative selection in the thymus and 
later become activated by a strong antigenic stimulus in the periphery can undergo 
apoptosis (Anderton et al., 2001, Wells et al., 1999). T cell death can also occur 
during activation by immature DC in the absence of co-stimulatory signals (Vella et 
al., 1995) through failure of upregulating anti-apoptotic signalling via Bcl-2, Bcl-xL 
and NFκb (Bansal-Pakala et al., 2001) or downregulating pro-apoptotic signalling via 
Fas, FasL and Bim (Mueller, 2010).  
 
1.3.2.2. Anergy / adaptation 
Originally the term anergy was used to describe a state of unresponsiveness in T cells 
that had been stimulated in vitro with insufficient co-stimulation (Jenkins et al., 
1987). This was found to result in reversible inhibition of IL-2 secretion and cell 
proliferation but did not affect T cell ability to produce effector cytokines (Mueller et 
al., 1989, Schwartz, 2003). How this observation reflects in vivo situation remains 
                                                                                                 INTRODUCTION 
 12
unclear. A different form of anergy is observed in vivo and is called adaptive 
tolerance. It results in a complete inhibition of both cell proliferation and effector 
cytokine production and requires persistent presence of the antigen (Rocha et al., 
1993, Singh and Schwartz, 2003).  
 
1.3.2.3. Regulation 
The third mechanism of peripheral tolerance is mediat  by regulatory T cells (Treg). 
There are several subsets of Treg and these include naturally-occurring Foxp3+ Treg 
(nTreg) originating from the thymus, Foxp3+ peripherally-induced Treg (iTreg) and 
also less well-characterized subsets such as Tr1 and Th3 which are Foxp3 negative. 
Treg subsets and their mechanisms of suppression will be discussed later on in this 
chapter. The importance of Foxp3+ Treg is emphasized by the naturally occurring 
mutation within the foxp3 gene that results in the development of severe multi-organ 
autoimmune disease in both human and mouse (Brunkow et al., 2001, Le Bras and 
Geha, 2006). 
 
The so-called ‘three pillars’ of immune tolerance provide a safety turn-off 
mechanism at different stages of T cell responses and very rarely breakdown. The 
breakdown of immune tolerance can result in autoimmunity and/or chronic 
inflammation.  
 
1.4. CD4+ T cell subsets 
Activated T cells can follow multiple differentiation pathways and the choice of the 
pathway is dictated by the APC-derived cytokines that are produced during T cell 
stimulation. In 1986 Mosmann and Coffman first described two types of antigen-
specific murine T cell clones that were defined by the cytokines they secreted and 
these two subsets were called Th1 and Th2 cells (Mosmann et al., 1986). Since then 
more CD4+ T cell subsets have been identified and these broadly include effector T 
cells and regulatory T cells. Each of the CD4+ T cell subsets is described in greater 
detail below and is illustrated in Figure 1.2 at the end of this section.  
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1.4.1. CD4+ effector T cells 
Different forms of infectious pathology require specialised T cell responses 
involving expression of appropriate homing molecules and cytokines to be able to 
effectively steer the immune response to fight off the infection. However, due to their 
potent effector mechanisms Teff also became prominent for their contribution to 
inflammatory diseases such as rheumatoid arthritis and asthma (Brennan et al., 2002, 
Medoff et al., 2008). The main Teff subsets include Th1, Th2 and the more recently 
discovered Th17 cells.  
 
1.4.1.1. Th1 cells 
Th1 cells were originally defined by their ability o produce interferon-γ (IFN-γ) 
(Mosmann et al., 1986) with tumour necrosis factor-α (TNF-α) and lymphotoxin 
(LT) discovered later as the other two signature cytokines (Wan, 2010). One of the 
most important functions of Th1 cells is stimulation of innate responses to 
intracellular bacteria. Th1 cells were also shown to have a pathogenic potential and 
contribute to autoimmune diseases such as multiple scl rosis (Lassmann and 
Ransohoff, 2004).  
 
In vitro studies have shown that differentiation of Th1 cells is induced by IL-12 
(Hsieh et al., 1993, Seder et al., 1993) and enhanced by IL-18 (Yoshimoto et al., 
1998). The requirement for IFN-γ is still unclear (Wang et al., 1994, Wenner et al., 
1996). Binding of IL-12 to its receptor on the surface of a T cell initiates signalling 
that activates STAT4, a transcription factor that is required for differentiation of Th1 
cells (Kaplan et al., 1996). On of its most important target genes is tbx21 which 
encodes T-bet, a master regulator of Th1 lineage (Szabo et al., 2000). T-bet drives 
expression of IFN-γ and other Th1-associated cytokines, and also of chemokine 
receptors such as CXCR3 and CCR5. IFN-γ secreted by Th1 cells can act in an 
autocrine fashion by enhancing T-bet expression via STAT1 (Afkarian et al., 2002) 
and in a paracrine fashion by acting on Th2 cells and limiting their proliferation 
(Oriss et al., 1997).   
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In addition to secreting IFN-γ, Th1 cells also express a co-stimulatory ligand CD40L 
which can bind to the surface receptor of the macrophage. IFN-γ and CD40 ligation 
activate macrophages making them more effective at destroying intracellular 
pathogens such as Mycobacterium or Leishmania via production of TNF-α and nitric 
oxide (Salgame, 2005). The macrophage also upregulat s the expression of MHC 
class II molecules and CD40 enabling it to efficiently re-activate rested T cells at the 
site of inflammation. Th1 cells can also express FaL promoting apoptosis of target 
cells and produce interleukin (IL)-2, IL-3 and granulocyte-macrophage colony-
stimulating factor (GM-CSF) important for maturation and activity of DC (Miller et 
al., 2002). The role of Th1 cells in driving pathogenic responses in autoimmune 
disease will be discussed later in this chapter.  
 
1.4.1.2. Th2 cells 
Th2 cells were identified at the same time as Th1 cells in 1986 (Mosmann et al., 
1986) and their signature cytokines include IL-4, IL-5, IL-13 and IL-10. Th2 cells 
are specialized to activate B cells and hence induce antibody responses required for 
clearance of extracellular pathogens. Th2 cells are also very important at maintaining 
mucosal immunity in the lung and their aberrant respon es can drive chronic 
inflammation which is observed in asthma (Robinson et al., 1992).  
 
Differentiation of Th2 cells requires the presence of IL-4 which via STAT6 
signalling induces high expression of GATA-3 binding protein (GATA-3), a key 
transcription factor reported to be necessary and sufficient for commitment to Th2 
lineage (Zheng and Flavell, 1997). GATA-3 induces and stabilizes expression of IL-
4, IL-5 and IL-13 (Zhang et al., 1997) and is thought to affect expression of Th2-
associated chemokine receptors such as CCR3 and CCR4. GATA-3 expression can 
also be induced in IL-4- and STAT6-independent way vi  STAT5 signalling (Zhu et 
al., 2003). Moreover, low expression of GATA-3 is important during T cell 
development (Ting et al., 1996) and is maintained in naïve T cells (Zhang et al., 
1997). Similar to IFN-γ in Th1 cells, IL-4 can act in an autocrine and paracrine 
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fashion by promoting Th2 responses and inhibiting Th1 responses (Wurtz et al., 
2004). 
 
One of the most important Th2 cell effector function s promoting B cell activation 
and antibody production to combat extracellular parasites. In addition to producing 
cytokines, Th2 cells express CD40L on their surface which binds to CD40 on the 
surface of a B cell and together with cytokines induces B cell proliferation and 
antibody class switching (Parker, 1993). Th2 cells can also produce eotaxin 
recruiting eosinophils from the bone marrow which upon activation degranulate 
releasing toxic substances able to kill parasites (Klion and Nutman, 2004). The 
powerful mechanisms of dealing with extracellular pthogens can sometimes become 
dysregulated and turn against the host leading to chr nic inflammation which is seen, 
for example, in asthma. The role of Th2 cells in allergic inflammatory diseases will 
be discussed later in this chapter.  
 
1.4.1.3. Th17 cells 
The original Th1/Th2 paradigm, whereby these two cell populations have a potential 
to cancel each other out as a means of immune regulation, was broken by the 
discovery of a new CD4+ T cell subset called Th17 (Langrish et al., 2005, Bettelli et 
al., 2007). Signature cytokines of Th17 cells include IL-17A, IL-17F, IL-21 and IL-
22 and appear to be important for the protection against mucosal pathogens such as 
fungi (Kolls, 2010).  
 
The differentiation of Th17 cells requires IL-6 and TGF-β signalling via Smad2 and 
STAT3 (Mangan et al., 2006, Malhotra et al., 2010, Zhou et al., 2007). This induces 
an expression of a master regulator of Th17 differentiation called retinoic acid-
related orphan receptor-γT (ROR-γT) (Ivanov et al., 2006). Another related nuclear 
receptor, ROR-α, was also shown to be required for Th17 differentiation (Yang et al., 
2008b). IL-23 initially thought to be required for Th17 differentiation, was shown to 
stabilise the Th17 phenotype instead (Stritesky et al., 2008). The differentiation of 
Th17 cells is inhibited by Th1-associated IFN-γ and Th2-associated IL-4 (Weaver et 
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al., 2007). Th17 cells also seem to exhibit high leve  of plasticity in terms of cytokine 
production (Lee et al., 2009) and conversion from Foxp3+ cells (Xu et al., 2007).   
 
Since their discovery, Th17 cells have been implicated in many autoimmune diseases 
(Lubberts, 2008, Durelli et al., 2009) and previously unclear evidence like 
exacerbation of ‘Th1-mediated’ autoimmune models with anti-IFN-γ therapy (Billiau 
et al., 1988) shed a new light on the pathogenesis in many diseases.    
 
1.4.1.4. Novel CD4 + T cells subsets 
Among the newly defined Teff subsets are T follicular helper cells (Tfh) which are 
antigen-experienced CD4+ T cells residing in B cell follicles in the secondary 
lymphoid organs. These cells are characterized by the expression of CXCR5 
(Schaerli et al., 2000) and the transcription factor Bcl6 (Nurieva et al., 2009) and aid 
the formation of B cell germinal centres (Crotty, 2011).   
 
The two other new subsets of Th cells include IL-9-secreting Th9 cells (Dardalhon et 
al., 2008) and IL-22-secreting Th22 cells (Trifari et al., 2009, Eyerich et al., 2009), 
however their role is still unclear and no master transcription factors driving their 
lineage have been yet defined.  
 
1.4.2. CD4+ regulatory T cells 
In addition to effector T cells eliciting immune responses during infections and 
inflammatory diseases there are several subsets of CD4+ T cells that are 
immunosuppressive and aim to dampen these responses. The existence of 
‘suppressive’ T cells was originally suggested in early 1970s by Gershon and Kondo 
who reported that antigen tolerance required the prsence of thymus-derived 
lymphocytes (Gershon and Kondo, 1970, Gershon and Kondo, 1971). Since the 
discovery of a master transcription factor that drives regulatory T cell lineage, 
Forkhead box P3 (Foxp3) in 2003 by the Sakaguchi group, the understanding of 
these cells has greatly progressed (Hori et al., 2003). It is now known that there are 
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two main subsets of Treg and these include naturally-occurring Treg (nTreg) and 
induced Treg (iTreg) that can be generated either in the periphery or in vitro.   
 
1.4.2.1. Natural Treg 
The first classification of regulatory T cells as a pecific T cell subset was reported 
by Sakaguchi et al. who showed that mice depleted of T cells expressing the high 
affinity IL-2 receptor α-chain (IL-2Rα, also called CD25) develop severe multi-organ 
autoimmunity (Sakaguchi et al., 1985). Reciprocally, the reconstitution with CD25+ 
T cells prevented disease development by limiting the responses to both self- but also 
to non-self antigens (Sakaguchi et al., 1995). Neonatal thymectomy and cell transfer 
experiments showed that CD25+ T cells, contained mostly within CD4+ cell 
population, are generated in thymus from day three onwards in mice and are 
responsible for maintaining peripheral tolerance (Asano et al., 1996). 
 
1.4.2.1.1. nTreg generation 
nTreg constitute approximately 5-10% of peripheral CD4+ T cells and are generated 
as a distinct lineage during thymic development (Itoh et al., 1999). Processes of 
positive and negative selection in thymus are based on the strength of antigen-self-
reactivity. As mentioned already, positive selection allows for survival of T cells 
weakly recognizing peptide-MHC complexes, whereas negative selection deletes the 
cells that bind to peptide-MHC complexes with too high affinity. Due to controversy 
over how self-reactive the TCR repertoire of nTreg is (Pacholczyk and Kern, 2008), 
the thymic selection of nTreg is still not thoroughly understood. An instructive model 
suggests that nTreg are selected on the basis of high affinity TCR for the self-peptide 
and this is an alternative fate to deletion during negative selection (Jordan et al., 
2001, Yu et al., 2008). A different, 2-step model, proposes that nTreg selection is 
random and involves an initial upregulation of CD25 on single-positive thymocytes 
which is followed by the expression of Foxp3 (van Santen et al., 2004, Lio and 
Hsieh, 2008). Signalling through TGF-β and CD28 is suggested to be critical as well 
(Liu et al., 2008, Tai et al., 2005). It was reported hat, once nTreg leave the thymus, 
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their full development and/or survival is dependent o  the presence of peripheral 
self-antigen (Modigliani et al., 1996, Seddon and Mason, 2000).  
 
1.4.2.1.2. TCR signalling and reactivity 
TCR signalling is critical for development and function of nTreg. TCR transgenic 
mice that lack recombination activating gene (RAG) responsible for VDJ-
rearrangements, have no nTreg. Moreover, the number of nTreg in TCR transgenic 
mice is lower than in wild type mice suggesting that certain αβ TCR are required for 
optimal nTreg generation (Olivares-Villagomez et al., 2000). Development of in 
vitro Treg suppression assay by the Shevach group greatly faci itated understanding 
of the importance of Treg antigen reactivity and the mechanisms of suppression 
(Thornton and Shevach, 1998, Thornton and Shevach, 2000). The suppression assay 
consists of an unchanged number of CD4+CD25- conventional T cells (Teff) and 
APC incubated with serially diluted Treg in the presence of stimulus. As the Teff to 
Treg ratio increases, the suppression decreases and modifications of this standardized 
assay allow for investigation of its different components. In terms of cell function, 
both in vitro and in vivo experiments show that activation of nTreg is TCR dependent 
(Thornton and Shevach, 1998, Walker et al., 2003) and once activated, they have a 
potential to suppress effector T cells in an antige non-specific fashion (Thornton 
and Shevach, 2000).  
 
Investigations into the TCR repertoire of nTreg in a steady state have shown that 
TCR of nTreg and conventional CD25- T cells are similar in diversity, but distinct 
and partially overlapping (Hsieh et al., 2006, Wong et al., 2007, Pacholczyk et al., 
2007). Proliferation within lymphopenic hosts of conventional T cells transduced 
with nTreg-derived TCR suggested that the TCR repertoir  of nTreg is skewed 
towards self-reactive when compared to the one of conventional T cells (Hsieh et al., 
2006). Other studies, however, demonstrated that that TCR of nTreg can recognize 
foreign antigens similarly to conventional T cells (Pacholczyk et al., 2007).   
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1.4.2.1.3. Cell surface markers 
CD25 is the high affinity α-chain of the IL-2 receptor and was originally used as a 
marker to differentiate nTreg (Sakaguchi et al., 1995). It also suggested the 
importance of IL-2 signalling in the development and/or suppressive function of 
nTreg. However, as CD25 is upregulated on activated conventional T cells, other 
markers expressed by nTreg were needed to be identif ed.  
 
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a negative co-stimulator of 
T cell activation, was shown to be constitutively expressed on naïve CD25+ CD4+ T 
cells and its in vivo blockade was demonstrated to lead to the development of 
spontaneous organ-specific autoimmunity (Takahashi et al., 2000). CTLA-4 
expression was also found to be critical for Treg-mediated regulation of intestinal 
inflammation (Read et al., 2000) and type 1 diabetes (Luhder et al., 1998). Finally, 
CTLA-4 was suggested to be the core mechanism throug  which Treg control the 
function of APC by, for example, inhibiting their maturation and in this way 
suppressing T cell activation (Onishi et al., 2008, Wing et al., 2008, Wing and 
Sakaguchi, 2010).  
 
Gene expression analysis of naïve CD4+ CD25+ T cells, in addition to CTLA-4, also 
revealed increased expression of glucocorticoid-induce  TNF receptor-related 
protein (GITR) (McHugh et al., 2002). GITR was found to be upregulated upon Treg 
activation and its stimulation via monoclonal antibody abrogated in vitro Treg-
mediated suppression (McHugh et al., 2002) and in vivo induced development of 
gastritis (Shimizu et al., 2002). It has been suggested that GITR, unlike CTLA-4, 
might act as a switch-off mechanism for Treg function (Ermann and Fathman, 2003). 
This was suggested to have potentially beneficial effects by enhancing responses to 
infections and tumours (Nocentini and Riccardi, 2009).   
  
1.4.2.1.4. Foxp3 expression 
The breakthrough in nTreg biology came with the discovery of Foxp3, a master 
transcription factor driving nTreg lineage (Hori et al., 2003, Fontenot et al., 2003). 
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Originally a mutation in the foxp3 gene was identified as the cause of the phenotype 
observed in scurfy mice which is manifested by multi-organ autoimmunity (Brunkow 
et al., 2001). The mutation in the X-linked foxp3 gene leads to splenomegaly, 
enlarged lymph nodes, and immune cell infiltration of major organs (Godfrey et al., 
1991). Increased T cell activation/proliferation due to hyper-responsive TCR and 
lower co-stimulatory threshold for T cell activation were also reported, all suggestive 
of an impaired regulatory mechanism (Clark et al., 1999). The phenotype of scurfy 
mice is very similar to the human disease immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, which was found to be 
caused by the mutation in the foxp3 gene as well (Bennett et al., 2001).  
 
The importance of Foxp3 expression in nTreg was further highlighted by the 
retroviral transduction of Foxp3 into naïve CD4+CD25- T cells which conferred a 
suppressive phenotype on the naïve cells (Hori et al., 2003, Fontenot et al., 2003). 
Foxp3-transduced naïve T cells effectively suppressed inflammatory bowel disease 
and autoimmune gastritis (Hori et al., 2003). Reciprocal experiments with ablated 
Foxp3 expression in nTreg showed that, unless Foxp3 expression is maintained, 
nTreg lose their suppressive potential and acquire an ability to extensively proliferate 
and produce Th1-associated cytokines (Williams and Ru ensky, 2007).   
 
Generation of a Foxp3-GFP mouse by Rudensky lab which as a knock-in allele of 
green-fluorescent protein (GFP) fused to the foxp3 gene provided a unique tool for 
easy identification and isolation of nTreg (Fontenot et al., 2005b). The phenotypic 
analysis of steady-state Foxp3+ CD4+ cells done in Foxp3-GFP mice revealed that 
majority (>97%) are CD4+, they include both CD25+ and CD25- cells, and they 
express CTLA-4 and GITR as shown before for CD25+ cells only (Fontenot et al., 
2005b).  
 
Foxp3 was shown to form a DNA-binding complex with nuclear factor of activated T 
cells (NFAT) to regulate transcription of ~1,100 target genes (Wu et al., 2006, 
Marson et al., 2007). Among the Foxp3 target genes which are positively regulated 
are cd25, gitr and programmed cell death-1 (pd-1) (Marson et al., 2007, Zheng et al., 
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2007). Interestingly, Foxp3 seems to predominantly suppress transcription of genes 
involved in T cell activation and function such as il-2 by occupying their promoter 
regions (Marson et al., 2007, Zheng et al., 2007).   
 
nTreg have been demonstrated to play an important role in suppressing and 
promoting resolution of inflammation in autoimmune and allergic disease settings 
(Tang et al., 2004, McGeachy et al., 2005, Leech et al., 2007). They have been also 
reported to dampen anti-tumour responses and hence contribute to tumour resistance 
(Casares et al., 2003, Clarke et al., 2006). Althoug  the knowledge about nTreg is 
exponentially increasing, the exact mechanisms of how they suppress different forms 
of inflammation in vivo are still elusive and a more definitive understanding of how 
nTreg function is critical for their effective manipulation. The general suppressive 
mechanisms have been suggested and are described in s ction 1.6.  
 
1.4.2.2. Induced Foxp3 + Treg 
It has been demonstrated that Foxp3 can be induced de novo in naïve CD4+ T cells 
under certain conditions both in vivo in a periphery and in vitro, and these cells have 
been called induced Treg.  
 
1.4.2.2.1. Discovery of iTreg  
One of the first reports on the de novo generation of CD4+ CD25+ regulatory T cells 
came from the study which used transferred antigen-specific T cells on a RAG2-/- 
background and demonstrated the appearance of CD25+ cells after low dose antigen 
administration intravenously or orally (Thorstenson and Khoruts, 2001). These CD4+ 
CD25+ cells established peripheral tolerance, had a low proliferation rate, were 
unable to produce IL-2 and had a suppressive potential, all characteristic of 
regulatory T cell phenotype. The generation of CD4+ CD25+ cells did not occur 
following antigen administration in adjuvant (Thorstenson and Khoruts, 2001) 
suggesting that antigen presentation by immature APC played a role in tolerance 
induction. Later studies on peripheral tolerance confirmed this phenomenon and 
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moreover showed that these CD4+ CD25+ T cells express FoxP3 and are IL-2-
dependent (Apostolou and von Boehmer, 2004, Knoechel et al., 2005).  
 
1.4.2.2.2. Importance of TGF- β signalling 
In addition to IL-2 signalling demonstrated to be ess ntial for Treg peripheral 
homeostasis (Knoechel et al., 2005, Fontenot et al., 2005a), transforming growth 
factor-β (TGF-β) was shown to be required for the generation of induced Treg, both 
in vivo and in vitro. TGF-β is a protein that can exist in a secreted and membrane-
bound form, and among its diverse functions (Shi and Massague, 2003), the 
membrane-bound form of TGF-β was found to be involved in a contact-dependent 
immunosuppression (Nakamura et al., 2001). TGF-β in the presence of TCR 
signalling was reported to induce Foxp3 expression in aïve CD4+ CD25- T cells in 
vitro, and these induced Foxp3+ cells expressed membrane-bound TFG-β and 
suppressed conventional T cells (Chen et al., 2003). TGF-β-converted antigen-
specific CD4+ CD25+ cells also suppressed T cell expansion in vivo and polyclonal 
iTreg were found to ameliorate lung inflammation in a house dust mite (HDM)-
induced murine model of asthma (Chen et al., 2003). This phenomenon was 
confirmed by other studies which also showed that in vitro pre-treatment of naïve 
CD4+ CD25- T cells with TGF-β promoted their conversion into Treg under 
tolerogenic conditions in vivo (Kretschmer et al., 2005).  
 
1.4.2.2.3. iTreg versus nTreg 
Since the discovery of peripherally-induced Treg, large amount of work has gone 
into investigating methods of differentiating between natural thymically-derived 
nTreg and de novo generated iTreg. Initially reported to be nTreg-specific, 
expression of Helios (Thornton et al., 2010) was found to occur in activated T cells 
and iTreg as well (Akimova et al., 2011, Gottschalk et al., 2012). Interestingly, it has 
been observed that nTreg have a stably demethylated conserved region of the foxp3 
gene, whereas iTreg do not (Floess et al., 2007). Epigenetic modification of the foxp3 
locus was suggested to be required for stable Foxp3 e ression and maintenance of 
                                                                                                 INTRODUCTION 
 23
the suppressive phenotype, as iTreg were found to rapidly lose Foxp3 expression 
upon re-stimulation in the absence of TGF-β (Floess et al., 2007). 
 
Rapid loss of Foxp3 in re-stimulated iTreg led to the concerns over their potential to 
convert into effector T cells and hence contribute to the inflammation when used in a 
therapeutic setting. However, it was shown that ex-iTreg do not acquire pathogenic 
phenotype and they can effectively suppress T cellsin vitro and in vivo (O'Connor et 
al., 2010).  
 
To sum up, it has been speculated that the driving force behind iTreg generation in 
the periphery is the need to maintain mucosal tolerance in the gut and the lung to 
innocuous antigens, whereas the primary function of nTreg is to control 
autoimmunity and promote resolution during inflammation (Curotto de Lafaille and 
Lafaille, 2009). 
 
1.4.2.3. Tr1 and Th3 cells 
Another regulatory cell type that was proposed to contribute to peripheral tolerance 
is T regulatory cell 1 (Tr1). These cells are characterized by the production of large 
amounts of IL-10 and TGF-β and low levels of IFN-γ and IL-2 (Groux et al., 1997). 
Similar to nTreg, they have very low proliferative capacity in vitro and can 
effectively suppress antigen-specific T cells in vitro and in vivo in a model of colitis 
(Groux et al., 1997). Tr1 cells can be induced from naïve CD4+ CD25- T cells in the 
presence of IL-10, however they do not acquire exprssion of Foxp3 (Groux et al., 
1997, Vieira et al., 2004). Immature DC have been implicated in the induction of Tr1 
cells in vivo (Jonuleit et al., 2000). Antigen-reactive Tr1 cells have to be activated 
through their TCR to suppresses T cells, however, once activated they can mediate 
bystander suppression via local release of anti-inflammatory IL-10 and TGF-β 
(Groux, 2003, Roncarolo et al., 2006).  
 
Another type of regulatory T cells called Th3 has been initially described in the 
context of oral tolerance. Th3 cells were reported to provide help to B cells for IgA 
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production and to produce large amounts of TGF-β (Weiner, 2001). Th3-derived 
TGF-β was shown to promote in vivo generation of Foxp3+ iTreg (Carrier et al., 
2007), thus suggesting a role for Th3 cells in peripheral tolerance.  
  
1.4.2.4. Other regulatory cell types 
Suppressor cells expressing CD8 were originally discovered by Gershon and Kondo 
in the 1970s (Gershon and Kondo, 1970, Gershon and Ko o, 1971). Difficulties in 
the characterization of these cells due to the lackof cell-specific marker and the 
discovery of CD4+ CD25+ Treg resulted in CD8+ regulatory cells (CD8+ Treg) being 
largely abandoned until recent rediscovery. CD8+ Treg were reported to be generated 
in vivo after immunization with OVA and they required IFN-γ to mediate TGF-β-
dependent suppression of CD4+ T cells responses (Myers et al., 2005). This 
suggested a means by which pathogenic Th1 cells could ‘self-regulate’ themselves. 
CD8+ Treg were also identified in multiple sclerosis (MS) patients where they 
showed cytotoxic activity against myelin-reactive CD4+ T cells (Correale and Villa, 
2008), and have been implicated in the recovery phase in the murine model of MS, 
experimental autoimmune encephalomyelitis (EAE) (Lee et al., 2008). CD8+ Treg 
are very diverse and some subsets were shown to express Foxp3 (Xystrakis et al., 
2004, Bienvenu et al., 2005).  
 
The role of B cells in potentiating immune responses in infections and autoimmune 
disease has been well established. However, more recently, it was suggested that they 
can have a regulatory role as well. B cells were shown to be capable of expanding 
Foxp3+ Treg and dictating their antigen-reactivity (Chen et al., 2009), and they were 
also reported to induce Foxp3+ iTreg from CD4+ CD25- T cells (Tu et al., 2008). B 
cell-derived IL-10 was demonstrated to mediate Treg expansion (Sun et al., 2008) 
and to have a potential in regulating autoimmune pathology (Fillatreau et al., 2002, 
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1.5. CD4+ T cell plasticity 
The concept of distinct CD4+ T cell lineages has been very useful for understanding 
how different CD4+ T cells and their signature cytokines are driving a d controlling 
different immune responses. However, recent evidence on the flexibility of CD4+ T 
cell lineages has led to the major rethinking of this paradigm (O'Shea and Paul, 
2010).   
 
1.5.1. Plasticity of cytokine production  
IL-9 previously designated as a signature cytokine for a still to be confirmed Th9 
subtype was demonstrated to be produced by both Th2 cells via TGF-β signalling 
(Veldhoen et al., 2008) and Th17 cells (Elyaman et al., 2009). Th17 cells were 
reported to acquire an ability to produce a Th1-associated cytokine by either 
becoming double producers of IL-17 and IFN-γ under certain inflammatory 
conditions (Wilson et al., 2007, Kebir et al., 2009), or by completely abrogating 
production of IL-17 and committing to IFN-γ secretion (Lee et al., 2009, Shi et al., 
2008). Interestingly, Th1 cells were never demonstrated to produce IL-17, however 
they were shown to be capable of secreting Th2-associated cytokine IL-13 and to 
promote airway hyper-responsiveness in a murine model f asthma (Sugimoto et al., 
2004). A Th2-dominated environment during helminth infection was observed to 
convert Th1 and Th17 cells into Th2 effectors secreting IL-4, which are more 
efficient at tackling extracellular parasites (Panzer et al., 2012). Conversely, IL-4 
producing Th2 cells were reported to switch to IFN-γ production after transfer into a 
model of Th1-skewing infection with lymphocytic choriomeningitis virus (LCMV) 
(Hegazy et al., 2010).  
 
1.5.2. Flexibility in expression of master transcri ption factors 
CD4+ T cell lineages are defined by the specific expression of master transcription 
factors and expression of these has been found to be not as fixed as it was thought 
initially. As mentioned above, Hegazy et al., has shown that transfer of Th2 cells into 
a model of Th1-associated infection with LCMV resulted in the Th2 cells not only 
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secreting IFN-γ but also stably co-expressing GATA-3 and T-bet (Hegazy et al., 
2010). This ‘Th1+2’ phenotype required TCR stimulation, type I and type II 
interferons and IL-12 signalling which induced T-bet expression and hence switched 
on IFN-γ production. Th2 ‘reprogramming’ was suggested to be critical for the 
control and clearance of LCMV infection. Another example of flexibility in 
expressing master transcription factors is provided by Th17 cells which were shown 
to co-express ROR-γt and T-bet in a model of hen egg lysozyme (HEL)-driven 
ocular inflammation (Shi et al., 2008). A substantil degree of plasticity has been 
also reported in Treg lineage and this will be discussed in more detail as it may have 
important implications in the potential therapeutic use of Treg.   
 
1.5.3. Plasticity of Treg lineage 
Suppressive capacity of Treg sparked an interest in their potential use in therapy and 
among the questions that have been posed was how stable Treg are and whether they 
have a potential to convert into pathogenic cells. Zhou et al. used a genetic lineage-
tracing system in which they could identify not only Foxp3+ cells but also cells that 
expressed Foxp3 at some point in their existence and are now Foxp3-, so called 
exFoxp3 cells (Zhou et al., 2009a). They demonstrated that in a naïve mouse ~20% 
of total peripheral T cells that once were able to express Foxp3, lost its expression. 
These exFoxp3 cells had an activated memory cell phnotype and produced IFN-γ 
and low level of IL-17. Using a spontaneous model of type 1 diabetes, they reported 
that a pro-inflammatory autoimmune environment promoted loss of Foxp3 and 
exFoxp3 cells had a substantial pathogenic potential. Interestingly, exFoxp3 cells 
were shown to be derived both from nTreg and periphal iTreg. Similar gain of 
ability to produce pro-inflammatory IL-17 and loss of Foxp3 expression by nTreg, or 
co-expression of Foxp3 and IFN-γ was reported in other studies (Xu et al., 2007, 
Yang et al., 2008a, Wei et al., 2009). However, substantial heterogeneity of Treg 
prompted a question as to whether a particular subset of Treg is more prone to lose 
Foxp3 and become pathogenic in an inflammatory context (Gadina and O'Shea, 
2009).  
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As mentioned before, Foxp3+ cells include both CD25+ and CD25- T cells. A study 
by Komatsu et al. showed that the CD25- fraction, but not CD25+, contained a minor 
population that upon transfer into lymphopenic hosts readily loses Foxp3 (Komatsu 
et al., 2009). Moreover, CD62Lhigh subpopulation of Treg was demonstrated to be the 
most effective at suppressing EAE and was shown to re ain Foxp3 expression 
significantly better than its CD62Llow counterpart (Stephens et al., 2009). More 
recently, Treg derived from the inflamed CNS, but no the spleen, during EAE were 
reported to resist conversion to IL-17-producing cells via IL-6 unresponsiveness 
indicating that intrinsic mechanisms exist within Treg to stabilize their Foxp3 
expression in an inflamed environment (O'Connor et al., 2012).  
 
In conclusion, the flexibility in expression of cytokines and master transcription 
factors has been suggested to have an evolutionary value as it may allow easier 
adjustment of immune responses to new pathogens (O'Shea and Paul, 2010). 
However, plasticity of regulatory cells shows that this possibly important feature of 
CD4+ T cells can be sometimes turned against the host and c n contribute to 
inflammation instead of dampening it. Epigenetic modifications are now suggested to 
stand behind the regulation of CD4+ T cell lineage commitment and the degree of 
plasticity that occurs within it (Wei et al., 2009).  
 
1.6. Mechanisms of regulation by Treg 
Treg have been suggested to mediate suppression via very diverse mechanisms and 
these were demonstrated to target either T cells directly by suppressor cytokines, IL-
2 deprivation and cytolysis, or to target APC (Shevach, 2009). Initial results from in 
vitro studies showed that Treg mediate suppression in a contact-dependent manner 
and neutralization of IL-10 and TGF-β did not break it (Thornton and Shevach, 1998, 
Takahashi et al., 1998). However, investigations into regulation in vivo soon revealed 
that Treg behaviour is much more diverse.  
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1.6.1. Suppressive cytokines 
The importance of TGF-β in maintaining immune homeostasis was initially observed 
in TGF-β1-deficient mice which showed uncontrollable lymphocyte proliferation and 
cellular infiltration of major organs (Christ et al., 1994). Multiple studies 
demonstrated that an important source of TGF-β in the immune system is Treg which 
expresses high levels both secreted and membrane-bound f rms of this cytokine 
(Nakamura et al., 2001, Schmidt et al., 2012). However, in vitro suppression 
experiments gave contradicting results as to how important TGF-β is in Treg-
mediated suppression (Nakamura et al., 2001, Levings et al., 2002, Piccirillo et al., 
2002). Investigations in vivo in a model of colitis gave unclear results as well. While 
one study reported that TGF-β is critical in preventing inflammation (Read et al., 
2000), a different one demonstrated that its protectiv  role is redundant (Kullberg et 
al., 2005). Interestingly, the membrane-bound form of TGF-β was implicated in 
infectious tolerance which can be induced by Treg capable of conferring a 
suppressive activity on conventional T cells (Andersson et al., 2008).  
 
Another cytokine abundantly produced by Treg is IL-10 and its importance in 
mediating immunosuppression has been well established. Blocking IL-10 or using 
IL-10-deficient Treg was shown to abrogate protective effects of Treg in models of 
colitis (Asseman et al., 1999) and allergic airways inflammation (Leech et al., 2007). 
Treg-derived IL-10 was also implicated in the naturl disease resolution in a model 
of EAE (McGeachy et al., 2005) and a high level of IL-10 expression within the CNS 
was shown to inhibit inflammation (Cua et al., 2001). Moreover, it was demonstrated 
that IL-10 is important in controlling antigen-activated and/or memory T cells but 
not naïve T cells (Kamanaka et al., 2011) suggesting that mechanisms of suppression 
may vary according to the activation status of a target cell (Schmidt et al., 2012).  
 
A novel inhibitory cytokine called IL-35, a member of IL-12 family, was reported to 
be constitutively expressed only by Treg and markedly upregulated upon co-culture 
of Treg with effector T cells (Collison et al., 2007). Ectopic expression of IL-35 in 
conventional T cells endowed them with a suppressiv capacity. IL-35 was shown to 
inhibit proliferation of Th17 cells in vitro and to suppress a murine collagen-induced 
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model of arthritis (Niedbala et al., 2007). Its ability to convert effector T cells into 
IL-35-producing T cells suggested that IL-35 can also contribute to infectious 
tolerance (Chaturvedi et al., 2011).   
 
1.6.2. Cytolysis 
One of the potential mechanisms that could explain reported observations that 
separation of Treg and effector T cells by a permeable membrane breaks the 
suppression or that it is unaffected by blocking suppressive cytokines (Thornton and 
Shevach, 1998, Takahashi et al., 1998) is a contact-dependent suppression via 
cytolysis (Shevach, 2002). Cytolysis is a mechanism in which cytotoxic molecules 
such as proteases produced by one cell induce apoptosis of the neighbouring cell. 
This ‘killing’ mechanism has been well documented in CD8+ T cells and natural 
killer (NK) cells, however it has been unclear if Treg were capable of similar 
behaviour. Gondek at al. demonstrated that indeed Tr g can produce granzyme B, a 
serine protease, which was observed to induce apoptosis in co-cultured effector T 
cells in a perforin-independent fashion in vitro (Gondek et al., 2005). Granzyme B-
deficient Treg were also shown to have reduced suppressive capacity in vitro 
(Gondek et al., 2005), and the relevance of this mechanism was confirmed in vivo in 
studies on tumour resistance (Cao et al., 2007, Boissonnas et al., 2010). Another 
example of cytotoxic Treg activity is suppression mediated by TNF-related 
apoptosis-inducing ligand (TRAIL) which induces apoptosis of Teff by binding to a 
death receptor 5 (DR5) upregulated on Teff upon activ tion (Ren et al., 2007).  
 
1.6.3. Metabolic disruption 
Treg are known to express the high affinity IL-2 receptor α-chain (CD25) and require 
IL-2 for their survival, growth and function (de laRosa et al., 2004). However, as 
they were shown to be incapable of producing IL-2 themselves, they were suggested 
to act as a ‘sink’ and deprive effector T cells of IL-2 which is critical for their 
activation, differentiation and proliferation (Sakaguchi et al., 1995). This was 
demonstrated to be true both in vitro and in vivo in a model of inflammatory bowel 
disease (IBD) (de la Rosa et al., 2004, Pandiyan et l., 2007).  
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1.6.4. Modulation of APC 
Conventional T cells have been shown to undergo apoptosis or become anergic if 
they are stimulated by APC in the absence of co-stimulatory signals (as discussed is 
section 1.3.2). Hence, one of the Treg-mediated suppressive mechanisms was 
suggested to act via APC. It was observed in vitro that CD4+ CD25+ T cells were 
able to down-regulate the expression of co-stimulatory molecules CD80 and CD86 
on DC via CTLA-4 (Cederbom et al., 2000, Oderup et al., 2006). Specific CTLA-4 
deficiency in Treg was shown to lead to spontaneous development of autoimmune 
lymphoproliferative disorder in mice (Wing et al., 2008). CTLA-4-deficient Treg 
were found to lack the capacity to down-regulate CD80 and CD86 expression on DC 
and hence were unable to limit T cell responses in that model. CTLA-4 ligation of 
CD80 and/or CD86 was also demonstrated to induce expression of idoleamine 2,3-
dioxygenase (IDO) pathway in DC leading to the production of tryptophan 
catabolites such as kynurenin that were suggested to exert immunosuppressive 
effects (Grohmann et al., 2002, Fallarino et al., 2003). Moreover, negative 
stimulation of DC through CTLA-4 was shown to induce nuclear localization of a 
transcription factor Foxo3 which inhibited production of pro-inflammatory cytokines 
IL-6 and TNF by DC compromising their stimulatory capacity (Dejean et al., 2009).    
 
A novel mechanism of Treg-mediated suppression of DC function via CTLA-4 was 
recently reported by the Sansom group who showed that CTLA-4 can remove co-
stimulatory CD86 from the cell surface of a DC via tr ns-endocytosis (Qureshi et al., 
2011). They have used a CTLA-4 expressing cell line to demonstrate this n vitro and 
in vivo and found that CD86 acquired in such a way was subequently degraded in 
endosomal compartments within CTLA-4-expressing cells. This finding was also 
confirmed to occur in Treg and shown to be antigen-d pendent (Qureshi et al., 2011).  
 
Another cell surface inhibitory molecule expressed by Treg is lymphocyte activation 
gene-3 (LAG-3) which binds to MHC class II on DC and i hibits DC maturation and 
their co-stimulatory capacity (Liang et al., 2008). Treg can also modulate the array of 
cytokines produced by DC skewing it towards an anti-inflammatory type which 
includes IL-10 (Misra et al., 2004, Veldhoen et al., 2006). Moreover, they were 
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shown to inhibit stable contacts between DC and naïve CD4+ T cells in vivo during 
priming which are required for T cell activation (Tadokoro et al., 2006).  
 
1.6.5. Other mechanisms - adenosine 
In addition to suppressive cytokines, a different type of anti-inflammatory mediator 
that was discovered to be produced by Treg is adenosine. Adenosine generation is 
catalyzed by two membrane-bound ecto-enzymes: CD39 is an ecto-ATP 
diphosphohydrolase which converts circulating ATP and ADP into 5’AMP and 
CD73 is an ecto-5’-nucleotidase which converts 5’AMP to adenosine. Adenosine can 
bind to adenosine receptors expressed on lymphocytes and myeloid cells and can 
very effectively regulate inflammation via a variety of mechanisms (Linden, 2006). 
Expression of CD73 on Treg was firstly reported by Kobie et al. who also showed 
that adenosine produced by Treg suppressed proliferation and cytokine production by 
Th1 and Th2 cells (Kobie et al., 2006). This was shortly followed by another study 
demonstrating that Treg can also express CD39 (Deaglio et al., 2007). This 
coordinated CD39/CD73 expression was suggested to be an important part of Treg 
suppressive machinery. 
 
Treg can clearly display a wide variety of mechanisms which they use to regulate 
inflammation. The summary diagram is provided at the end of this section in Figure 
1.3. This complexity and possibly cross-regulation allows for the best chances to 
keep self- and excessive inflammatory responses under control. Moreover, at least 
some of the mechanisms mentioned above have been demonstrated to be redundant 
or plastic. Pillai et al. showed that IL-10/IL-35-deficient Treg are fully functional in 
vivo and can still mediate suppression by upregulating cytolysis via TRAIL (Pillai et 
al., 2011).  
 
The very important questions to answer are whether different Treg subsets such as 
nTreg and iTreg vary in their regulatory mechanisms and whether different 
mechanisms occur in different types and/or sites of inflammation.  
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A) Production of anti-inflammatory cytokines. B) Cytolysis via granzyme B or ligation
of death receptor-5 (DR5) on CD4+ T cell surface by TRAIL. C) Metabolic disruption
via IL-2 deprivation. D) Modulation of APC: inhibition of co-stimulatory activity and/or
maturation of APC via CTLA-4 and LAG-3 signalling, induction of IDO expression and
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1.7. Regulatory CD4 + T cells in autoimmune disease 
Autoimmune disease occurs when the central and/or peripheral tolerance is 
compromised and an inflammatory response directed by the immune cells at self-
tissues becomes uncontrollable. Autoimmune diseases can be broadly divided into 
systemic such as systemic lupus erythematosus or organ-specific such as type 1 
diabetes mellitus or rheumatoid arthritis. The causes underlying most autoimmune 
diseases are unknown and it is speculated that they include a mixture of both genetic 
and environmental factors (Davidson and Diamond, 2001). A classic example of an 
autoimmune disease is multiple sclerosis which willbe thoroughly discussed in this 
thesis.   
 
1.7.1. Multiple sclerosis 
Multiple sclerosis (MS) is a complex demyelinating autoimmune disease of the 
central nervous system (CNS) characterized by chronic inflammation. It affects 
woman more frequently than man, and usually starts be ween 20 and 40 years of age 
(Sellner et al., 2011) MS is most prevalent in northe n Europe, southern Australia 
and North America (Kurtzke, 1991). The etiology of MS is still unknown and 
multiple genetic and environment factors have been implicated (Sospedra and 
Martin, 2005).    
 
1.7.1.1. Symptoms and clinical courses of MS 
MS is a very heterogeneous disease and more accurately it is considered to be a 
group of neurological disorders rather than one disase. The symptoms vary from 
one patient to another and are associated with the location of the lesions within the 
CNS (Charil et al., 2003, Kincses et al., 2010). MSmost commonly starts with vision 
problems due to optic neuritis, numbness sensations and other sensory disturbances, 
muscle weakness and spasms, problems with balance and coordination, and fatigue 
(Noseworthy et al., 2000). Cognitive impairment usually appears as the disease 
progresses. The diagnosis is based on the clinical and aboratory criteria, and usually 
involves magnetic resonance imaging (MRI) which enables visualisation of the 
lesions within the CNS.  
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There are three recognized clinical courses in MS: relapsing-remitting MS (RR-MS), 
secondary progressive MS (SP-MS) and primary progressiv  MS (PP-MS). RR-MS 
is the most frequent and occurs in 85-90% of patients with women affected twice as 
often as man (Sospedra and Martin, 2005). This form f MS is characterized by 
periods of symptoms of the disease which are followed by months to years of 
remission. Gradually the patients have shorter and scarcer periods of remission, and 
most of them go on to develop SP-MS which means progressive neurodegeneration. 
An estimated 10-15% of patients display PP-MS, with both genders affected equally, 
where the disease is characterized by steady disease progression (Noseworthy et al., 
2000). It is speculated that disease initiation and relapse phases in RR-MS are 
associated with active inflammation within the CNS, which eventually leads to 
irreparable axonal damage and neuronal loss, marking SP-MS (Bruck, 2005).   
 
1.7.1.2. Causes underlying MS 
The causes of MS remain unclear and they have been suggested to include both 
genetic susceptibility and environmental triggers. The genetic contribution was 
reported in many studies which found that first degre  relatives of an MS patient are 
15 to 25 times more likely to develop MS relative to the general population (Dyment 
et al., 2004). This likelihood increases by 150-fold if both parents have MS, and 170-
fold if one of the monozygotic female twins is affect d (Dyment et al., 2004). The 
search for susceptibility genes using a genome-wide linkage studies has confirmed 
significance in the MHC region on the chromosome 6p21 (Games and Cooperative, 
2003) which was first suggested in 1970s. The specific genes that were found to 
confer risk of MS are HLA-DR and –DQ genes, and the susceptibility haplotypes 
include HLA-DR15, HLA-DR2 and HLA-DQ6 (Olerup and Hillert, 1991, Barcellos 
et al., 2003). How MHC class II genes confer susceptibility to MS at the molecular 
level is unclear, however it is known that they encode antigen presentation 
machinery which is critical to T cell activation. Among the suggested mechanisms 
are the preference for presentation of self-peptides and escaping negative selection 
through binding only selective peptides (Sospedra and Martin, 2005). Multiple 
genome-wide association studies (GWAS) also identifi d MS-associated single 
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nucleotide polymorphisms (SNPs) that are located outside the MHC region and are 
within the genes encoding CD25, IL-7Rα chain (Hafler et al., 2007), CD40 and 
CYP27B1 (Consortium, 2009) which is an enzyme generating an active from of 
vitamin D implicated in MS as discussed below.  
 
The fact that key susceptibility genes in MS encode components of the immune 
system strongly supports the idea that MS is an autoimmune disease and implicates 
autoreactive CD4+ T cells in driving its pathology.     
 
In addition to genetic links, the etiology of MS is thought to have environmental 
contributions as well. There is an observed increase in MS prevalence with 
increasing distance north or south of the equator and migration from the area of high 
prevalence to the area of low prevalence, at the age of less than 15-16, was reported 
to lower the risk of disease (Kurtzke, 1991). The latitudal distribution of MS 
prevalence has been associated with decreased sun exposure indicating that sunlight 
is a protective factor in MS. Ultraviolet B radiation from sunlight induces synthesis 
of the precursor of vitamin D in the skin and has been first linked to MS by Goldberg 
in 1974 (Hayes, 2000). Some studies have indicated that intake of vitamin D may 
lower the risk of developing MS (Munger et al., 2004) and, some but not all, also 
reported on the lower serum levels of vitamin D in the blood of MS patients (Soilu-
Hanninen et al., 2005).  Protective effects of vitamin D were also demonstrated in the 
animal model of MS, experimental autoimmune encephalomyelitis (EAE). Calcitriol, 
an active metabolite of vitamin D3, has been shown to suppress both the induction 
and progression of EAE  and this is thought to occur via inhibition of Th1 responses 
and promotion of IL-10 signalling (Mattner et al., 2000, Spach and Hayes, 2005, 
Spach et al., 2006).  
 
A different environmental trigger implicated in MS is a viral infection. As discussed 
in section 1.3.2, self-reactive T cells that escape negative selection can be activated 
in the periphery in the presence of danger signals, for example via molecular 
mimicry or bystander activation. Several viruses have been linked to MS and these 
include Epstein-Barr virus (EBV) and human herpes virus-6 (HHV-6) (Ascherio et 
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al., 2001, Soldan et al., 1997), and potential molecular mimics for the CNS self-
peptide, myelin basic protein (MBP), have been identifi d in both species (Challoner 
et al., 1995, Holmoy et al., 2004). The involvement of an infectious trigger in MS is 
supported by animal studies which show that TCR-transgenic mice specific for MBP 
which are housed in non-sterile conditions develop spontaneous EAE, whereas those 
housed in a pathogen-free environment are disease free (Goverman et al., 1993).  
 
It is very likely that such a heterogeneous disease as MS has multiple genetic and 
environmental links which interact with each other and the underlying causes vary 
among the patients as do the symptoms and immunopath logy.   
 
1.7.1.3. Immunopathology 
It is believed that multiple sclerosis starts with the formation of acute inflammatory 
lesions as a result of a breakdown of the blood-brain-b rrier (BBB) (McFarland and 
Martin, 2007). The BBB is made of cerebral endothelial cells and is impermeable to 
solutes and cells only selectively allowing the entra ce of essential nutrients. The 
trigger for BBB breakdown is unknown, however, it is speculated to involve the 
effect of cytokines which could be produced in response to ongoing infection 
(Minagar and Alexander, 2003). The reasons for the initiation of the immune 
response remain unidentifiable as well but it is supected to target self-peptides 
found within the CNS. Among the putative antigens are components of myelin 
protein such as myelin oligodendrocyte glycoprotein (MOG), myelin basic protein 
(MBP) and proteolipid protein (PLP) (Sospedra and Martin, 2005). The immune 
responses implicated in immunopathology in MS are summarised in Figure 1.4. at 
the end of this section. 
 
1.7.1.3.1. CD4+ T cell-driven inflammation 
Inflammatory reaction in MS is thought to be driven by self-reactive CD4+ T cells 
which are activated by APC in the periphery and are abl  to cross BBB into the CNS 
to orchestrate immune response directed at myelin sheath (Ransohoff et al., 2003, 
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Goverman, 2009). This is supported by the fact thatCD4+ T cells detected in the 
peripheral blood and cerebrospinal fluid (CSF) of MS patients were found to be 
reactive to MBP and PLP, and were contained mostly wi hin the memory/activated T 
cell population (Illes et al., 1999, Burns et al., 1999, Bielekova et al., 2004). 
Originally it was considered that Th1 cells drive CNS inflammation as increased IL-
12 and IFN-γ levels were reported in serum and CSF of MS patients (Nicoletti et al., 
1996, Drulovic et al., 1997, Gutcher and Becher, 2007), and IFN-γ given to MS 
patients led to the substantial disease deterioration (Panitch et al., 1987). Discovery 
of Th17 cells and detection of IL-17+ T cells infiltrating the CNS of MS patients 
(Tzartos et al., 2008) led to the conclusion that bo h Th1 and Th17 cells are 
implicated in driving inflammation. This is further supported by observations made 
from the animal model of MS, EAE, which will be discussed in more detail later in 
this chapter.   
 
Once CD4+ T cells gain access to the CNS, they are thought to be reactivated by 
CNS resident APC such as microglia and start producing pro-inflammatory cytokines 
that activate local APC and recruit other immune cells (Benveniste, 1997, Goverman, 
2009). In addition to autoreactive CD4+ T cells, CD8+ T cells, B cells and myelin-
specific antibodies have been also detected in inflammatory lesions of MS patients 
(Esiri, 1977, Genain et al., 1999, Friese and Fugger, 2005) and hence are implicated 
in MS pathology. The inflammatory reaction targeted at the myelin sheath results in 
its damage and loss, and this demyelination causes axonal death and eventually 
neurodegeneration. It is known that axons can be remyelinated by oligodendrocyte 
precursor cells under certain circumstances, however this process seems to fail in MS 







































Hypothetical view of immuneresponses in acute MS lesions. (1) Unknown trigger leads
to the release of CNS-derived antigenswhich (2) are taken upby APC andpresented to T
cells and B cells in secondary lymphoid organs. Alternatively, autoreactive T cells and B
cells may become activated during, fox example, on-going infection via molecular
mimicry. (3) Activated CD4+ cells proliferate, (4) provide help for B cells and CD8+ cells
and traffic into the CNS. (5) Within the CNS, CD4+ cells become re-activated by local
APC such as microglia and orchestrate an inflammatory reaction targeted at myelin
sheath by producing pro-inflammatory cytokines such as IFN-γ and IL-17. These
increase thepermeability of BBB, recruit more immunecells into theCNS and promote
neuronal demyelination. (6) Following migration into the CNS, activated CD8+ cells
destroy neuronal cells via cytolysis and activated B cells become plasma cells that
produce antibodies directed at self-antigens. The CD4+ cells thought to drive the
inflammatory reaction are Th1 and Th17cells. Doted line indicates compromised myelin
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1.7.1.3.2. Impaired Treg regulation 
The breakdown of self-tolerance in MS and hence the dis ase pathology is thought to 
be caused not only by pro-inflammatory responses but also by compromised 
regulatory mechanisms. As described in section 1.4.2, CD4+ regulatory T cells are 
critical to peripheral tolerance by their ability to suppress T cells. Vigiletta et al. have 
reported that although the frequency of peripheral Treg is similar in relapsing-
remitting (RR)-MS patients and healthy controls, Treg function is significantly 
impaired (Viglietta et al., 2004). The incapability to generate Treg clones from MS 
patients led to the suggestion of a possible clonal exhaustion of Treg in vivo 
(Viglietta et al., 2004). Another study extended those results by showing that Treg 
from healthy donors suppress MOG-stimulated T cells, whereas Treg from RR-MS 
patients do not, and this is most likely related to the intrinsic defect in Treg 
regulatory mechanism and not Treg survival or resistance of responder cells (Haas et 
al., 2005). Comparisons of peripheral Treg from RR-MS and secondary progressive 
(SP)-MS patients confirmed unchanged Treg frequencies in both groups of MS 
patients and found that SP-MS patients had normal Treg function compared to RR-
MS patients (Venken et al., 2006). Treg from SP-MS patients effectively suppressed 
T cell proliferation and IFN-γ production, and had normal levels of Foxp3 
expression. Investigations into more disease-relevant Treg revealed that Treg 
frequencies in the blood and CSF of RR-MS patients are comparable, however the 
function of CSF-derived Treg has not been tested due to insufficient cell numbers 
(Haas et al., 2005).  
 
Reports on Treg in the inflamed CNS itself are controversial. As it is impossible to 
extract CNS cells from the patients, the only studies that can be done are 
immunohistological analyses of post-mortem MS brain. Tzatros et al. have found no 
evidence of the presence of Foxp3+ cells in the MS lesions (Tzartos et al., 2008). 
However, another study has reported detectable but very low Foxp3+ Treg numbers 
in RR-MS active brain lesions (Fritzsching et al., 2011). Moreover, as the numbers of 
apoptosis-prone Treg from CSF were reported to be higher than their numbers from 
the peripheral blood of the corresponding patients, Fritzsching et al. suggested a 
model of intracerebral elimination of Treg via CD95L-mediated apoptosis.  
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As most studies investigate the function of peripheral Treg, an important question to 
ask is how well these reflect the disease-relevant CNS-derived Treg (O'Connor and 
Anderton, 2008). Observations made from the animal odels of MS suggested that 
peripheral and CNS-derived Treg are two very different cell populations.  
 
1.7.1.4. Current treatments 
All of the current treatments for MS target the immune system and aim to modulate it 
in a non-specific way. The main ones include interferon-β, glatiramer acetate, 
mitoxantrone and natalizumab (Berger, 2009).  
 
Interferon-β therapeutics (Avonex®, Rebif®, Betaseron®, Extavia®) are clinically 
approved for the treatment of RR-MS and include both interferon-β1a and interferon-
β1b. They have been shown to reduce the frequency of relapses (Jacobs et al., 1996, 
Kappos, 2002) and although the mode of action remains unclear, they are thought to 
shift the cytokine production away from pro-inflammatory cytokines and repress T 
cell responses (Ozenci et al., 2000, Markowitz, 2007).  
 
Glatiramer actetate (Copaxone®) is a synthetic amino acid polymer also approved 
for the treatment of RR-MS. It was originally developed to mimic CNS self-antigen 
MBP to induce an animal model of MS, EAE, but was found to inhibit it (Teitelbaum 
et al., 1971). Initially thought to mainly displace autoantigenic peptides from MHC 
class II-binding groves (Aharoni et al., 1999), it was also shown to interfere with DC 
differentiation (Weber et al., 2004) and shift the T cell response towards Th2 type 
(Duda et al., 2000).  
 
Mitoxantrone (Novantrone®) is an immunosuppressive cytotoxic drug mostly 
prescribed to treat SP-MS and aggressive forms of RR-MS in which interferon-β and 
glatiramer actetate treatment fails (Correale et al., 2005). It intercalates with DNA 
leading to DNA damage and death of actively proliferating cells such as T cells, B 
cells and macrophages (Fidler et al., 1986, Fox, 2006). It has been shown to slow 
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down disease progression in SP-MS and extend the time between relapses in RR-MS 
(Hartung et al., 2002, Fox, 2006).  
 
Natalizumab (Tysabri®) is a humanized monoclonal antibody directed against the 
cell adhesion molecule α4-intergin and was shown to inhibit the entry of 
lymphocytes into the CNS (Engelhardt and Kappos, 2008). Natalizumab was 
reported to slow down the disease progression and the rate of relapses in RR-MS 
(Polman et al., 2006, Hutchinson, 2007). It was briefly removed from the market in 
2005 following deaths of several patients who develop d progressive multi-focal 
encephalopathy (PML), which is an opportunistic infection caused by reactivation of 
JC virus and leads to CNS demyelination (Langer-Gould et al., 2005). The drug was 
re-introduced and rare cases of PML are still being reported.  
 
Other novel treatments include fingolimod (FTY 710, Gilenya®), alemtuzumab 
(Campath®) and rituximab (Rituxan®). Fingolimod is a sphingosine 1-phosphate 
receptor modulator that sequesters lymphocytes in lymph nodes preventing them 
from trafficking into the CNS (Brinkmann et al., 2010). Alemtuzamab and rituximab 
are both monoclonal antibodies which target CD52 expr ssed on the surface of 
mature lymphocytes (Minagar et al., 2010) and CD20 expressed on B cells, 
respectively (Hauser et al., 2008).  
 
All of the current MS treatments target the immune system in a non-specific way 
leaving the patients substantially immunocompromised and prone to infections. The 
need to target pathogenic T cells specifically or to promote regulatory mechanisms is 
unquestionable and the animal models of MS provide a promising tool for the 
investigation of potential therapeutic agents. 
 
1.7.2. EAE as a model of MS 
Experimental autoimmune encephalomyelitis (EAE) is an animal model of 
autoimmune CNS inflammation which shares many histopathological similarities 
with MS. The origins of the EAE model date back to 1885 when Louis Pasteur 
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developed a vaccine against rabies which consisted of mulsions of pre-dried spinal 
cords of rabbits infected with the virus (Baxter, 2007). Reported cases of paralysis 
led to more thorough investigations which identified cellular infiltrates in the brain 
and demyelination, both characteristic of encephalomyelitis (Baxter, 2007). Since 
then, the model has been replicated in a variety of animal species and improved to 
include one injection of CNS homogenate or a myelin component in a complete 




EAE can be induced in susceptible mouse strains by immunization with the whole 
protein or encephalitogenic peptides from the CNS-derived MBP, MOG or PLP 
(Zamvil et al., 1986, Mendel et al., 1995, Greer et al., 1992). The disease can be also 
transferred by CD4+ T cells isolated from immunised wild-type (WT) mice or by in 
vitro activated TCR transgenic T cells injected into naïve WT hosts which supports 
the fact that EAE is a CD4+ T cell-driven disease (Zamvil et al., 1985, Stromnes and 
Goverman, 2006).  
 
The importance of CD4+ T cells in initiating and mediating EAE was also confirmed 
by cell depletion experiments in which monoclonal antibody directed against CD4+ T 
cell marker prevented and reversed EAE when given to paralysed mice (Waldor et 
al., 1985, Abdul-Majid et al., 2003). The role of CD8+ T cells in driving EAE 
pathology is somewhat controversial. Some studies demonstrated that CD8+ T cell 
depletion does not affect the disease (Abdul-Majid et al., 2003) and CD8+ T cells 
themselves are not able to transfer disease in a MOG-driven EAE model (Leech et 
al., 2011). Others have shown that CD8+ T cells have pathogenic potential and can 
induce EAE in both MOG- and MBP-driven models (Huseby t al., 2001, Sun et al., 
2001). As antibodies against MBP and MOG can be detct d in EAE and have been 
shown to contribute to disease pathology (Iglesias et al., 2001), B cells were also 
implicated in the disease initiation. B cell-depleted mice were found to have a similar 
time of EAE onset and overall disease severity as WT mice, however their recovery 
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time was prolonged (Wolf et al., 1996). This suggested that whereas B cells do not 
have a role in the activation of pathogenic T cells, they might contribute to the 
disease regulation. In support of this, B cells have been later demonstrated to 
contribute to EAE recovery via IL-10 production (Fillatreau et al., 2002).   
 
In order to traffic into the CNS and initiate inflammation, CD4+ T cells have to be 
first activated in the periphery by APC (Goverman, 2009). In EAE, CD4+ T cells are 
either activated by antigen in CFA in lymph nodes draining the site of immunization 
(Furtado et al., 2008) or they are injected intravenously after being activated in vitro. 
Once CD4+ T cells enter the CNS, they are re-activated by CNS-resident 
macrophages and DC and start producing pro-inflammatory cytokines (Greter et al., 
2005). These activate CNS-resident microglia (Ponomarev et al., 2005), and recruit 
more immune cells into the CNS such as peripheral macrophages which have been 
shown to be important for initiating inflammation iEAE (Tran et al., 1998). 
Activated microglia upregulate MHC class II expression and co-stimulatory 
molecules and become competent APC (Ponomarev et al., 2005). They also start 
producing pro-inflammatory cytokines such as IL-1, IL-6, TNF-α (Bauer et al., 1993, 
Renno et al., 1995), reactive oxygen species and nitric oxide synthase (Ruuls et al., 
1995, Tran et al., 1997) contributing to further disruption of BBB and cell 
recruitment into the CNS (Prendergast and Anderton, 2009). Pro-inflammatory 
mediators produced by activated T cells, macrophages and microglia lead to 
demyelination and axonal death (Benveniste, 1997, Goverman, 2009).  
 
It is still unclear how CD4+ T cells activated in the periphery gain entry into the 
CNS. Several routes of entry and chemokine receptors and adhesion molecules that 
facilitate this process have been implicated (Prendergast and Anderton, 2009). 
Monoclonal antibody to α4β1-integrin, which mediates attachment and rolling of 
activated T cells and macrophages to the inflamed brain epithelium, was found to 
inhibit EAE (Yednock et al., 1992). This has led to successful translation into 
therapy as an effective drug natalizumab (Rice et al., 2005). A chemokine receptor 
CCR6 has been found to be expressed by a subset of pathogenic Th17 cells and 
shown to facilitate their entry into the CNS via choroid plexus (Reboldi et al., 2009). 
                                                                                                 INTRODUCTION 
 45
This, however, was questioned by other studies showing that CCR6-deficient mice 
develop more severe EAE than WT mice (Elhofy et al., 2009, Villares et al., 2009). 
A chemokine receptor CXCR3 was reported to be over-exp essed in CSF of MS 
patients (Sorensen et al., 1999), and it is known to be preferentially expressed by Th1 
cells. However, its role in T cell recruitment into the CNS has been left unclear after 
demonstration that its blockade can inhibit active model of EAE, but not a passive 
model (Sporici and Issekutz, 2010).  
 
CD4+ T cells driving EAE were originally considered to be Th1 cells (Ando et al., 
1989, Bright et al., 1998b). IL-12 mediating Th1 differentiation was found to be 
expressed in the CNS and lymphoid tissues of mice wth EAE (Bright et al., 1998b), 
and inhibition of IL-12 signalling suppressed EAE (Leonard et al., 1996, Bright et 
al., 1998a). However, IFN-γ deficient mice hypothesised to be resistant to EAE 
displayed a severe form of disease (Ferber et al., 1996). These conflicting results 
were cleared up by the discovery of IL-23, a heterodimeric cytokine which shares a 
p40 subunit with IL-12 (Oppmann et al., 2000). Cua at al. generated specific IL-12-
deficient (p35-/-) and IL-23-deficient (p19-/-) mice for comparison with p40-/- mice 
lacking both IL-12 and IL-23 (Cua et al., 2003). It was the p19-/- mice that were 
found to be resistant to EAE, and not p35-/- mice, highlighting the importance of IL-
23 in mediating EAE (Cua et al., 2003). Soon after, IL-23 was demonstrated to drive 
differentiation of a new Th cell subset, Th17 (Langrish et al., 2005), pointing out the 
importance of these cells in driving EAE. Since then, however, conflicting evidence 
as to whether Th17 cells are able to initiate CNS inflammation has been reported 
(Komiyama et al., 2006, O'Connor et al., 2008).   
 
Currently it is thought that both Th1 and Th17 cells are important in mediating EAE 
and more recently an attention has been drawn to a different pro-inflammatory 
cytokine, GM-CSF, produced by both Th1 and Th17 cells (El-Behi et al., 2011), as it 
was found to be essential for the EAE induction (Codarri et al., 2011).  
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1.7.2.2. TCR transgenic models of EAE 
The use of TCR transgenic mice enables tracing and studying myelin-reactive T cells 
as their frequency in WT mice is very low. These have been generated by a 
combination of Vα and Vβ genes that were found in encephalitogenic T cell clones 
made from T cells isolated from mice immunised with a particular CNS autoantigen. 
Tg4 TCR transgenic mice have CD4+ T cells that specifically recognize the Ac1-9 
peptide of MBP (Liu et al., 1995), CD4+ T cells from 2D2 TCR transgenic mice 
recognize the 35-55 peptide of MOG protein (Bettelli et al., 2003) and CD4+ T cells 
from 5B6 TCR transgenic mice recognize peptide 139-51 of PLP protein (Waldner 
et al., 2000).  
 
EAE can be induced as an ‘active’ EAE’ or a ‘passive transfer’ EAE. Active EAE is 
induced in susceptible mouse strains upon immunisation with CNS autoantigen, 
either a whole protein or an encephalitogenic peptid , in CFA. The susceptible 
strains for MBP include B10.PL or PL/J mice (both H-2u haplotype), for MOG 
C57BL/6 mice (H-2b haplotype) and for PLP SJL (H-2s haplotype). In active EAE 
traceable naïve CD4+ T cells isolated from TCR transgenic mice can also be injected 
to study pathogenic T cells (O'Connor et al., 2010). Passive EAE uses either Th1 
polarised MOG35-55-reactive cells isolated from MOG-immunised mice or in vitro 
stimulated and polarised MBP-reactive CD4+ T cells isolated from Tg4 mice 
(O'Connor et al., 2007, O'Connor et al., 2010). 
 
There are also different models of EAE characterised by differences in clinical 
disease curves and these include monophasic (self-resolving) EAE, chronic 
relapsing-remitting EAE and spontaneous EAE, all recapitulating different aspects of 
MS. These models of EAE depend on the type of CNS autoantigen and the strain of 
mouse that is used. In this thesis a monophasic EAEis studied, which is induced in 
C57BL/6 mice by immunisation with MOG35-55-peptide.  
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1.7.2.3. Regulation of EAE by Treg 
Regulatory T cells were demonstrated to be capable of actively regulating CNS 
inflammation in EAE. One of the first reports used polyclonal CD4+ CD25+ T cells 
and showed that they suppressed both active and passive models of EAE (Kohm et 
al., 2002). Interestingly, the initial priming and activation of pathogenic T cells in 
draining lymph nodes were unaffected by Treg, however the numbers of IL-2 
secreting effector T cells were reduced and the T cll response was skewed towards 
Th2 (Kohm et al., 2002). Depletion of CD25+ cells prior to EAE induction was 
demonstrated to significantly exacerbate the disease (Zhang et al., 2004). Moreover, 
IL-10-deficient CD4+ CD25+ T cells were less efficient at suppressing EAE which 
suggested a natural role for Treg-derived IL-10 in co trolling the CNS inflammation 
(Zhang et al., 2004).  
 
Treg were also shown to mediate natural recovery in a monophasic MOG35-55-driven 
EAE model (McGeachy et al., 2005). The recovery was as ociated with an 
accumulation of IL-10-secreting Foxp3+ Treg in the CNS which constituted 
approximately one third of total CD4+ T cells at that time-point. Depletion of CD25+ 
cells at the peak of EAE inhibited the recovery, and depletion after the recovery 
removed the natural resistance to EAE re-induction. Moreover, the transfer of a small 
number of highly activated CNS-derived Treg, and not p lyclonal Treg, partially 
suppressed EAE suggesting the importance of the activation status and antigen 
reactivity in Treg-mediated suppression (McGeachy et al., 2005). The accumulation 
of Treg within the CNS during EAE was later shown to be associated with rapid 
proliferation of Treg driven by the inflamed CNS itself (O'Connor et al., 2007) and 
not with de novo induction of Foxp3+ cells (Korn et al., 2007). The CNS-derived 
Treg were reported to be enriched for myelin-reactive Treg (O'Connor et al., 2007, 
Korn et al., 2007), and were found to suppress IFN-γ production by CNS-derived 
effector T cells in vitro, but not IL-17 secretion (O'Connor et al., 2007). High levels 
of IL-6 and TNF-α in the inflamed CNS were suggested to adversely affect Treg-
mediated suppression (Korn et al., 2007).   
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1.7.2.4. Therapeutic transfer of Treg 
In the light of the potential of Treg to inhibit EA, further investigations have been 
undertaken to determine the exact mechanism of Treg-m diated suppression when 
given as a prophylactic measure but also to explore the therapeutic application in an 
on-going disease. Naïve and in vitro expanded MBP-reactive, but not polyclonal, 
nTreg were demonstrated to suppress MBP-induced EAEand moderately improve 
PLP-induced EAE when given prior to EAE induction (Stephens et al., 2009). 
Moreover, they were able to ameliorate disease in a chronic model of EAE when 
given after disease onset. Importantly, a stable expression of Foxp3 was key to 
efficient suppression and it was only maintained by CD62Lhigh Treg reflecting 
superior potential of this Treg subset in suppressing pathogenic T cells. Another 
study has demonstrated that nTreg can inhibit EAE mediated by different 
autoantigens if they are first activated by their cognate antigen (Yu et al., 2005).  
 
As nTreg are present at a relatively low frequency in the periphery and obtaining 
sufficient numbers of antigen-reactive cells has proved difficult, attention has been 
drawn to in vitro induced Treg (iTreg) which provide an easy means of generating 
robust numbers of antigen-reactive cells. Zhang at al. have demonstrated that PLP-
reactive iTreg expand in vivo upon antigen exposure and efficiently suppress PLP-
driven EAE when transferred before disease induction (Zhang et al., 2010). They 
have also shown that iTreg can only suppress EAE driven by the same peptide as 
their cognate antigen and hence are incapable of performing bystander suppression. 
Opposing results were found by a different group who demonstrated that polyclonal 
iTreg can efficiently suppress MOG-driven EAE when given prior to disease 
induction and ameliorate its severity when given after priming but before the onset of 
clinical sings of disease (Selvaraj and Geiger, 2008). IL-10 secretion and ability to 
induce ‘infectious tolerance’ were among suggested m chanisms of iTreg-mediated 
suppression (Selvaraj and Geiger, 2008).   
 
To-date experimental results provide conflicting evid nce as to how important is 
antigen reactivity in both nTreg and iTreg-mediated suppression of EAE. The 
mechanisms involved are equally unclear, however an important emerging fact is 
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that Treg subsets seem to differ in their efficacy to suppress T cell responses and this 
may have important implications in their potential use in therapy.   
 
1.8. Regulatory CD4 + T cells in allergy 
Harmful immune responses directed against self-tissue  occur not only in 
autoimmune diseases but also in allergic responses to otherwise innocuous antigens. 
For an allergic reaction to occur, the first encounter with a foreign antigen must lead 
to the production of IgE antibody that sensitizes immune cells such as mast cells, and 
then upon every subsequent exposure to the same antigen, an immune reaction 
follows. Normally associated with protective immunity to parasites, IgE responses to 
harmless environmental antigens lead to allergies such as allergic rhinitis, food 
allergies or asthma. In this thesis asthma, which is a chronic inflammatory disease of 
the airways, will be discussed in more detail.  
 
1.8.1. Asthma 
Asthma is a complex chronic inflammatory disease of the conducting airways that 
develops in response to harmless environmental antigens, called allergens. It is one 
of the most prevalent chronic conditions in Western countries affecting 1 in 7 
children and 1 in 12 adults, and frequently occurs concurrently with other allergies 
(Holgate et al., 2009). Although the antigens causing asthma are usually easily 
identifiable, the underlying pathology seems to be multifactorial and is still unclear.  
 
1.8.1.1. Symptoms and underlying causes of asthma 
Allergic asthma is characterised by reversible obstruction of airways and airway 
hyperresponsiveness (AHR) leading to symptoms such as wheeze, cough, shortness 
of breath and chest tightness. The allergic reaction can be divided into two phases 
with the first one occurring within minutes of encountering an allergen and resulting 
in bronchospasm which includes mucosal oedema and airway narrowing (Wills-
Karp, 1999). The second phase occurs within hours of exposure and is associated 
with inflammation, persistent airway obstruction and AHR.  
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In terms of asthma etiology, there is evidence of in utero influences and early life 
events that confer a risk of developing asthma later in life (Warner, 2004). 
Suboptimal foetal growth, maternal micronutrient defici ncies (such as retinoic acid) 
and type of diet, maternal smoking and maternal atopy are all among factors 
associated with an impaired infant lung function and later development of asthma 
(Cardoso et al., 1995, Warner, 2004). There is also uggested inverse correlation 
between early exposure to microbes and a reduced risk of developing allergies 
including asthma (Holgate et al., 2009). Evidence impl es that at birth, an infant’s 
immune responses are skewed towards Th2 as these ar protective in pregnancy 
(Warner, 2004) and an early encounter with endotoxins helps to even out the 
imbalance between Th1 and Th2 responses. This is the basis of the hygiene 
hypothesis suggesting that reduced exposure to microbes observed in industrialised 
countries is responsible for the skewed Th2 responses and hence increased incidence 
of allergies (Strachan, 1989, Holgate et al., 2009).     
 
Asthma has been also shown to have strong genetic links. In contrast to MS, the 
HLA-associations are less evident in asthma but HLA-DR, HLA-DQ, HLA-DP and 
HLA-G were suggested by some studies to be among the susceptibility haplotypes 
(Nicolae et al., 2005, Shiina et al., 2004). The genes implicated in asthma 
pathogenesis can be broadly subdivided into four categories (Holloway et al., 2010) 
with the first one representing genes directly modulating the responses to 
environmental exposures such as TLRs which are expressed on innate immune cells 
and detect microbes (Yang et al., 2006). The second group comprises genes 
implicated in the maintenance of the epithelial integrity at the mucosal surfaces such 
as flg encoding filagrin (Rodriguez et al., 2009). The third group is mainly associated 
with the genes that regulate immune cell responses primarily Th1 and Th2 
differentiation/function such as gata3, stat6, il13, il4R and tbx21 (Holloway et al., 
2010). The last group features the genes implicated in the responses of tissue to 
chronic inflammation such as airway remodelling andexamples include a disintegrin 
and metalloproteinase (adam3) and pde4d.   
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1.8.1.2. Immunopathology of asthma 
A combination of genetic and environmental factors is believed to be the reason why 
some people react to innocuous inhaled antigens whereas others remain tolerant to 
them. Several hundreds of allergens have been identified from diverse sources such 
as house dust mite (HDM) faeces, pollen and animal dander. Although some of them 
share structural and functional similarities, it is still unclear what constitutes an 
allergen (Traidl-Hoffmann et al., 2009). It has been r ported that some allergens, for 
example Der p1 (HDM), have an enzymatic activity which enables them to disturb 
the Th1/Th2 balance (Schulz et al., 1998) and to disrupt epithelial tight junctions 
(Wan et al., 1999). It is believed that the route of exposure, dose and function of an 
allergen are critical to the sensitization and vary with each individual (Traidl-
Hoffmann et al., 2009). The immune responses implicated in asthma pathology are 
summarised in Figure 1.5 at the end of this section.  
 
1.8.1.2.1. CD4+ T cells orchestrate inflammatory reaction 
Allergen sensitization occurs via immunoglobulin-E (IgE) production which has 
been closely linked to asthma severity (Burrows et al., 1989) and initial and sustained 
responses to allergen (Busse and Lemanske, 2001). For the IgE response to occur, an 
inhaled allergen is taken up by DC that line mucosal airway surfaces and presented 
to T cells and B cells in draining lymph nodes (Holt et al., 1990, Lambrecht and 
Hammad, 2009). The mechanism of DC activation is thoug t to involve an allergen 
itself as it was demonstrated that HDM allergens can activate TLR signalling and 
induce local release of cytokines that not only skew the immune response towards 
Th2 but also promote DC maturation and activation (Trompette et al., 2009, 
Hammad et al., 2009).  
 
CD4+ T cells are strongly implicated in the pathogenesis of asthma as the increased 
numbers of T cells have been consistently observed in bronchoalveolar lavage (BAL) 
fluids and bronchial biopsies from asthmatic patients (Gerblich et al., 1991, Azzawi 
et al., 1990). Distinct CD4+ T activation status and cytokine profile has been reported 
in BALF and bronchial biopsies of asthmatic patients versus peripheral blood and 
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this includes increased expression of CD25 and Th2-associated cytokines such as IL-
4, IL-5, IL-13 and GM-CSF (Walker et al., 1992, Robinson et al., 1992, Del Prete et 
al., 1993). A positive correlation has been made betwe n the levels of these 
cytokines and the levels of IgE and eosinophils in the lung tissue which strongly 
suggests their pathogenic role in asthma (Robinson et al., 1993, Wills-Karp, 1999). 
Recently, a Th17 cell subset was also implicated in the most severe, often 
neutrophilic, forms of asthma as several studies report d IL-17 expression in airway 
biopsies and sputum of asthmatic patients (Bullens t al., 2006, Al-Ramli et al., 
2009).  
 
Th2 cells are thought to play a critical role in orchestrating immune responses in 
asthma as the cytokines they produce not only promote Th2 differentiation and IgE 
synthesis but also have been shown to contribute to ac ivation of mast cells, and 
recruitment and activation of neutrophils and basophils (Wills-Karp, 1999). Mast 
cells, eosinophils and basophils are large secretory cells that upon activation release 
granules containing toxic and pro-inflammatory molecul s such as histamine, 
cytokines and cationic proteins (O'Donnell et al., 1983, Welle, 1997). As mentioned 
in section 1.2.1, the main role of these cells is defence against extracellular parasites 
but in asthma they have been reported to enhance activation of other immune cells, 
cause microvascular leakage, increase mucus producti n, bronchoconstriction and 





































Schematic diagram of immune responses thought to contribute to asthma pathology.
(1) Upon first allergen exposure, DC lining up mucosal surfaces in the lung take up
antigen and (2) migrate to draining lymph nodes to present it to T cells. (3) Activated
CD4+ T cells differentiate into Th2 cells and produce (4) IL-4 which induces an antibody
class switch to IgE. (5) IgE binds to andsensitizes mast cells. (6) Uponevery subsequent
allergen exposure, allergen binds to IgE and induces mast cell degranulation and release
of (7) pro-inflammatory mediators such proteases, growth factors and cytokines. (8) In
addition, memory Th2 cells, generated during the first allergen exposure, become re-
activated and produce pro-inflammatory cytokines such as IL-4, IL-5 and IL-13 leading
to (9) goblet cell hyperplasia, recruitment of eosinophils from thebone marrow, damage
to airway epithelium and microvascular leakage. This results in mucus production,
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1.8.1.2.2. Breakdown in regulatory mechanisms 
There is strong experimental evidence for the induction of Treg populations with low 
dose inhaled antigen in the absence of adjuvant (Akbari et al., 2002, Ostroukhova et 
al., 2004) which suggests an important role for in vivo allergen-induced Treg in 
natural protection against sensitization in addition t  thymically-derived nTreg. 
Reduced numbers and impaired function of CD4+ CD25+ T cells as well as decreased 
Foxp3 expression have been reported specifically within the lung compared to the 
blood of asthmatic children (Hartl et al., 2007). A different study observed unaltered 
numbers of CD4+ CD25+ T cells but decreased Foxp3 expression in the periph al 
blood of adult asthmatic patients, however Treg functio  was not assessed (Provoost 
et al., 2009).  
 
An important mechanism of Treg-mediated suppression is the secretion of anti-
inflammatory IL-10, and levels of IL-10 production appear to be relevant to asthma 
pathology (O'Garra et al., 2008). Several studies have reported decreased IL-10 
levels in BAL fluid (John et al., 1998) and reduced numbers of IL-10+ T cells in the 
peripheral blood of asthmatic patients versus healty controls (Akdis et al., 2004).    
 
1.8.1.3. Current treatments 
Most current treatments of asthma rely on the long-term suppression of airway 
inflammation by corticosteroids or on the use of bronchodilators (van der Velden, 
1998). Corticosteroids are potent inhibitors of inflammation and they were shown to 
function by directly suppressing expression of genes encoding pro-inflammatory 
mediators such as IL-1β or GM-CSF and promoting expression of genes coding for 
anti-inflammatory mediators such as IL-10 (Mozo et al., 2004). Although the 
treatment with corticosteroids is effective and hasbeen shown to suppress bronchial 
inflammation and improve lung function (Booth et al., 1995), these drugs act in an 
antigen non-specific fashion, leaving the patient significantly immunocompromised 
and prone to opportunistic infections. Another type of treatment used in conjunction 
with corticosteroids includes short-acting β2-agonists such as salmeterol. β2-agonists 
act on β2-adrenergic receptor and induce smooth muscle relaxation resulting in 
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bronchodilatation (Woolcock et al., 1996). Leukotriene-receptor antagonists are also 
used and have been shown to control bronchoconstriction and airway inflammation 
(Fanta, 2009).  
 
Newer approaches in asthma therapy target IL-4, IL-5 and IgE. Soluble recombinant 
IL-4 receptor delivered in a nebulized form has been d monstrated by several studies 
to be a safe and effective treatment of moderate ashma without the use of 
corticosteroids (Borish et al., 2001). IL-5 blocking monoclonal antibody was shown 
to reduce the number of eosinophils in patients’ sputum but did not affect AHR 
(Leckie et al., 2000). Another blocking compound is a humanized monoclonal 
antibody (omalizumab) that forms complexes with free IgE and hence blocks IgE 
from binding to mast cells and basophils (Busse and Lemanske, 2001). It has been 
shown to effectively attenuate allergen-induced airw y obstruction and eosinophil 
accumulation in the airways and has been approved for use in adults and children 
(Fahy et al., 1997, Fanta, 2009).  
 
The fact that most of current asthma treatments targe  the immune system 
emphasizes the important role of inflammation in the disease pathogenesis. However 
antigen non-specific immunosuppression has proven to have many side effects and 
has a limited efficacy. That is why a large amount of work is currently going into 
investigation of allergen-specific immunotherapies and animal models of allergic 
airways inflammation (AAI) provide a very useful tool to verify their potential.   
 
1.8.2. Allergic airways inflammation as a model of asthma 
Allergic airways inflammation is an animal model of allergic asthma and can be 
induced in a variety of species such as guinea pigs, rat  and mice. Similarly to human 
asthma, AAI is characterized by infiltration of the lung with mast cells, lymphocytes 
and eosinophils, airway hyper-responsiveness and mucus production. The most 
widely used species are mice and as they do not develop asthma spontaneously, the 
disease is induced in them artificially. The allergens include the well-known human 
allergens such as HDM or animal dander but also chicken ovalbumin (OVA). There 
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are many different murine models of allergic asthma and each of them represents 
certain morphological and functional features of the uman disease (Nials and 
Uddin, 2008).  
.  
1.8.2.1. Immunopathology 
AAI can be induced in mice by sensitization with an antigen in adjuvant consisting 
of aluminium hydroxide and magnesium hydroxide (alum) in order to induce IgE 
synthesis and Th2 memory response and subsequent airway challenges with the 
antigen (Leech et al., 2007). The disease can also be transferred by activated TCR 
transgenic antigen-specific T cells polarised towards Th2 phenotype in vitro or by 
CD4+ T cells isolated from antigen-sensitized animals into naïve recipients and 
subsequent antigen airway challenges (Cohn et al., 1997, Hogan et al., 1998) 
supporting the hypothesis that CD4+ T cells drive and orchestrate the inflammation 
in AAI.  
 
The direct evidence of the causal role for CD4+ T cells in driving the inflammation in 
AAI came from the cell depletion studies which showed that depleting CD4+ T cells 
with a monoclonal antibody prior to airway challengs with the antigen suppressed 
lung eosinophilia and AHR (Gavett et al., 1994), and ttenuated subepithelial fibrosis 
and mucus cell metaplasia (Foster et al., 2002). Conversely, the depletion of CD8+ T 
cells did not have an effect on AAI (Gonzalo et al., 1996). More recently, it was 
demonstrated that depletion of CD4+ T cells during chronic AAI results in a reduced 
airway inflammation but does not affect progressive airway remodelling (Doherty et 
al., 2009). This observation highlights the differenc s among variable AAI models 
and suggests that CD4+ T cells could have different roles at different stages of the 
disease.   
 
CD4+ T cells driving AAI are thought to be Th2 cells. Abolishing the synthesis of 
Th2 signature cytokines, IL-4 and IL-5, either via monoclonal antibody approach or 
genetic manipulation, has shown that these cytokines play a major role in disease 
pathogenesis (Wills-Karp, 1999). IL-5 was shown to be important for differentiation, 
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migration and activation of eosinophils (Weller, 199 , Ohnishi et al., 1993) and its 
blockade prior to antigen airway challenge in OVA-induced model of AAI resulted 
in a reduced eosinophil mobilization and hence decreased numbers of eosinophils in 
the lung and BALF (Hogan et al., 1997). Targeting IL-4 during sensitization in AAI 
revealed that it is critical for IgE and IL-5 synthesis, and for the development of lung 
eosinophilia (Coyle et al., 1995). The importance of IL-4 in AAI is further 
highlighted by the discoveries that it regulates Th2 cell differentiation (Zheng and 
Flavell, 1997) and induces antibody class switch to IgE during B cell activation 
(Kashiwada et al., 2010). Another Th2 signature cytokine, IL-13, was shown to be 
implicated in goblet cell development, mucus cell metaplasia and AHR (Yang et al., 
2001). Finally, targeting the master regulator of Th2 lineage, GATA-3, was found to 
significantly inhibit the development of AAI (Zhang et al., 1999).   
 
What causes an aberrant Th2 cell activation and expansion is still unclear. As 
discussed in section 1.2.3.5 the cytokines produced by APC during T cell activation 
dictate the T cell differentiation pathway. There aseveral types of APC present in 
the airways and these include alveolar macrophages nd DC (Wills-Karp, 1999). A 
subset of intraepithelial DC lining the mucosal surfaces in the lung has been shown 
to efficiently take up an inhaled allergen, migrate to the draining mediastinal lymph 
nodes, present it to T cells and induce Th2 phenotype (Hammad et al., 2010). 
Interestingly, previously implicated in this process basophils (Sokol et al., 2009) 
were shown to be important in amplifying T cell responses but redundant in initiating 
them (Hammad et al., 2010). DC implicated in the induction of Th2 responses in 
AAI were termed ‘inflammatory’ DC and their influx into the airways during 
inflammation has been reported, however the driving/activating signal is unclear 
(Lambrecht and Hammad, 2009). One of the cytokines thought to be involved in DC 
activation in AAI is IL-33 (Besnard et al., 2011).  
 
Primary antigen exposure leads to the generation of Th2 cells and synthesis of IgE 
which binds to high affinity FcεR1 receptors on the surface of mast cells in the lung
(Wills-Karp, 1999). Upon every subsequent antigen exposure, antigen binds to pre-
bound IgE on mast cells leading to FcεR1 receptors cross-linking and mast cell 
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degranulation. The mediators released by mast cells include histamine, 
prostaglandins, serine proteases, chemokines and cytokines such as TNF-α and IL-5 
which contribute to the recruitment of eosinophils from the bone marrow, increased 
vascular permeability and mucus production (Stone et al., 2010). Th2 cells have been 
shown to be re-stimulated in the airways by DC and basophils (Lambrecht and 
Hammad, 2009) to produce Th2-associated cytokines ad chemokines promoting an 
influx and activation of eosinophils and other immune cells. Activated eosinophils 
produce a range of cytotoxic molecules, cytokines and growth factors which damage 
airway epithelium and can induce AHR and influence airway remodelling in chronic 
models of AAI (Hogan et al., 1997, Bochner and Gleich, 2010). 
  
Recently, a Th2-independent mechanism of asthma pathology has been discovered. 
In addition to Th2 cells being an important source of IL-13, a novel type of innate 
lymphoid cell identified by the McKenzie group was found to produce high levels of 
IL-13 as well (Neill et al., 2010). Due to their ability to produce IL-13 and ‘nu’ being 
the 13th letter of the Greek alphabet, these innate cells were termed nuocytes and 
were shown to be critical in mediating type-2 responses responsible for worm 
expulsion in helminth infection (Neill et al., 2010). Soon after, nuocytes have been 
demonstrated to contribute to AHR in a murine model of virus-induced asthma 
(Chang et al., 2011) and in a murine model of OVA-induced AAI (Barlow et al., 
2012).  
 
1.8.2.2. Models of AAI 
As mentioned already there is a wide variety of antige s used as allergens to induce 
AAI and the most common include antigens derived from HDM extracts and OVA. 
The model of OVA-induced AAI is particularly useful as TCR transgenic mice for 
OVA-derived peptide OVA323-339 are available which enable tracking and 
investigating allergen-specific T cells. Those are OT-II mice (haplotype H-2b) 
(Barnden et al., 1998) on C57BL/6 background or DO11.10 mice (haplotype H-2d) 
(Murphy et al., 1990) on BALB/c background.  
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AAI is most commonly induced by intraperitoneal injection of an antigen in alum 
which marks the sensitization phase and subsequent airway challenge with the 
antigen which is given either intranasally or intratracheally (Nials and Uddin, 2008). 
Alum was originally thought to act as an antigen depot enabling the antigen to be 
slowly released over long periods of time (Marrack et al., 2009). However, it is now 
known that alum exerts variety of immunomodulatory functions, for example it 
activates and recruits innate immune cells such as DC to the site of injection 
(Marrack et al., 2009). AAI can also be induced by an adoptive transfer of activated 
TCR transgenic antigen-specific T cells polarised towards Th2 phenotype in vitro or 
by CD4+ T cells isolated from antigen-sensitized animals into naïve recipients 
followed by antigen airway challenges (Cohn et al., 1997, Hogan et al., 1998).  
 
Mouse models of AAI can also be divided into acute and chronic, each representing 
certain morphological and functional features of the uman disease (Nials and 
Uddin, 2008). Acute AAI models are usually self-resolving and are useful in 
investigating the pathogenesis of the inflammatory responses in asthma. They 
reproduce many key features of allergic asthma such as elevated levels of IgE, 
airway inflammation, mucus cell metaplasia and AHR. However, in order to 
investigate the chronic features of asthma such as per istent AHR and airway 
remodelling, a number of chronic models of AAI were established and these are 
mostly based on long-term antigen exposure (Wegmann, 2008).     
 
1.8.2.3. Regulation of AAI by Treg 
One of the first studies implicating regulatory T cells in the control of Th2-driven 
lung inflammation in AAI showed that low-dose antigen exposure in the absence of 
adjuvant induces high IL-10 expression by previously transferred OT-II CD4+ cells 
into naïve recipients (Akbari et al., 2002). Adoptive transfer of these ‘tolerogenic’ 
IL-10+ T cells into OVA-sensitized mice significantly inhibited antigen-induced IgE 
levels, AHR and eosinophilia in the BALF. This was followed by the report from 
Jaffar et al. who demonstrated that depleting Th2-polarised OT-II cells of CD4+ 
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CD25+ T cell population prior to transfer into naïve hosts and airway challenges with 
OVA significantly exacerbated the disease (Jaffar et al., 2004).  
 
The direct evidence that Treg control AAI was given by Kearley et al. who showed 
that the transfer of OVA-reactive CD4+ CD25+ cells prior to antigen airway 
challenge reduced AHR, lung eosinophilia and decreased expression of Th2-
associated IL-5 and IL-13 in the lung (Kearley et al., 2005). Moreover, this 
protective effect was reversed by blockade of IL-10, however IL-10-deficient Treg 
were still capable of improving AAI by enhancing IL-10 production from recipient 
CD4+ T cells (Kearley et al., 2005). This suggested that Treg could exert their 
suppressive function via ‘infectious tolerance’ mechanisms in the context of not only 
Th1- but also Th2-mediated inflammation. A different study used a cell depletion 
approach and showed that anti-CD25-mediated Treg depletion results in exacerbated 
AAI and implied that Treg mediate their protective effects via suppression of DC 
activation (Lewkowich et al., 2005).  
 
A model of acute self-resolving AAI demonstrated that Foxp3+ Treg accumulate in 
the lung and draining mediastinal lymph nodes upon antigen exposure and are 
critical to the resolution of inflammation (Leech et al., 2007). The depletion of Treg 
using anti-CD25 before antigen airway challenge ledto the increased lung 
eosinophilia and enhanced allergic responses. On the other hand, an adoptive transfer 
of polyclonal CD4+ CD25+ Treg suppressed IgE levels, eosinophilia and levels of 
Th2-associated cytokines in the lung in an IL-10 independent manner (Leech et al., 
2007).   
 
Newer approaches of assessing Treg function involve the use of DEREG mice which 
express eGFP and diphtheria toxin receptor (DTR) under the foxp3 promoter (Lahl et 
al., 2007), and administration of diphtheria toxin (DTx) in this system enables 
selective depletion of Foxp3+ cells. Baru et al. have confirmed the significance of 
Treg function in early phases of AAI by selectively depleting Foxp3+ Treg during the 
sensitization phase and demonstrated that this leads to significantly exacerbated 
disease (Baru et al., 2010).  
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1.8.2.4. Therapeutic transfer of Treg 
As Treg have been shown to be capable of suppressing AAI, further work has been 
undertaken to determine the potential of in vitro expanded nTreg and in vitro 
generated iTreg in both prophylactic and therapeutic application. The transfer of 
TGF-β-converted polyclonal CD4+ CD25- T cells prior to sensitization and airway 
challenge with HDM antigen was shown to decrease inflammatory cell infiltration in 
the lung and reduce the levels of Th2 cytokines produced by splenocytes upon re-
stimulation in vitro (Chen et al., 2003). These promising results are further supported 
by the recent findings from Xu et al. who demonstrated that both in vitro expanded 
polyclonal nTreg and TGF-β induced polyclonal iTreg can improve AAI when 
transferred prior to antigen challenge (Xu et al., 2012). In that study increased 
percentage of total Foxp3+ cells and decreased percentage of DC in mediastinal 
lymph nodes were observed suggesting a possible mechanism of suppression. 
Moreover, polyclonal nTreg and iTreg transfer after he first antigen airway 
challenge decreased AAI severity indicating that Treg could be effective at the very 
early stages of the disease (Xu et al., 2012).  
 
Efficacy of Treg-mediated suppression in already developed AAI was shown in mice 
with an already established AHR that were the treated with polyclonal CD25+ and 
CD25- T cells isolated from the spleen and lung of naïve mice (McGee and Agrawal, 
2009). Both Treg subsets from the spleen and lung were shown to reverse AHR, 
decrease lung infiltration, mucus production and eosinophilia in the BALF, reduce 
the levels of Th2 cytokines and increase IFN-γ in the BALF. However, an inability to 
track Treg in that study did not allow for more detailed analysis of their function and 
phenotype.  
 
To date, there is no experimental evidence on the importance of the antigen reactivity 
in both nTreg- and iTreg-mediated suppression of lung inflammation in AAI which 
may have important implications in their potential use in therapy. Similarly, the 
stability of Treg suppressive phenotype in Th2-mediated inflammation in vivo and 
the inhibitory mechanisms involved are unclear, however, they seem to vary in 
different AAI models.   
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1.9. Treg in clinical trials 
Human nTreg similarly to their murine counterparts express CD4, CD25 and Foxp3. 
However, as activated T cells were shown to transiently upregulate Foxp3 
expression, other markers are used to distinguish them from activated conventional T 
cells such as low/absent expression of IL-7 receptor (CD127) (Liu et al., 2006, 
Seddiki et al., 2006). Isolation of live highly pure human regulatory T cells from the 
peripheral blood is still very problematic and there is a continuous search for better 
more specific cell surface markers that would reduc the risk of transferring either 
unstable or contaminated Treg populations (Edinger and Hoffmann, 2011). Protocols 
for efficient in vitro expansion of human nTreg have been established (Hoffmann et 
al., 2004, Hippen et al., 2011), however variable loss of Foxp3 expression is being 
reported (Hoffmann et al., 2009, Putnam et al., 2009). The use of pharmacological 
agents such as rapamycin which is thought to selectively promote expansion of 
Foxp3+ cells has been suggested to improve the yield of more pure Treg populations 
(Strauss et al., 2007). Additionally, sorting for CD45RA+ Treg prior to expansion has 
been shown to generate more stable Foxp3+ Treg population (Miyara et al., 2009).  
 
Most clinical trials using Treg have been conducted in graft versus host disease 
(GvHD). In one of the first small phase I clinical trials, the stem cell transplantation 
(SCT) group from the University of Perugia, Italy, used freshly isolated donor CD4+ 
CD25+ Treg and infused them into 28 patients receiving a haploidentical graft 
without an additional immunosuppressive treatment (Di Ianni et al., 2011). The study 
found that 26 out of 28 patients remained free of clinically relevant GvHD at the 
median follow-up time of 11.2 months and 2 other patients developed grade II acute 
GvHD. A different phase 1 clinical trial led by Blaz r and colleagues involved in
vitro expanded CD4+ CD25+ T cells isolated from partially HLA-matched third-party 
umbilical cord blood (Brunstein et al., 2011). Transfused Treg were detectable in all 
23 GvHD patients, who co-received immunosuppression at that time, two weeks 
after the cell transfer and a reduced incidence of grade II to grade IV acute GvHD 
was observed.  
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In a more relevant setting to autoimmune disease, the results of the phase I/II clinical 
trial with antigen-specific Treg in Crohn’s disease have been recently presented 
(MedicalNewsToday, 2011). In that open-label and uncontrolled trial the drug 
OvaSave® by TxCell SA was given as a single dose to 20 patients with severe 
Crohn’s disease. 38% of patients were reported to go into remission 5 weeks after the 
treatment. The drug has been now moved into a controlled phase II study. Another, 
much larger phase 1 clinical trial in type 1 diabetes (T1D) led by Bluestone and 
colleagues at the University of California is currently recruiting patients to 
investigate the therapeutic potential of in vitro expanded autologous CD4+ CD25+ 
CD127low/- polyclonal Treg (ClinicalTrials.gov, 2012).  
 
The initial results from phase I clinical trials  indicate that Treg therapy has a 
potential to be safe and effective, however thorough investigation into Treg 
phenotype, function and stability in different disea  settings is required. The 
question of paramount importance is whether Treg have to be antigen-reactive to 
exert their immunomodulatory functions in the most efficacious way. Moreover, 
optimisation of the techniques that will enable pure, efficient and cost-effective 
generation of Treg is critical to the advancement of cellular therapies (Edinger and 
Hoffmann, 2011, Wang et al., 2011).  
 
1.10. Specialized subsets of Treg - do Treg adjust to the 
type of inflammation? 
It is well established that conventional CD4+ T cells upon stimulation and cytokine 
signalling received from the DC follow different differentiation pathways which are 
optimized to fight against different types of pathogens. It is also known that CD4+ T 
cells responses and the inflammation they orchestrat  are controlled by regulatory T 
cells to make sure there is no excessive damage to the host tissues. The question 
which follows these two important features of the immune response and may have 
important implications in immunotherapy is whether Treg themselves can specialize 
to better control different types of inflammation.      
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Treg can express tissue-specific homing receptors and chemokine receptors which 
control their trafficking and localization to different organs, and this differential 
migration capacity was suggested to be critical for their in vivo suppressive functions 
(D'Ambrosio et al., 2001, Campbell and Koch, 2011). Thymically-derived Treg 
display a naïve-like phenotype, lacking expression of adhesion molecules or 
chemokine receptors, whereas activation of Treg in sk -draining lymph nodes (LN) 
and gut allows acquisition of a ‘memory-like’ phenotype (Siewert et al., 2007). 
These activated Treg can be distinguished through the expression of α4β7 integrin 
(gut-associated mesenteric LN) versus P- and E-selectin ligands (skin-draining LN) 
that control migration to the appropriate tissue in vivo. To date, multiple studies have 
reported on the differential expression of receptors and ligands by Treg depending on 
the environment they were activated in (Kohm et al., 2002, Piccio et al., 2002, 
Muller et al., 2007). 
 
More recently, transcription factors previously thought to be expressed specifically in 
effector CD4+ T cells were identified in Treg as well. The expression of T-bet, which 
is the master regulator driving the Th1 phenotype, was detected in Treg in a model of 
Th1-mediated infection, and was found to be critical for Treg migration to the site of 
infection, homeostasis and function (Koch et al., 2009). Similarly, Treg lacking 
interferon regulatory factor-4 (IRF-4), a transcription factor essential for Th2 effector 
differentiation (Lohoff et al., 2002), were reported to fail to control Th2 responses 
and lead to autoimmune lymphoproliferative disease (Zheng et al., 2009). Both of 
these studies suggested that Treg utilize components of the transcriptional machinery 
responsible for driving particular type of the CD4+ T cell lineage and use them in 
their favour to regulate the corresponding type of CD4+ T cells during inflammatory 
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1.11. Hypothesis and aims 
The central hypothesis of this project is that  Treg acquire a different phenotype in 
Th1- versus Th2-mediated inflammatory diseases in-line with their effector CD4+ T 
cell (Teff) counterparts and can therefore optimally specialize to control such Teff 
responses.  
 
The aims of this project were to:  
1) Determine whether Treg specialization occurs in vivo by comparing CNS-
derived Treg in Th1/Th17-mediated EAE versus lung-derived Treg in a 
model of Th2-mediated AAI. 
2) Test if Treg can be polarised in vitro and hence recapitulate in vivo 
observations, and establish what conditions are most optimal. 
3) Assess whether antigen responsiveness or specialized ph notype are the key 
factors in the efficacy of Treg function in EAE and AAI. 
4) Establish and characterize a model of MOG-induced AAI which will allow 
testing aim 3. 
5) Investigate the mechanism of Treg-mediated suppression in EAE and AAI. 
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2 Materials and Methods 
 
2.1. Mice 
C57BL/6 (H-2b background) mice were either purchased from Harlan L boratories 
Ltd (Shardlow, UK) or were bred under specific pathogen-free conditions at the 
University of Edinburgh. 2D2 (CD90.1, CD90.2 or CD90.1/CD90.2) (Bettelli et al., 
2003), MOG-/- (CD45.1) (Delarasse et al., 2003), Foxp3-GFP (CD90.2) (Fontenot et 
al., 2005), OT-II (CD45.1) (Barnden et al., 1998) and Foxp3.LuciDTR-4 (CD90.1, 
CD90.2) (Suffner et al., 2010) mice (all on H-2b background) were bred under 
specific pathogen-free conditions at the University of Edinburgh. 2D2 mice are 
transgenic for a TCR reactive to MOG35-55. OT-II mice are transgenic for a TCR 
reactive to OVA323-339. Foxp3.LuciDTR-4 mice express eGFP, diphtheria toxin 
receptor (DTR) and luciferase under the foxp3 promoter. 2D2xFoxp3.LuciDTR4 
mice were generated at the University of Edinburgh by crossing 2D2 mice with 
Foxp3.LuciDTR4 mice. IL-4-GFP reporter mice were kindly provided by Dr M. 
Taylor. All mice used were female aged 6-12 weeks of age, unless otherwise 
specified. All experiments had University of Edinburgh ethical approval and were 
performed under UK legislation.  
 
2.2. Peptides and proteins 
Myelin oligodendrocyte glycoprotein peptide 35-55 of MOG protein (MOG35-55; 
MEVGWYRSPFSRVVHLYRNNGK) was synthesised by Cambridge Research 
Biochemical (Cambridge, UK). Recombinant MOG (rMOG) was synthesised using 
an Escherichia coli expression system [ORIGAMI (DE3)] (Fillatreau et al., 2002) 
and was tested for the presence of LPS with E-toxate kit (Sigma-Aldrich, Poole, 
UK). Chromatographically purified chicken ovalbumin (OVA) was obtained from 
Worthington Biochemical Corporation (Lakewood, USA). OVA peptide 323-339 of 
OVA protein (OVA323-339; ISQAVHAAHAEINEAGR) was synthesized by PepLogic 
(Essex, UK). 
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2.3. Adjuvants 
Complete Freund’s adjuvant (CFA) containing 1 mg/ml heat-killed Mycobacterium 
Tuberculosis H37Ra (MTB) was purchased from Sigma-Aldrich. Imject Alum 
containing 40mg/ml of aluminium hydroxide and 40mg/l magnesium hydroxide 
was obtained from Pierce (Rockford, USA).  
 
2.4. General reagents 
2.4.1. Wash buffer 
RPMI 1640 medium containing 25mM Hepes (Gibco, Paisley, UK). 
 
2.4.2. RPMI-5% and RPMI-10% 
RPMI 1640 medium, supplemented with 2mM Glutamine (PAA Laboratories Ltd, 
Somerset, UK), 100U/ml Penicillin (PAA), 100µg/ml Streptomycin (PAA), 50µM 2-
mercaptoethanol (Gibco) and 5% or 10% heat-inactivated fetal calf serum (FCS, 
Labtech, East Sussex, UK).   
 
2.4.3. MACS buffer 
HANKS balanced salt solution (PAA) supplemented with 2% heat-inactivated FCS 
(Labtech, Ringmer, UK).  
 
2.4.4. FACS buffer 
Phosphate-buffered saline solution (PBS) supplemented with 2% heat-inactivated 
FCS (Labtech) and 0.1% sodium azide (Sigma). 
  
2.4.5. X-VIVO serum-free medium 
X-VIVO 15 serum-free medium (BioWhittaker, USA) supplemented with 2mM 
Glutamine (PAA) and 50µM 2-mercaptoethanol (Gibco).  
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2.5. Cell isolation, purification and sorting 
2.5.1. Isolation of cells from spleen and lymph nod es 
Single cell suspensions from spleen and lymph nodes (LN) were obtained by 
mashing through sterile gauze and re-suspending in wash buffer. Cells were then 
centrifuged at 350×g for 5 min and resuspended in fresh wash buffer.  All subsequent 
wash steps followed the same protocol. Splenic red blood cells (RBCs) were lysed at 
room temperature (RT) with RBC lysis buffer (Sigma) and washed once. Cells were 
counted using trypan blue (Sigma) exclusion.  
 
2.5.2. Isolation of cells from CNS 
Mice were sacrificed with CO2 asphyxiation and perfused through the eyes with 
10ml cold PBS. The brain was removed by dissection, and the spinal cord by 
intrathecal hydrostatic pressure. Tissues were cut into small pieces and further 
disrupted using a 1ml syringe prior to digestion with 2.5mg/ml collagenase (Lorne 
Laboratories, Reading, UK) and 1mg/ml deoxyribonuclease (Sigma) at 3:1 ratio for 
40 minutes at 37°C. Mononuclear cells were isolated from the interface of a 30:70% 
discontinuous Percoll gradient (GE Healthcare, Stockh lm, Sweden) by 
centrifugation at 850xg for 20 minutes without brake, and washed in RPMI. All wash 
steps were done at 300xg for 5 minutes. RBCs were lys d if needed in RBS lysis 
buffer. Cells were counted using trypan blue (Sigma) exclusion.  
 
2.5.3. Isolation of cells from lung 
Mice were sacrificed by intraperitoneal injection of pentobarbitone and perfused 
through the right ventricle with 15ml of cold PBS. In most experiments following 
perfusion and prior to fixation, the left lobe was tied off, removed and used for cell 
isolation. Lung tissue was finely chopped and digested in 0.23mg/ml collagenase 
(Type I-AS, Sigma-Aldrich) for 60 minutes at 37°C. Tissue was then disaggregated 
using rapid flushing through a 20G needle. Cell suspen ions were washed twice in 
PBS, lysed in RBC lysis buffer (Sigma-Aldrich) and passed through a 40µm cell 
strain strainer prior to counting using trypan blue (Sigma-Aldrich) exclusion. All 
wash steps were done at 300xg for 5 minutes.  
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2.5.4. Purification of CD4 + T cells 
Cells were isolated are described in 2.5.1 and incubated in 45µl of MACS buffer and 
5µl of anti-CD4 conjugated magnetic beads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) per 107 cells for 15 minutes at 4°C. Cells were washed in MACS buffer 
and resuspended at 2x108 cells/ml of MACS buffer. CD4+ cells were positively 
selected using an autoMACS Pro Separator or LS column and MidiMACS separator 
as per manufacturer’s instructions (Miltenyi Biotec). Purity of CD4+ T cells was 
routinely 95% ± 5%.   
 
2.5.5. Purification of CD4 + CD62L+ naïve cells by AutoMACS 
Pro Separator 
Cells were isolated as described in 2.5.1 and purified using CD4+ CD62L+ T cells 
isolation Kit II (Miltenyi Biotec) according to manufacturer’s instructions. Briefly, 
cells were incubated in 400µl of MACS buffer with 100µl of CD4+ T cells Biotin-
Antibody Cocktail II for 10 minutes at 4°C. All volumes are given per 108 cells. 
Without washing, a further 300µl of MACS buffer and 200µl of Anti-Biotin 
MicroBeads were added for 15 minutes. Cells were then washed in MACS buffer, 
resuspended at 2x108 cells/ml of MACS buffer and negatively selected using 
AutoMACS (Miltenyi Biotec). Following washing, cells were resuspended in 800µl 
of MACS buffer and 200µl of CD62L MicroBeads and incubated for 15 minutes at 
4°C. Cells were washed and positively selected using AutoMACS. Purity of CD4+ 
CD62L+ cells was routinely 90% ± 5%.    
 
2.5.6. Sorting of CD4 + T cell subsets by FACS 
CD4+ cells were purified as described in 2.5.4 and sorted by fluorescence-activated 
cell sorting (FACS) according to their GFP and/or cell surface marker expression. 
Post-sort purity was routinely 95% ± 5%. Cells were sorted using a Becton 
Dickinson (Franklin Lakes, USA) FACS ARIA II flow cytometer.  
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2.5.6.1. Sorting of nTreg from naïve Foxp3-GFP mice  
Cells were stained with anti-CD4 and/or anti-CD62L (Table 2.1) and selected for 
CD4+ CD62L+ GFP+ cells. 
 
2.5.6.2. Sorting of naïve CD4 + CD62L+ GFP- (Vβ11+ or Vα3.2+) cells  
If Foxp3.LuciDTR4 or Foxp3-GFP mice were used, cells were stained with anti-CD4 
and anti-CD62L and selected for CD4+ CD62L+ GFP- cells. When 
2D2xFoxp3.LuciDTR4 mice were used, cells were stained with anti-CD4, anti-
CD62L, anti-Vβ11 or anti-Vα3.2 and selected for CD4+ CD62L+ Vβ11+ (Vα3.2+) 
GFP- cells. When non-Foxp3-GFP reporter mouse lines were used, cells were stained 
as above but not selected for GFP expression. The staining for Vβ11+ or Vα3.2+ cells 
was used to increase the purity of MOG-reactive cells within 2D2 cells.   
 
2.5.6.3. Sorting of nTreg from the CNS/spleen of EA E mice and 
from naïve spleen for transfer 
Cells were stained with anti-CD4 and anti-CD11b and selected for CD4+ CD11b- 
GFP+ cells. Cells from the CNS were not pre-sorted for CD4+ cells as described in 
section 2.5.4.     
 
2.6. In vitro cell culture and T cell polarisations 
All cells were cultured at 37°C in a humidified atmosphere at 5% CO2.  
 
2.6.1. Th1, Th2, Th17 and GM-CSF-polarising conditi ons 
Cells were obtained from spleen and/or peripheral LN as described in 2.5.1 and 
resuspended at 4x106 cells/ml in RPMI-5%. Cells were cultured in 48-well p ates 
when used for in vitro experiments, or 6-well plates (Corning Costar, High 
Wycombe, UK) when used for in vivo transfers. Cells were stimulated with 1µg/ml 
anti-CD3 (eBioscience, Hatfield, UK) or 10µg/ml MOG35-55, unless otherwise stated. 
For Th1 polarisation, cells were cultured with 10U/ml rIL-2 (purified from the x63-
IL-2 hybridoma, a gift from David Gray, University of Edinburgh), 25ng/ml rIL-12 
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and 25ng/ml rIL-18 (R&D Systems, Minneapolis, USA) for 72 hours. For Th2 
polarisation, cells were cultured with 40U/ml rIL-2, 4ng/ml rIL-4 (Peprotech EC Ltd, 
London, UK), 5µg/ml anti-IL-12 (clone C17.8, BioXcell, New Hampshire, USA) and 
5µg/ml anti-IFN-γ (clone XMG1.2, BioXcell) for 72 hours or 96 hours. For both 
polarisation protocols, cells were split after 48 hours and fresh polarising media 
(without the addition of anti-CD3 or MOG35-55) was replenished. For Th17 
polarisation, cells were cultured with 20ng/ml rIL-6, 20ng/ml rIL-23 and 3ng/ml 
rTGF-β (all R&D Systems) for 72 hours. For GM-CSF-skewing conditions, cells 
were stimulated with 5µg/ml anti-CD3 and 5µg/ml anti-CD28 (eBioscience) or 
40µg/ml MOG35-55 in the presence of 10µg/ml anti-IL-12 and 10µg/ml anti-IFN-γ for 
72 hours (Codarri et al., 2011). Cells were split after 48 hours and fresh polarising 
media was replenished.  
 
When sorted CD4+ T cells and nTreg were polarised, cells were resuspended at 
4×105 cells/ml in RPMI-5% and stimulated with 2µg/ml of plate-bound anti-CD3 
and anti-CD28 (eBioscience). Polarising conditions used were the same as described 
above, unless otherwise specified.   
 
2.6.2. Generation of iTreg 
Naïve CD4+ T cells were sorted using AutoMACS (see section 2.5.5) or FACS (see 
section 2.5.6.2) and resuspended in RPMI-10% at 3.75×105 cells/ml. Tissue culture 
24-well plates (Corning Costar) were coated with 2µg/ml anti-CD3 and 2µg/ml anti-
CD28 in PBS and incubated for 2 hours at 37°C. The plates were washed three times 
in PBS and seeded with 3.75×105 cells per well in the presence of 5ng/ml TGF-β and 
100U/ml rIL-2. Cells were cultured for 120 hours. If the Foxp3.LuciDTR-4 or 2D2x 
Foxp3.LuciDTR-4 mouse lines were used, cells after 5-day culture were sorted for 
GFP+ cells using FACS.  
 
2.6.3. Expansion of nTreg 
nTreg were obtained as described in section 2.5.6.1 and resuspended at 1x106 
cells/ml in RPMI-10%. Following resuspension, 1x105 cells were added per well to a 
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96-well round bottomed micro-titre plate (Corning Costar) at a 1:4 ratio with anti-
CD3/anti-CD28 T cell expander Dynabeads (Dynal Biotech, Invitrogen, Paisley, 
UK) in the presence of 1000U/ml rIL-2. Cells were maintained at a concentration of 
0.5 – 1x106 cells/well and cultured for 7 to 10 days.  
 
2.6.4. Ex vivo re-stimulation assays 
Cells were isolated as described in section 2.5 and resuspended in RPMI-5%. 
Splenocytes were resuspended at 8x106 cells/ml, dLN and cells from lung at 6x106 
cells/ml and cells from CNS at 3 - 4x106 cells/ml, and cultured overnight with or 
without 20µg/ml MOG35-55 and/or OVA323-339 in 48-well or 96-well flat bottomed 
plates (Corning Costar). Brefeldin A (eBioscience) was added at 1:1000 dilution for 
the final 4 to5 hours of culture, followed by intracellular cytokine staining.   
 
2.6.5. Ex vivo recall cytokine assays 
Cells were obtained from the spleen and dLN as described in section 2.5.1 and 
resuspended at 8x106 cells/ml or 6x106 cells/ml, respectively in X-VIVO medium. 
Cells were cultured in duplicate in 96-well flat bottomed micro-titre plates (Corning 
Costar) in the presence of increasing MOG35-55 concentrations (0-30µM) for 72 
hours. Cytokine levels in supernatants were measured by enzyme-linked 
immunosorbent assay (ELISA).  
 
2.6.6. In vitro suppression assays 
Sorted nTreg from naïve mice (2.5.6.1), in vitro expanded nTreg (2.6.3) or iTreg 
(2.6.2) were resuspended at 4x105 cells/ml in RPMI-10% and plated with either 
purified naïve CD4+ T cells or purified in vitro polarised CD4+ T effector cells 
(Tresp) at different ratios in triplicates in 96-well round bottomed micro-titre plates 
(Corning Costar). Irradiated splenocytes from C57BL/6 mice (resuspended at 4x106 
cells/ml) were added to each well as antigen presenting cells. Cells were pulsed with 
10ug/ml MOG35-55 and cultured for 72 hours prior to addition of 0.5µCi of [
3H]-
thymidine (Amersham Biosciences, Amersham, UK) to each well. Wells with nTreg 
or iTreg only, Tresp only or unstimulated Tresp were used as controls. After 16 to 18 
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hours, incorporation of [3H]-thymidine was measured using a liquid scintillation β-
counter (Wallac, Turku, Finland) and expressed as mean counts per minute. 
Duplicate plates were used to measure cytokine levels at 72 hours of culture.  
 
2.7. In vivo manipulations 
2.7.1. Immunisations 
Mice received 100µg MOG35-55 emulsified in complete Freund’s adjuvant (CFA) 
containing 1mg/ml heat-killed Mycobacterium tuberculosis H37Ra (Sigma). A total 
volume of 100µl was injected subcutaneously (s.c.) (50 µl into each hind limb).  
 
2.7.2. CD4+ T cell transfers 
Purified naïve CD4+ T cells, Th2 polarised cells, naïve and CNS-derived nTreg or in 
vitro generated iTreg were washed three times in sterile PBS and resuspended at the 
desired concentration. Cells were injected intravenously (i.v.) in a total volume of 
200ul. 
 
2.7.3. In vivo CFSE-proliferation / suppression assays  
CD4+ T cells were purified as described in section 2.5.4, resuspended at 5x107 
cells/ml in wash buffer and incubated with 500nM carboxyfluorescein succinimidyl 
ester (CFSE, Molecular Probes, Paisley, UK) per 107 cells for 5 min at 37°C. Cells 
were washed twice in ice-cold 10% FCS complete media and counted. Cells were 
injected i.v. (2.7.2), with or without iTreg. This was followed by MOG35-55/CFA 
immunization as described in 2.7.1. Unimmunized mice were used as controls.  
 
2.7.4. Induction and assessment of EAE 
Mice were immunised as in described in section 2.7.1. Doses of 2mg/ml or 4mg/ml 
CFA were used in some experiments as specified. Mice were given 200ng of 
pertussis toxin (PTX) (Health Protection Agency, Dorset, UK) in 500µl PBS, 
intraperitoneally (i.p.) on the day of immunisation, repeated 2 days later. Clinical 
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signs of EAE were assessed daily from day 6 post-immunization, and scored as 
follows: 
0 – No disease 
1 – Flaccid tail 
2 – Impaired righting reflex and/or abnormal gait 
3 – Partial hind limb paralysis 
4 – Total hind limb paralysis 
5 – Partial forelimb paralysis 
6 – Moribund or dead 
Mice with grade 5 on two consecutive days and/or with the body weight loss exceeding 
30% were euthanized.   
 
2.7.5. Induction and assessment of rMOG-induced AAI  
2.7.5.1. Intraperitoneal sensitisation 
For the sensitization model of AAI, mice received two i.p. injections of 100µg or 
200µg rMOG in an aqueous solution of aluminium hydroxide adjuvant at a 3:1 ratio 
(Imject Alum, Pierce, Rockford, USA) on day 0 and 14.  
 
2.7.5.2. Th2 cell transfer 
When airway inflammation was induced via Th2 cell transfer, mice received CD4+ 
sorted 5×106 Th2 polarised 2D2 cells i.v. in a total volume of 200 µl PBS on day 0.  
 
2.7.5.3. Intratracheal instillation 
Mice were anaesthetised with i.p. injection of ketamine (Fort Dodge Animal Health 
Ltd, Hampshire, UK) and medetomidine hydrochloride (Pfizer Ltd, Surrey, UK). A 
blunt cannula was gently introduced through the larynx into the trachea. A volume of 
50µl of rMOG (50µg) in sterile PBS was injected intratracheally (i.t.). Anaesthesia 
was reversed by s.c. injection of antipamezole hydrochloride (Pfizer). Three i.t. 
injections were given 3 days apart: on days 21, 24 and 27 in the sensitisation AAI 
model, and on days 1, 4 and 7 in an adoptive Th2 cell transfer AAI model.  
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2.7.5.4. Bronchoalveolar lavage 
Mice were sacrificed by i.p. injection of pentobarbitone. Bronchoalveolar lavage 
(BAL) was collected by cannulation of the trachea with a 27-gauge needle encased in 
0.96-mm polyethylene tubing (Fanning Ltd, UK). Lungs were lavaged three times 
with 500µl PBS to obtain BAL fluid (BALF). BALF cells were counted, centrifuged 
at 350xg for 5 minutes, and supernatant was collected for the detection of cytokines. 
Cells were resuspended in PBS and cytospins prepared using a Shandon Cytospin 3 
centrifuge at 300rpm for 3 minutes. Slides were air dried for 20 minutes, fixed in ice-
cold 100% methanol for 20 minutes and stained with Quick-Diff red stain for 1.5 
minutes, followed by Quick-Diff blue stain for 15 seconds (both Gamidor Technical 
Services, Didcot, UK). Slides were rinsed in water and air dried. Differential cell 
counts were performed, blinded to experimental conditions, using light microscopy 
and a total of 200 cells per slide were counted.  
 
2.7.5.5. Histological scoring 
Lung were perfused through the right ventricle as de cribed in 2.5.3, inflated and 
fixed in 10% formalin. Tissue was embedded in paraffin and sections were stained 
using hematoxylin and eosin (H&E) or Periodic Acid-Shiff (PAS) stains to detect 
mucus-producing cells (all provided by University of Edinburgh histology service). 
Inflammatory scoring of H&E stained slides was done manually at x200 
magnification as previously described (Leech et al., 2007) Briefly, 10 consecutive 
fields were scored which included one complete blood vessel and one complete 
bronchiole (with diameters less than half of a field, equivalent to 300µm). Infiltration 
scores were applied to the peri-vascular and peri-bronchiolar compartments as 
follows: 
1 - no cells 
2 - less than 20 cells 
3 - more than 20 cells but less than 100 cells 
4 - more than 100 cells 
 
The percentage of goblet cells in small airways (diameter ≤300 µm) and large 
airways (diameter >300 µm) was determined by calculating the average percentag  
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of goblet cells within 10 consecutive airways for small airways and as many as 
possible for large airways. All histological scoring was carried out blinded to 
experimental conditions.     
 
2.8. Depletion of Foxp3 + cells using DTx 
Foxp3.LuciDTR-4 were used which express eGFP, diphtheria toxin receptor (DTR) 
and luciferase under the foxp3 promoter (Suffner et al., 2010). In this system 
administration of diphtheria toxin (DTx) enables selective depletion of Foxp3+ cells. 
A dose of 24ng/kg DTx was administered i.p. in a volume of 100µl on two 
consecutive days, and then every 3-4 days to maintain depletion. Blood was sampled 
every 2-4 days to determine depletion, using either GFP expression or intracellular 
Foxp3 expression.  
 
2.9. Enzyme Linked Immunosorbent Assays 
2.9.1. Cytokine quantification in cell supernatant  
96-well plates (Maxisorp, Nunc, Rochester, USA) were coated with cytokine capture 
antibodies (Table 2.2) diluted in 1x bicarbonate buffer (Sigma) and incubated 
overnight at 4°C. Plates were washed twice in 1x PBS containing 0.1% Tween (PBS-
Tween, Sigma) and blocked with 1% bovine serum albumin (BSA, Sigma) for 1 hour 
at 37°C. Plates were washed twice in PBS-Tween, loaded with cell supernatant and 
known cytokine standards, and incubated for 2 hours at oom temperature. Standards 
were generated by performing doubling dilutions of recombinant mouse cytokines in 
1% BSA-PBS. The sensitivity of cytokine assays was as follows; IFN-γ: 0.2-
100ng/ml (BD Pharmingen, Oxford, UK), IL-17: 0.1-10ng/ml (R&D), IL-4: 0.01-
5ng/ml (R&D), IL-13: 0.02-10ng/ml (eBioscience). Plates were washed 4 times in 
PBS-Tween prior to addition of biotinylated antibody (Table 2.2) diluted in 1% 
BSA-PBS for 1 hour at room temperature. Plates were washed 6 times in PBS-
Tween and loaded with extravidin peroxidase (Sigma) diluted 1:1000 with 1% BSA-
PBS. After 30 minutes of incubation at room temperature, plates were washed 6 
times in PBS-Tween and the ELISA was developed by addition of phosphate-citrate 
buffer containing H2O2 and 100ng/ml tertramethyl-benzidine (TMB, Sigma). The 
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reaction was stopped by adding 2M sulphuric acid. Plates were read for optical 
absorbance at 450nm using a Biotek Synergy HT microplate reader (Winooski, 
USA) and analyzed by Gen5 software (Biotek)  
 
GM-CSF was measured using ELISA development kit as per manufacturer’s 
instructions: Mouse GM-CSF ELISA Ready-Set-Go (eBiosc ence). The sensitivity of 
the kit was 4-500pg/ml.      
 
2.9.2. Measurement of rMOG-specific IgE in serum 
Blood was taken via an axillary approach post-mortem, serum collected and frozen at 
-20°C for detection of rMOG specific IgE, IgG1 and IgG2a. For IgE detection, serum 
was diluted 1:4 with PBS and incubated with fast flow protein G sepharose beads 
(Sigma-Aldrich) overnight at 4°C on a rotator for the depletion of IgG, as described 
previously (Leech et al., 2007). 96-well plates (Maxisorp, Nunc) were coated with 
5µg/ml rMOG in 0.05M carbonate buffer and incubated overnight at 4°C. Plates 
were blocked with 1% BSA-PBS for 1 hour at 37°C. Serum was centrifuged twice at 
13000xg for 5 minutes to remove beads and diluted 1:10 in PBS. Serial dilutions of 
serum were prepared by performing doubling dilutions in 1% BSA-PBS. Plates were 
washed 5 times in 0.1% PBS-Tween, loaded with duplicates of pre-diluted serum, 
and incubated overnight at 4°C. Plates were washed 5 times in PBS-Tween and 
biotinylated rat anti-mouse IgE antibody (clone R35-118, BD Bioscience) at 2µg/ml 
was added to each well. Plates were incubated for 1 hour at 37°C and washed 5 times 
in PBS-Tween prior to addition of extravidin peroxidase (Sigma), diluted 1:200 with 
1% BSA-PBS. After 1 hour incubation at room temperature, plates were washed 6 
times in PBS-Tween and the ELISA was developed by the addition of phosphate-
citrate buffer containing H2O2 and 100ng/ml tertramethyl-benzidine (TMB, Sigma). 
The reaction was stopped by adding 2M sulphuric acid. Since no standard was used, 
each plate was developed for exactly the same time prior to stopping the reaction. 
Plates were read for optical absorbance at 450nm using a Biotek Synergy HT 
microplate reader (Biotek) and analyzed using Gen5 software (Biotek).   
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2.9.3. Measurement of rMOG-specific IgG1 and IgG2a in 
serum 
96-well plates (Maxisorp, Nunc) were coated with 5µg/ml rMOG in 0.05M carbonate 
buffer and incubated overnight at 4°C. Plates were blocked with 3% BSA-PBS for 1 
hour at 37°C. Serum was diluted 1:5 in PBS-Tween and doubling dilutions were 
prepared. Plates were washed 5 times in 0.1% PBS-Tween, loaded with duplicates of 
pre-diluted serum and incubated for 1 hour at 37°C. Plates were washed 5 times in 
PBS-Tween and detection antibody diluted in PBS-T was added to each plate: goat 
anti-mouse IgG1AP and IgG2aAP (both 1:500) (Southern Biotech, Birmingham, 
USA). Plates were incubated for 1 hour at 37°C and washed 5 times in PBS-Tween. 
The ELISA was developed by addition of pNNP (Southern Biotech) in a substrate 
buffer containing 0.24mM magnesium chloride hexahydrate and 96mM 
diethanolamine (Sigma) and the plates were read at 405 nm (Anthos ELISA reader, 
Biochrom Ltd, Cambridge, UK). As no standard was used, each plate was developed 
for exactly the same time prior to reading.  
 
2.10. Cytokine analysis using 13-plex Flowcytomix 
Multiplex 
Mouse Th1/Th2/Th17/Th22 13plex FlowCytomix Multiplex kit (eBioscience) was 
used to measure cytokines in BALF as per manufacturer’s instructions. Briefly, a 
mixture of antibody-coated beads and a mixture of secondary antibodies were added 
to 25µl of each sample and incubated at room temperature for 2 hours on a 
microplate shaker at 500rpm. Followed by two washes, Streptavidin- Phycoerythrin 
solution was added and incubated at room temperatur for 1 hour. Followed by two 
washes, the samples were analyzed by flow cytometry. Different bead sizes and 
intensities of conjugated dye enabled differentiation between different cytokines. The 
use of standard allowed for a calculation of cytokine concentration in a sample.  
 
2.11. Immunohistochemistry 
Slides were placed for 15 minutes at 59°C to soften th  paraffin, then deparaffinized 
by sequential immersion in the following: xylene for 10 min, absolute alcohol for 40 
seconds, 95% alcohol for 20 seconds, 70% alcohol for 20 seconds, then washed in 
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water for 1 minute. Next, they were mounted onto Shandon coverplates 
(ThermoFisher Scientific, Waltham, USA) and put into a Shadon Sequenza Slide 
Rack. The slides were blocked with 3% hydrogen peroxide solution for 30 minutes at 
room temperature and washed once with wash buffer containing 0.05M Tris-HCl, 
0.15M NaCl and 0.05% Tween (all from Sigma). Next, they were blocked with 
avidin D solution (Vector Laboratories Ltd, Peterborough, UK) in 1.5% Normal 
Rabbit Serum (NRS) for 20 minutes at room temperature and washed once in wash 
buffer. The rat anti-mouse Major Basic Protein monoclonal antibody (clone MT-
14.7, provided by Dr James Lee, Mayo Clinic, USA) was used at 1 in 500 in 1.5% 
NRS and added to slides for 40 minutes at room temperature. Rat IgG1κ antibody 
(Vector Laboratories Ltd) was used an isotype control. The slides were washed 3 
times in wash buffer and incubated with a secondary anti-rat IgG-Biotinylated mouse 
adsorbed antibody (Vector Laboratories Ltd) for 30 minutes at room temperature. 
The slides were then washed, and Streptavidin-HRP (Vector Laboratories Ltd) was 
added at 1:1000 for 1 hour at room temperature. Following a washing step, DAB 
reagent (Vector Laboratories Ltd) was added for 10 minutes at room temperature, 
slides were counterstained with 0.1% methyl green (Sigma) and mounted with 
VectaMount (Vector Laboratories Ltd). The staining was visualized using light 
microscopy.  
 
2.12. Flow cytometric analysis 
2.12.1. Antibodies for flow cytometric analysis 
Antibodies used for flow cytometry were from eBioscience unless otherwise stated 
and are summarised in Table 2.1.  
 
2.12.2. Viability staining 
Where stated, cells prior to surface staining were washed twice in PBS, stained with 
fixable viability dye eFluor780 (eBioscience) at 1:1000 in a total volume of 500µl 
PBS for 20 minutes at 4°C. Cells were then washed in FACS buffer. 
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2.12.3. Surface staining 
Cells were washed in FACS buffer and stained with the indicated antibodies (see 
Table 2.1) in 50µl FACS buffer for 20 min at 4°C. After washing in FACS buffer, 
cells were either resuspended in FACS buffer for immediate analysis, or fixed in 1% 
paraformaldehyde (PFA) and stored at 4°C for next day analysis. 
 
2.12.4. Intracellular cytokine staining 
Cells were incubated with Brefeldin A (eBioscience) for the final 4 to 5 hours of 
culture. Where stated, cells were also incubated with 50ng/ml phorbol myristate 
acetate (PMA) and 1µg/ml ionomycin (both from Sigma) for the same amount of 
time. Cells were washed in FACS buffer and, where stated stained with viability dye 
(eBioscience, see section 2.12.2). Cells were stained for cell surface markers as 
described in 2.12.3, resuspended in 200µl of BD Cytofix/Cytoperm solution (BD 
Pharmingen) and incubated for 20 minutes at 4°C. Cells w re washed twice in 1x BD 
Perm/Wash buffer (BD Pharmingen) and stained for intracellular cytokines using the 
indicated antibodies (Table 2.1) diluted in 50µl Perm/Wash buffer (BD Pharmingen) 
at 4°C for 30 minutes. Cells were washed in Perm/Wash (BD Pharmingen) buffer 
and resuspended in FACS buffer for immediate or next day analysis. Alternatively, 
in earlier experiments, after cell surface staining cells were stained for intracellular 
cytokines using Foxp3 Fixation/Permeabilisation buffers from eBioscience as 
described below for intracellular staining for transcription factors (2.12.5).  
 
2.12.5. Intracellular staining for transcription fa ctors 
Cells were surface-stained as described in 2.12.3 and resuspended in 400µl Foxp3 
Fixation/Permeabilisation buffer (eBioscience). After overnight incubation at 4°C, 
cells were washed in FACS buffer and stained with the indicated antibodies (Table 
2.1) diluted in 50µl of 1×Permeabilisation buffer (eBioscience) for 30 min at 4°C. 
Cell were then washed and resuspended in FACS buffer for immediate or next day 
analysis.  
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2.12.6. Flow cytometric data analysis 
Flow cytometric data was acquired using a Becton Dickinson (Franklin Lakes, USA) 
LSRFortessa II and analysed using FlowJo software (Tree Star version 3.2.1, 
Ashland, USA).  
 
2.13. Statistics  
All statistics was performed using GraphPad Prism software (San Diego, USA). 
Unpaired t-test or Mann-Whitney U test were used when comparing two groups. To 
compare three and more groups a one-way analysis of variance (ANOVA) was used 
with Tukey’s multiple comparison post test. Alternatively, an unpaired t-test was 
used to test differences between the groups of interest. The Kruskal-Wallis test with 
Dunn’s multiple comparison post test was used to compare three of more groups 
where data were non-parametric. Bonferroni’s post te was used for analysis of 
ELISA data. Due to the ranked nature of EAE disease scores, a Fisher’s exact test 
was used to determine differences in disease severity (i.e. the number of mice with a 
score ≤2, versus the number of mice with a grade ≥3). Data were considered 
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Antibody Conjugate Clone Final concentration 
CD3 PerCP-Cy5.5 145-2C11 1µg/ml 




2µg/ml                  
1µg/ml 
CD45.1 PE^, PerCP-Cy5.5 A20 1µg/ml 
CD45.2 APC 104 1µg/ml 
CD90.1 APC HIS-51 1µg/ml 
CD90.2 PE^ 53-2.1 1µg/ml 
Vα3.2 FITC^, PE* RR3-16 1µg/ml 
Vβ11 Biotinylated CTVB11 1µg/ml 
CD11b APC, eFluor450 M1/70 1µg/ml 
CD62L PE, Biotinylated^ MEL-14 2.5µg/ml 
CD44 APC-Cy7* IM7 1µg/ml 
CD73 PE Ty/11.8 1µg/ml 
CXCR3 APC CXCR3-173 5µg/ml 
T-bet PerCP-Cy5.5 eBio4B10 1µg/ml 







IFN-γ APC, FITC, PE^ XMG1.2 2µg/ml 
IL-17A PerCP-Cy5.5 eBIO17B7 2µg/ml 
TNF-α eFluor450 MP6-XT2 2µg/ml 
GM-CSF PE^ MP1-22E9 4µg/ml 
IL-13 AF647 eBio13A 2µg/ml 
IL-5 PE TRFK5 2µg/ml 


























Armenian hamster IgG APC HTK888 5µg/ml 
Streptavidin PerCP-Cy5.5^ N/A 2µg/ml 
Table 2.1 Antibodies used for flow cytometry. 













anti-IFN-γ R4-6A2 2µg/ml anti-IFN-γ XMG1.2 0.5µg/ml 
anti-IL-17A TC11-
18H10 
0.5µg/ml anti-IL-17A TC11-8H4.1 0.25µg/ml 
anti-IL-13 eBio13A 2µg/ml anti-IL-13 eBio1316H 0.5µg/ml 
anti-IL-4 11B11 2µg/ml anti-IL-4 BVD6-24G2 1µg/ml 
Table 2.2 Capture and detection antibodies used for cytokine ELISA. 
All from BD Pharmingen apart from anti-IL-13 antibodies which were obtained from 
eBioscience.  
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3 Developing a model of rMOG-induced allergic 
airways inflammation  
 
3.1. Introduction 
One of the main aims of this project was to determine whether Treg can acquire a 
different phenotype in Th1/Th17-mediated autoimmune CNS inflammation in EAE 
and in Th2-mediated allergic lung inflammation in AAI and if so, to test how this 
affects their suppressive capacity. It has been previously demonstrated that antigen 
reactivity is important for an effective Treg-mediated inhibition of CD4+ T cell 
responses both in vitro and in vivo (Thornton and Shevach, 2000, Tang et al., 2004). 
In a model of MOG35-55-induced EAE it was shown that CNS-derived Treg have  
superior capacity to suppress disease severity over polyclonal Treg (McGeachy et al., 
2005) and an increased frequency of myelin-specific Treg was reported in the 
inflamed CNS of mice in a self-resolving model of EAE (O'Connor et al., 2007, 
Korn et al., 2007). Moreover, therapeutic transfers of Treg demonstrated that only 
antigen-reactive and not polyclonal Treg were capable of suppressing EAE (Stephens 
et al., 2009). In models of AAI it has been demonstrated that polyclonal Treg 
effectively inhibit disease (Kearley et al., 2005, Leech et al., 2007). However, no 
study has directly compared the suppressive efficiency of antigen-reactive versus 
polyclonal Treg in the context of this disease.  
 
Hence, in order to distinguish between the effect of a different Treg phenotype and 
different antigen responsiveness it was decided that Treg of the same antigen 
reactivity would have to be transferred from a Th1-mediated inflammatory disease 
into a Th2-driven disease, and vice versa. For this to be achieved, a new model of 
autoantgien-mediated AAI had to be developed as the CNS inflammation in EAE can 
only be driven by a myelin-derived self-peptide. Extracellular domain of MOG, 
recombinant MOG (rMOG), has been shown to effectively induce EAE (Fillatreau et 
al., 2002). Previously in the Anderton lab it was demonstrated that sensitisation of 
C57BL/6 mice with rMOG in alum resulted in an increas d level of Th2-associated 
rMOG-specific IgG1 antibody in serum (Mel Leech, unp blished observations). For 
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this reason it was decided to use rMOG as an allergen to establish a new model of 
Th2-driven AAI.  
 
3.1.1. Aims 
The aims of the experiments described in this chapter were to: 
1) Induce AAI in C57BL/6 mice using rMOG. 
2) Characterize the disease and immunological readouts of this model. 
3) Establish disease kinetics and recovery time. 
4) Assess the importance of Foxp3+ Treg in the control of lung inflammation in 
this model. 
 
3.1.2. Experimental approach 
The first approach was to develop an rMOG-induced AAI model in C57BL/6 mice 
using standard alum sensitization and airway challenge protocols (Kearley et al., 
2005, Leech et al., 2007). In the light of possible self-tolerance mechanisms, MOG-
deficient mice (Delarasse et al., 2003) were used to test whether their lack of 
endogenous MOG expression would make them more susceptible to developing 
rMOG-induced AAI. A different approach to induce AAI was also taken that 
involved an adoptive transfer of traceable activated MOG-reactive CD4+ T cells 
isolated from a 2D2 mouse (Bettelli et al., 2003) which were polarised in vitro 
towards Th2 phenotype. These were transferred into naïve mice followed by antigen 
airway challenge. To investigate changes within Foxp3+ cell population, Foxp3-GFP 
mice (Fontenot et al., 2005b) were used in some experiments as it enabled 
identification of Treg without the need for intracellular Foxp3 staining. 
Foxp3.LuciDTR4 mice (Suffner et al., 2010), in which administration of DTx allows 
for selective depletion of Foxp3+ cells, were used to investigate the importance of 
Foxp3+ Treg in a model of rMOG-induced AAI.  
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3.2. Results 
3.2.1. Sensitization with rMOG in alum and subseque nt 
airway challenges do not induce AAI in C57BL/6 mice   
A dose of antigen in alum required to sensitize wild-type (WT) C57BL/6 mice varies 
according to the protocol and allergen used for an induction of AAI, and is typically 
within a range of 10ug to 100ug (Leech et al., 2007, Zhang et al., 2009, Mackenzie, 
2011). In addition to Th2-associated IgE, immunoglobu in isotypes IgG2a and IgG1 
are commonly used as markers of Th1 and Th2 responses, respectively (Mosmann et 
al., 1986, Snapper and Paul, 1987). In order to establi h an effective sensitization 
dose of rMOG in alum, C57BL/6 mice were given two intraperitoneal injections of 
100µg or 200µg of rMOG adsorbed to alum 14 days apart and serum was analysed 
on day 21 for the presence of rMOG-specific IgG2a and IgG1. rMOG-specific IgG1 
but not IgG2a was detected in serum of mice sensitised with 200µg but not with 
100µg of rMOG (data not shown), and hence this dose was cho en to be used in the 
AAI induction protocol.  
 
To induce AAI, C57BL/6 mice were given two intraperitoneal injections of 200µg of 
rMOG in alum followed by three intratracheal challeng s with 50µg of rMOG or 
PBS as a control (Figure 3.1A). In order to trace antigen-reactive T cells, naïve 2D2 
CD4+ cells, expressing TCR recognizing the 35-55 peptid of MOG protein (Bettelli 
et al., 2003), were transferred intravenously prior t  sensitization phase in one 
experimental group. Bronchoalveolar lavage (BAL) fluid was collected to prepare 
cytospins for differential BAL counts and the whole lung was perfused with 10% 
formalin to be used for histology or left unperfused for flow cytometric analysis. 
Sensitization and airway challenges with rMOG were not found to affect total cell 
numbers in BAL fluid (Figure 3.1B) and although the presence of eosinophils was 
more pronounced in rMOG-challenged groups the increase compared to PBS-
challenged mice was not significant (Figure 3.1C). The cellular infiltration of the 
lung was quantified using a previously published inflammatory scoring system 
(Leech et al., 2007). The infiltration of the blood vessels and bronchioles was very 
low or absent in rMOG-challenged mice and not significantly different from the 
control mice (Figure 3.1D&E). Period Acid Schiff (PAS) staining which detects 
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mucus produced by goblet cells revealed low percentages of goblet cells in small and 
large airways of rMOG-challenged mice without 2D2 cell transfer, and in large 
airways of those mice that received 2D2 cells (Figure 3.1D&F). In order to confirm 
that the mice were sensitized, serum levels of rMOG-specific IgE, IgG2a and IgG1 
were tested using ELISA. Both IgE and IgG1 were detect d in serum of mice 
sensitized and airway challenged with rMOG (Figure 3.2A&B) and IgG2a was 
undetectable (Figure 3.2C). Transfer of 2D2 cells did not enhance antibody titers.  
 
Flow cytometric analysis of ex vivo 2D2 cells from the lung, mediastinal lymph 
nodes (medLN) and spleen of rMOG-challenged mice showed that 2D2 cells became 
activated in response to antigen in vivo but their low total cell numbers indicated 
poor expansion and/or survival (data not shown). It was concluded that sensitisation 
and airway challenges with rMOG in C57BL/6 mice do not result in an allergic lung 
inflammation.  
 
3.2.2. MOG-deficient mice develop eosinophilia but not lung 
inflammation upon sensitization and challenge with 
rMOG 
As already mentioned, a possible explanation for the failure of rMOG to induce Th2-
mediated AAI in WT C57BL/6 mice could be the fact that numerous tolerance 
mechanisms towards self-antigens have evolved to limit autoimmune reactions 
(section 1.3). To test this hypothesis it was decidd to use MOG-deficient mice in 
which the gene encoding MOG protein is disrupted (Delarasse et al., 2003). These 
mice present no clinical or histological abnormalities otherwise. In this system MOG 
should be considered a foreign antigen. To induce AAI, MOG-deficient mice were 
given two intraperitoneal injections of 100µg of rMOG in alum followed by three 
intratracheal challenges with 50µg of rMOG or PBS as a control (Figure 3.3A).  
 
Total BAL cells were not significantly different between rMOG- and PBS-
challenged groups (Figure 3.3B) however a significant increase in the percentage of 
eosinophils in BAL was noted upon antigen challenge, accounting for ~35% of total 
BAL cells (Figure 3.3C). Eosinophils constituted less than 1% of total BAL cells in 
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the control group where the majority of cells were alveolar macrophages. Low 
inflammatory infiltrates around the blood vessels and bronchioles were observed in 
both rMOG- and PBS-challenged groups. (Figure 3.3 D&E). The percentages of 
goblet cells were very low and similar in both groups in large airways and present in 
small airways only in the rMOG-challenged group (Figure 3.3D&F). rMOG-specific 
IgE and IgG1 but not IgG2a were detected in serum of both rMOG- and PBS-
challenged mice and were not significantly different (Figure 3.4A,B&C).  
 
Flow cytometric analysis of the lung, medLN and spleen revealed that total cell 
numbers across organs were similar in rMOG- and PBS-challenged mice (data not 
shown). The percentages and total numbers of CD4+ T cells were also unchanged 
(Figure 3.5A&B) however there was a significant increase in the frequency and total 
number of Foxp3+ CD4+ cells specifically within the lung of rMOG-challenged mice 
(Figure 3.5C&D). Although MOG-deficient mice displayed better allergic response 
to MOG and developed lung eosinophilia, this AAI model was considered not to be 
robust enough for investigating the role and theraputic potential of Treg. A different 
approach was adopted which involved a transfer of antigen-reactive CD4+ T cells 
polarised in vitro towards Th2 phenotype prior to antigen airway challenge.  
 
3.2.3. Optimisation of Th2 polarising protocol of            
MOG35-55-reactive cells.  
To develop an optimal protocol for polarising pure Th2 cells in vitro, IL-4-GFP 
CD4+ cells, which express GFP under the il4 promoter, were studied. IL-4-GFP 
whole splenocytes were stimulated with soluble α-CD3 for 3 days in the presence of 
Th1-inducing cytokines (IL-12 and IL-18) or Th2-inducing conditions (IL-4, α-IL-
12, α-IFN-γ) with or without IL-2 (Figure 3.6A). The presence of IL-4, α -IL-12 and 
α-IFN-γ resulted in IL-4 production in approximately 16% of CD4+ cells and a 
specific upregulation of Th2 master regulator GATA-3 (data not shown). Addition of 
exogenous IL-2 greatly enhanced cell survival and promoted GATA-3 expression 
and expansion of IL-4-secreting CD4+ cells to approximately 28% (Figure 3.6B&C). 
IL-4+ cells, but very low GATA-3 expression, were also detected in Th1 conditions 
which could be explained by non-specific IL-4 upregulation during the first few days 
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of polarisation (Figure 3.6B&C). T-bet expression was specific to Th1 cells and was 
very low in Th2 cells (Figure 3.6C). The extent of Th2 polarisation was also tested 
by cytokine assays which detected higher levels of IL-13 and IL-5 in Th2-polarised 
cell culture supernatants versus Th1 supernatants (Figure 3.6D). In order to assess 
whether contaminating IFN-γ+ cells were present in Th2 cultures and to verify Th2 
polarisation protocol in a TCR transgenic system, MOG35-55-reactive 2D2 cells were 
stimulated for 3 days under polarising conditions ad stained for the intracellular 
expression of IFN-γ and IL-13. Approximately 11-15% of 2D2 CD4+ T cells 
polarised under Th2 conditions were IL-13+ and 1% was IFN-γ+ compared to less 
than 1% of IL-13+ and approximately 47% of IFN-γ+ cells generated under Th1 
polarising conditions (Figure 3.6E). Less than 1% of double producers was detected 
in each condition (Figure 3.6E).  
 
It was concluded that IL-2 boosts Th2 polarisation and 3-day stimulation under 
polarising conditions in vitro allows for enough time to obtain Th2 cells.  
 
3.2.4. Adoptive transfer of Th2 polarised 2D2 CD4 + cells 
followed by airway challenge induces AAI   
In order to assess the potential of Th2 polarised 2D2 CD4+ cells to infiltrate the lung 
and induce airway inflammation, 5×106 of traceable CD4+ sorted Th2 polarised 2D2 
cells were transferred into WT hosts followed by three consecutive intratracheal 
injections with rMOG or PBS as a control (Figure 3.7A). The number of transferred 
cells was based on previous reports which used Th2 polarised OVA-reactive CD4+ T 
cells to induce an OVA-mediated model of AAI (Cohn et al., 1997, Hogan et al., 
1998). Th2 polarisation of 2D2 cells on the day of transfer was confirmed by ELISA 
for IL-13 and IL-5 and GATA-3 staining (data not shown). Analysis of the cellular 
composition of BAL and lung tissue revealed that the greatest evidence for 
inflammation was on day 9 (Appendix 1&2). This time point was therefore chosen 
for further detailed investigation of the inflammatory and CD4+ cell response.    
 
Two days after the third intratracheal injection the left lobe of the lung, medLN and 
the spleen were harvested and analysed by flow cytometry. BAL fluid was collected 
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to prepare cytospins for differential BAL counts and the two right lobes of the lung 
were perfused with 10% formalin and used for histology. BAL analysis revealed that 
the total cell number was significantly increased in mice challenged with rMOG 
(Figure 3.7B). The percentages of cell types varied b tween the experiments and the 
average contribution of eosinophils from pooled experiments was approximately 25-
30%, macrophages 70-75% and lymphocytes 2-3% (Figure 3.7C&E). The frequency 
of neutrophils was negligible. Eosinophils constituted less than 1% of total BAL cells 
in the control group where the majority of cells were alveolar macrophages (Figure 
3.7C&E). The absolute numbers of eosinophils, macrophages and lymphocytes were 
significantly increased in the rMOG-challenged group (Figure 3.7D, F&G). Cytokine 
bead array analysis of BAL fluid detected Th2-associated IL-13 and IL-5 and low 
levels of IL-4 and IL-10 (Figure 3.8). No IFN-γ or IL-17 was found.   
 
In the lung tissue itself, significantly increased cellular infiltrates were detected 
around the blood vessels and bronchioles of rMOG-challenged mice (Figures 
3.9A&B). Staining for major basic protein, a major component of secretory vesicles 
in eosinophils, revealed that eosinophils substantially constituted to the lung infiltrate 
(Figure 3.9D). PAS staining revealed that in rMOG-challenged mice ~12% of small 
airway epithelial cells and ~30% of large airway epithelial cells were goblet cells 
(Figure 3.9A&C). Control mice had negligible percentage of goblet cells in small 
airways and approximately 5% in large airways (Figure 3.9A&C). Naïve 2D2 CD4+ 
CD62Lhigh CD44- cells were used as an additional control in some experiments and 
were not found to induce lung eosinophilia and infiltration (data not shown). 
Moreover, 2D2 cells polarised towards Th2 phenotype for 4 to 6 days were also 
compared for their ability to induce lung inflammation and were found to give 
comparable results to inflammation driven by 2D2 cells polarised for 3 days (data not 
shown). 
 
3.2.5. rMOG-induced AAI is characterized by increas ed 
frequency of Th2 2D2 cells within the lung and medL N  
The analysis of total cell numbers revealed significantly increased cell numbers in 
the lung and medLN and no major changes in the spleen cellularity upon rMOG 
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challenge (Figure 3.10B). Using flow cytometry the differences in the percentages of 
total CD4+ cells and donor Th2 2D2 cells were investigated. The percentage of total 
CD4+ cells was significantly increased in the lung in response to rMOG challenge 
from approximately 10% to 14% and no significant changes were detected in the 
medLN and spleen where the CD4+ cell percentages varied between 19% and 25% 
(Figure 3.10C). The total numbers of CD4+ cells followed the same pattern and were 
only significantly increased in the lung tissue (data not shown).  
 
Looking at the transferred Th2 2D2 cells, their percentages and absolute cell 
numbers were significantly increased within the lung and medLN of rMOG-
challenged mice and were unchanged in the spleen compared to PBS-challenged 
mice (Figure 3.11 A&B). In the lung the percentage of Th2 2D2 cells was ~11% and 
in the medLN ~15% compared to 2% observed in the spl en (Figure 3.11A). The 
percentage of 2D2 cells in uninvolved lymph nodes from rMOG-challenged mice 
was found to be very low (data not shown). In terms of mean total cell numbers, a 
~9-fold increase in the lung and a ~70-fold increase in the medLN were noted upon 
rMOG challenge whereas numbers in the spleen were not altered (Figure 3.11B). 
This suggests a requirement for the in vivo presence of antigen in the migration / 
survival / proliferation of activated Th2 2D2 cells.   
 
3.2.6. Th2 2D2 cells have a stable phenotype in vivo following 
rMOG challenge 
Th2 2D2 cells prior to transfer expressed high levels of GATA-3 and produced IL-13 
and IL-5 as determined by ICS and ELISA (Figure 3.6E, data not shown). In order to 
determine how stable this phenotype was in vivo after transfer, the cells from the 
lung, medLN and spleen were stained for the intracellular expression of GATA-3 and 
analysed by flow cytometry. Th2 2D2 cells from the rMOG-challenged lung retained 
higher expression of GATA-3 compared to Th2 2D2 cells isolated from the PBS-
challenged control (Figure 3.12A). Moreover, within the rMOG-challenged group, 
Th2 2D2 cells from the lung retained the highest GATA-3 expression versus the cells 
from the medLN and the spleen (Figure 3.12A&B). This organ-specific elevation in 
GATA-3 expression was not noted in host CD4+ cells.  
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Cells isolated from the lung, medLN and spleen were r -stimulated overnight with 
MOG35-55 followed by intracellular staining for IL-13. The lung and medLN of PBS-
challenged mice did not have sufficient numbers of Th2 2D2 cells for re-stimulation 
assays and the data from the spleen are not shown. On average approximately 7% of 
Th2 2D2 cells from the rMOG-challenged lung produced IL-13 which was 
significantly higher compared to Th2 2D2 cells isolated from the rMOG-challenged 
medLN and spleen (Figure 3.13A&B). The percentages of IL-13+ Th2 2D2 cells 
from the medLN were very low (>0.5%) and from the spleen they reached ~2% 
(Figure 3.13B). IFN-γ production by Th2 2D2 cells within the lung was investigated 
in one of the experiments and its value from 4 pooled mice was found to be below 
1.5% which is similar to IFN-γ production by Th2 2D2 cells on the day of transfer 
(data not shown). These results suggest that the antigen challenge and the 
inflammatory environment of the lung maintain the Th2 phenotype of 2D2 cells.   
 
3.2.7. Percentage and total number of Foxp3 + cells is 
elevated in the lungs of rMOG-challenged mice 
It was previously reported that Foxp3+ CD4+ cells accumulate in the lung and 
medLN during lung inflammation in a murine model ofHDM-induced AAI 
involving alum sensitization (Leech et al., 2007). To test whether the same 
phenomenon occurs in rMOG-induced AAI using an adoptive transfer of Th2 2D2 
cells, the cells were stained for the intracellular expression of Foxp3. A significant 
increase in the percentages of total Foxp3+ CD4+ cells from 6% to 10% was observed 
in the lung of rMOG-challenged mice and this translted into a ~3.5-fold increase in 
the total Foxp3+ cell numbers (Figure 3.14A&B). The percentages of F xp3+ CD4+ 
cells were unchanged in the medLN (~10-13%) however th  total numbers increased 
~7-fold (Figure 3.14A&B) as the medLN in rMOG-challenged mice were 
significantly more cellular (Figure 3.10B). The perc ntages (~13%) and total 
numbers of Foxp3+ CD4+ cells in the spleen were unchanged (Figure 3.14A&B).  
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3.2.8. DTx administration protocol for depletion of  Foxp3 + 
cells during AAI 
To assess the importance of Foxp3+ CD4+ cells in the control of lung inflammation in 
rMOG-induced AAI, Foxp3+ cells were depleted prior to and throughout the duration 
of the disease. Transgenic Foxp3.LuciDTR-4 mice were used in which 
administration of diphtheria toxin (DTx) allows for selective ablation of Foxp3+ cells 
by utilizing the human diphtheria toxin receptor (DTR) system (Suffner et al., 2010). 
Moreover, Foxp3+ cells can be easily detected in this system by their expression of 
eGFP. The DTx treatment protocol was adapted from the s udy by Suffner at al. who 
observed that two doses of DTx on consecutive days are required for ~90-95% 
depletion of Foxp3+ cell compartment within 24 hours after the second treatment. As 
the effect of DTx was shown to wear off, additional DTx injections on days 2, 5 and 
8 were performed during AAI induction (Figure 3.15A). It has to be noted that in 
Foxp3.LuciDTR-4 mouse ~5-10% of Foxp3+ cells do not have DTR and hence 
Foxp3+ cells surviving DTx treatment can rapidly reconstitute the Foxp3+ cell 
compartment by 2 weeks (Suffner et al., 2010).  
 
In order to determine the extent of Foxp3+ cell depletion during AAI, the blood of 
DTx- and PBS-treated mice was sampled prior to the treatment and on days 2, 5 and 
9 of the AAI protocol. Foxp3+ cell ablation was determined by both eGFP expression 
and by intracellular staining for Foxp3 expression. Due to the Foxp3 staining 
requirements, simultaneous analysis of eGFP and Foxp3 e pression was not possible. 
This is due to the fact that Foxp3 staining requires a permeabilisation/fixation step 
which leads to eGFP bleaching making it undetectable. Two doses of DTx on days -2 
and -1 were shown to deplete ~99.4% of eGFP+ cells as checked 24 hours after the 
second treatment (Figure 3.15B). The Foxp3 staining could not be performed on this 
day due to simultaneous Th2 2D2 cell transfer and hence insufficient amount of 
blood taken for both analyses. Blood analysis 72 hours after DTx treatment (d2) and 
prior to the third DTx injection revealed depletion f ~95.4% of eGFP+ cells and 
~51.3% of Foxp3+ CD4+ cells (Figure 3.15B). Whereas, additional doses of DTx on 
days 2, 5 and 8 resulted in ~84.7% and ~95.4% depletion of eGFP+ cells as checked 
on day 5 and 9, the analysis of Foxp3 staining reveal d no significant differences in 
the percentages of Foxp3+ CD4+ cells on these days (Figure 3.15B). These results 
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suggest that Foxp3+ cells were significantly depleted at the start of AAI induction 
and recovered in blood by day of the second antigen challenge.     
  
3.2.9. Host Foxp3 + CD4+ cells are important in controlling 
rMOG-induced AAI 
Following the depletion of host Foxp3+ cells prior to and during induction of AAI 
increased total cell numbers in BAL of DTx-treated mice were noted irrespective of 
challenge, however they were not significantly elevat d when tested against PBS-
treated groups (Figure 3.16A). The percentage composition of BAL revealed no 
significant changes in the eosinophil or lymphocyte contribution upon DTx treatment 
(Figure 3.16B). Total numbers of eosinophils were low in the PBS-treated rMOG-
challenged group in this experiment and were not significantly affected by DTx 
treatment (Figure 3.16C). Total numbers of alveolar m crophages were significantly 
higher in the DTx-treated PBS-challenged group (Figure 3.16D) and no changes in 
the low neutrophil counts were observed (Figure 3.16E). Total numbers of 
lymphocytes were not significantly elevated in any of the groups, however they 
seemed to be higher in the DTx-treated rMOG-challenged group (Figure 3.16F).  
 
In terms of lung pathology, both peri-vascular and peri-bronchiolar infiltration scores 
were significantly higher in the DTx-treated rMOG-challenged group compared to 
the PBS-treated group (Figure 3.17A&B). Percentages of goblet cells in small and 
large airways were low in the PBS-treated rMOG-challenged group and were not 
significantly affected by DTx treatment (Figure 3.17C).  
 
The total cell numbers in the lung and medLN were not significantly changed by 
DTx treatment (Figure 3.18A). However, the percentages of CD4+ cells were 
significantly increased in the lung upon DTx treatment in both rMOG- and PBS-
challenged mice (Figure 18B). In the medLN, the frequ ncy of CD4+ cells was 
significantly decreased in DTx-treated rMOG-challeng d mice (Figure 18B). The 
total cell numbers and percentages of CD4+ cells in the spleen were unaffected 
(Figure 18A&B). The percentages and total numbers of Th2 2D2 cells in the lung 
and medLN were not significantly affected by DTx treatment (Figure 3.19A&B).  
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The ability of lung-derived Th2 2D2 cells to produce Th2-associated cytokines was 
assessed by re-stimulating them overnight with MOG35-55. In rMOG-challenged 
DTx-treated mice, significantly higher percentages of IL-13+ and GM-CSF+ Th2 2D2 
cells were detected compared to the PBS-treated group (Figure 3.20). Similar pattern 
of results was found in the spleen (data not shown). These results collectively 
indicate that depletion of Foxp3+ cells by DTx treatment enhances certain disease 
parameters of rMOG-induced AAI.  
 
3.2.10. Depletion of host Foxp3 + cells is associated with 
increased frequency of Foxp3 + Th2 2D2 cells 
In order to determine the efficiency of Foxp3+ cell depletion in the lung and medLN 
at the time of harvest, the cells were stained for the intracellular expression of Foxp3. 
The percentages and the absolute numbers of total Foxp3+ cells were not 
significantly affected by DTx treatment in neither the lung, medLN nor the spleen 
(Figure 21A&B). The percentage of host Foxp3+ cells was found to be unaffected in 
the lung (data not shown). However, it was significantly reduced in the medLN of 
both DTx-treated groups (Figure 3.21C). The total numbers of host Foxp3+ cells in 
the medLN were, however, comparable to the PBS treated controls (Figure 3.21C). 
 
To investigate what accounted for the unchanged percentage of total Foxp3+ cells 
and decreased percentage of host Foxp3+ cells in the medLN, Foxp3 expression was 
assessed in the transferred Th2 2D2 cells (Figure 3.22A). On the day of transfer, 
Foxp3+ cells constituted less than 1% of Th2 2D2 cells (data not shown). The 
percentages of Foxp3+ Th2 2D2 cells were significantly increased specifically within 
the medLN and spleen of DTx-treated rMOG-challenged mice (Figure 3.22A&B). 
The total number of Foxp3+ Th2 2D2 cells within the medLN, lung and spleen were 
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Figure 3.1 Sensitization and airway challenge with rMOG does not dr ive
eosinophilia and lung inflammation in WT C57BL/6 mice.
Mice were sensitized with rMOG in alum and challenged with rMOG or PBS as a
control. One of the rMOG challenged groups received traceable CD90.1+ naïve 2D2
CD4+ cells. (A) Experimental scheme. (B) Total numbers of BAL cells, n=4. (C)
Percentages of cell types in BAL, n=4. (D) H&E and PAS staining of the lung tissue,
n=2. (E) Infiltrationscoresand(F) percentages of goblet cells in the lung, n=2. Black line
represents 100µm. Data are from one experiment. Similar data was obtained from
experiment with 100µg rMOG sensitization. Data are shown as mean +/- SEM. ns = not
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Figure 3.2 rMOG-specific IgE and IgG1 but not IgG2a are detected in serum from
WT CD57BL/6 micesensitized and challenged with rMOG.
Experimental approach isshown in Figure 3.1. (A) rMOG-specific IgE, (B) IgG1 and (C)
IgG2a in serum. Data are from oneexperiment, n=4. Data are shown as mean +/- SEM.
*p<0.05, **p< 0.01, ** *p<0.001 between rMOG and PBS challenged groups as
determined by a two-way variance (ANOVA) using Bonferroni’s multiple comparison
test.
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D0 and D14 D21, D24 and D27
rMOG/alum
100µg






Flow cytometry on 
































Sensitization    Challenge
rMOG              PBS















Figure 3.3 MOG-deficient mice develop lung eosinophilia but not lung
inflammation.
MOG-deficient mice were sensitized with rMOG in alum and airway challenged with
rMOG or PBS as a control. (A) Experimental scheme. (B) Total numbers of BAL cells.
(C) Percentages of cell types in BAL. (D) H&E and PAS staining. (E) Infiltration scores
and (F) percentages of goblet cells in the lung. Black line represents 100µm. Data are
from one experiment, n=4-5. Data are shown as mean +/- SEM. ** p<0.01, ns = not
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Figure 3.4 rMOG-specific IgE and IgG1 but not IgG2a are detected in serum from
MOG-deficient micesensitized with rMOG.
Experimental approach isshown in Figure 3.3. (A) rMOG-specific IgE, (B) IgG1 and (C)
IgG2a in serum. Data are from oneexperiment, n=4. Data are shown as mean +/- SEM.
ns=not significant between rMOG and PBS challenged groups as determined by an






























































































Figure 3.5 Antigen challenge in rMOG-sensitized MOG-deficient mice does not
affect total CD4+ cellsbut significantly increasesFoxp3 expression within the lung.
Experimental approach is shown in Figure 3.3.(A) Percentages of CD4+ cells of all cells.
(B) Total numbers of CD4+ cells. (C) Percentages of Foxp3+ CD4+ cells of all CD4+ cells
and (D) total numbers of Foxp3+ CD4+ cells. Data are from one experiment, n=4-5.
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Figure3.6Optimisation of Th2 polarising conditions in vitro.
Splenocytes fromIL-4-GFP reporter mouse or a 2D2 mouse were stimulated with α-CD3
or MOG35-55, respectively, under different polarising conditions for 3 days. (A)
Experimental scheme. (B) Flow cytometry plots showing gating strategy on CD4+ cells
and IL-4 expression under different conditions. Numbers indicate percentages of gated
cells within CD4+ cell population. (C) Expression levels of T-bet and GATA-3. Blueline
marks GATA-3, red linemarks T-bet andshaded area is an isotypecontrol. (D) Cytokine
production measured in cell culture supernatants by ELISA. (E) Intracellular cytokines
produced by polarised 2D2 CD4+ cells. Data are representative of at least 4 experiments.
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Figure 3.7 Adoptive transfer of Th2 polarised 2D2 CD4+ cells followed by rMOG
challengeinduceseosinophilsin BAL consistent with AAI .
CD90.1+ 2D2 splenocytes were stimulated with MOG35-55 under Th2 polarising
conditions, sorted for CD4+ cells and transferred into WT mice followed by three
intratracheal challenges with rMOG. (A) Experimental scheme. (B) Total cell numbers in
BAL. (C) Percentages of cells in BAL. (D) Total numbers of eosinophils and (E)
representative BAL cytospins. (F) Total numbers of macrophages and (G) lymphocytes
in BAL. Black line represents 100µm Data was pooled from 6 experiments, n=19-25.


























































Figure 3.8 Th2-associated IL-13 and IL-5 are the predominant cytokines
detectablein BAL fluid of rMOG-challenged mice.
Experimental approach is shown in Figure 3.7.Cytokines in BAL fluid were measured






































































Figure 3.9 Th2 polarised 2D2 CD4+ T cells induce lung infiltration, goblet cell
hyperplasia and lung eosinophilia upon airway challengewith rMOG.
Experimental approach is shown in Figure 3.7. (A) H&E and PAS staining (B)
Infiltration scores and (C) percentages of goblet cells in the lung. (D) α-major basic
protein staining for eosinophils. Black line represents 100µm. Data was pooled from 6
experiments, n=14-17. Data are shown as mean +/- SEM. *p<0.05, ** p<0.01,






























































































Figure 3.10 Increased total cell numbers in the lung and medLN, and an increased
percentage of total CD4+ cells within the lung following transfer of Th2 2D2 cells
and rMOG challenge.
Experimental approach is shown in Figure 3.7. (A) Representative flow cytometry plots
showing thegating strategy for CD4+, Foxp3+ and Th2 2D2 (CD90.1+) cell populations.
(B) Total cell numbers and (C) percentages (%) of CD4+ T cells of all cells. Data was












































Figure 3.11Percentages and total numbers of Th2 2D2 cells increase upon rMOG
challengespecifically within the lung and medLN.
Experimental approach is shown in Figure 3.7 and the gating strategy in Figure 3.10.
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(A) Percentages of Th2 2D2 cells of all CD4+ cells and (B) total cell numbers of Th2
2D2 cells. Data was pooled from 5 experiments, n=12-20. **p< 0.01, ***p< 0.001 as
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GATA-3 expression in the rMOG-challenged group
Figure 3.12Transfer red Th2 2D2 cells retain the highest expression of GATA-3 in
therMOG-challenged lung.
Experimental approach is shown in Figure 3.7 and the gating strategy in Figure 3.10.
(A) Representative histograms of GATA-3 expression in Th2 2D2 cells in rMOG- and
PBS-challenged groups. (B) Mean fluorescence intensity (MFI) of GATA-3 expression
in Th2 2D2 cells and host CD4+ cells in the rMOG-challenged group. Dotted lines
represent isotypecontrol. Data are representative of 3 experiments, n=4. Data are shown




























































































Figure 3.13 Transfer red Th2 2D2 cells from the challenged lung retain ability to
produceTh2-associated IL-13.
Experimental approach is shown in Figure 3.7. On day 9 cells isolated from the lung,
medLN and spleen were cultured with (+) or without (-) MOG35-55 overnight andeffector
cytokine production was determined by ICS. A) Representative flow cytometry plots
showing the gating strategy for Th2 2D2 (CD90.1+) and IL-13+ Th2 2D2 cell
populations. (B) Percentages of IL-13+ Th2 2D2 cells. Each data point from thelung and
medLN represents 2-3 pooled mice. Data are pooled from 4 experiments for lung and









Figure 3.14 Percentages and absolute cell numbers of total Foxp3+ CD4+ cells
increaseupon rMOG challengespecifically within the lung.
Experimental approach is shown in Figure 3.7 and the gating strategy in Figure 3.10.
(A) Percentages of Foxp3+ CD4+ cells of all CD4+ cells and (B) total cell numbers of
Foxp3+ CD4+ cells. Data are pooled from 3 experiments, n=7-12. *p<0.5, **p<0.01,
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Figure 3.15Depletion of Foxp3+ cells following diphther ia toxin (DTx) treatment in
Foxp3.LuciDTR4 micedur ing and throughout the induction of AAI .
Foxp3.LuciDTR-4 mice were given DTx or PBS on two consecutive days before
transferring traceable CD90.1+Th2 2D2 cells and received further 3 doses on days 2, 5
and 8. Blood was sampled prior to DTx treatment and then every 2 to 4 days to
determinedepletion of Foxp3+ cells by either eGFP expression or ICS for the expression
of Foxp3 protein. (A) Experimental scheme. (B) Percentages of eGFP+ CD4+ cells and
Foxp3+ CD4+ cells of total CD4+ cell population pre- and post-DTx treatment. Due to
insufficient cell numbers there is no data for the ICS expression of Foxp3 on day 0.
Dashed arrows mark DTx injections. Data are from oneexperiment, n=5-8. ***p< 0.001
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Figure 3.16Depletion of Foxp3+ cells pr ior to and dur ing induction of AAI does not
significantly affect thepercentageand number of BAL eosinophils.
Experimental approach is shown in Figure 3.15. (A) Total numbers of cells and (B)
percentages of cells in BAL. (C) Total cell numbers of eosinophils, (D) macrophages, (E)
neutrophils and (F) lymphocytes in BAL. Data are from oneexperiment, n=3-4. Data are
shown as mean +/- SEM. ns = not significant, *p<0.05 as determined by a one-way
variance(ANOVA) usingTukey’smultiplecomparisontest.
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Figure 3.17Depletion of Foxp3+ cells resulted in the increased lung infiltration but
did not affect percentagesof goblet cells.
Experimental approach is shown in Figure 3.15.(A) H&E staining. (B) Infiltration scores
and (C) percentages of goblet cells in the lung. Black line represents 100µm. Data are
from oneexperiment, n=3-4. Data are shown as mean +/- SEM. *p<0.05 as determined
by aMann-Whitney U test.
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Figure 3.18Depletion of Foxp3+ cells pr ior to and dur ing AAI induction resulted in
the increased percentageof total CD4+ cellswithin the lung.
Experimental approach is shown in Figure 3.15.(A) Total cell numbers. (B) Percentages
of CD4+ cells of all cells. Data are from one experiment, n=3-4. *p<0.05, ** p<0.01,
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Figure 3.19 Depletion of Foxp3+ cells pr ior to and dur ing AAI induction did not
affect percentagesand total numbersof Th2 2D2 cellswithin the lung and medLN.
Experimental approach is shown in Figure 3.15. (A) Percentages of Th2 2D2 cells of all
CD4+ cells and (B) total cell numbers of Th2 2D2 cells in theleft lunglobe, medLN and
spleen. Data are from oneexperiment, n=3-4. ns= not significant, *p<0.05,**p< 0.01 as
determined by aone-way variance(ANOVA) usingTukey’smultiplecomparisontest.
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Figure 3.20 Increased frequency of IL-13+ and GM-CSF+ Th2 2D2 cells from the
lung of micedepleted of Foxp3+ cells.
Experimental approach is shown in Figure 3.15.On day 9 cells isolated fromthelungs of
rMOG-challenged mice were cultured with (+) or without (-) MOG35-55 overnight and
effector cytokine production was determined by ICS. Cells from unstimulated controls
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Figure 3.21 Administration of DTx pr ior to and dur ing AAI induction did not affect
the percentage and absolute numbers of total Foxp3+ CD4+ cells but decreased
percentageof host Foxp3+ cells in themedLN.
Experimental approach is shown in Figure 3.15.Intracellular staining was used to detect
Foxp3expression. (A) Percentages of total Foxp3+ CD4+ cells of all CD4+ cells and (B)
total numbers of Foxp3+ CD4+ cells in the left lung lobe, medLN and spleen. (C)
Percentage (of host CD4+ cells) and total number of host Foxp3+ cells in medLN. Data
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Figure 3.22 Depletion of host Foxp3+ cells resulted in the increased frequency of
Foxp3+ Th2 2D2 cells in themedLN and spleen.
Experimental approach is shown in Figure 3.15.Intracellular staining was used to detect
Foxp3 expression. (A) Representative flow cytometry plots showing percentages of
Foxp3+ Th2 2D2 cells of total Th2 2D2 cells. (B) Percentages of Foxp3+ Th2 2D2 cells
of total Th2 2D2 cells and (C) total numbers of Foxp3+ Th2 2D2 cells in the left lung
lobe, medLN and spleen. Data are from one experiment, n=3-4. ns = not significant,
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3.3. Discussion 
3.3.1. Why does rMOG sensitization do not induce lu ng 
inflammation? 
In this project the sensitization of C57BL/6 mice with rMOG and subsequent airway 
challenges were not found to induce eosinophilia and lung inflammation 
characteristic of AAI. Detection of rMOG-specific IgE and IgG1, associated with 
Th2 responses, suggested that mice were successfully ensitized. However, this was 
not sufficient to promote the inflammatory response in the lung. A possible 
explanation for this observation could be immune tol rance towards MOG as it is a 
self-antigen. As described in section 1.3.2, a number of mechanisms exist to prevent 
uncontrollable T cell responses towards self-antiges which can otherwise lead to 
autoimmunity (Ryan et al., 2007). Nevertheless, it is known that rMOG can 
effectively induce Th1/Th17-mediated autoimmune CNS inflammation as seen in 
EAE which is induced by immunization of WT mice with rMOG in CFA (Fillatreau 
et al., 2002). Alum used in a sensitization is a less strong adjuvant than CFA and 
although it was shown to promote production of IgE and IgG1, the Th2-associated 
antibody response induced by rMOG in alum might not be sufficiently robust for an 
induction of AAI.  
 
In order to verify whether a degree of self-tolerance to MOG was implicated in the 
failure to induce AAI, the lung inflammatory reaction was investigated in MOG-
deficient mice, in which rMOG can be considered a foreign antigen. Despite ~35% 
of eosinophils in BAL no lung infiltration or goblet cell hyperplasia was evident in 
these mice. The sensitization was confirmed by the det ction of rMOG-specific IgE 
and IgG1 in serum, although the levels of IgE were low and did not increase upon 
rMOG challenge. This suggests that possible self-tolerance mechanisms to MOG are 
not implicated in the lack of lung inflammation following AAI protocol.  
 
An explanation for the lack of allergic inflammatory reaction in the lung observed in 
both WT and MOG-deficient mice could be poor allergenic properties of rMOG. As 
already described in section 1.8.1, it is not known hat constitutes an allergen 
although enzymatic activity has been implicated in allergenicity of some peptides 
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such as HDM-derived Der p1 (Schulz et al., 1998). It has been determined that an 
allergen such as OVA323-339 has to have at least two allergenic determinants that bind 
to IgE on mast cells and cross link them to cause mast cell degranulation (Honma et 
al., 1996). It is possible that rMOG which is not a natural allergen may not have the 
properties that would make it a true allergen even though it can be considered a 
foreign antigen in MOG-deficient mice. A contributing factor could be the strain of 
mice used in this project. Both WT and MOG-deficient mice used in all experiments 
described in this thesis are on the C57BL/6 background and it has been demonstrated 
by multiple studies that C57BL/6 mice are less susceptible to developing allergic 
airway inflammation and as they do not generally display detectable AHR most 
induction protocols use BALB/c mice (Gueders et al., 2009, Conrad et al., 2009, 
Sahu et al., 2010).   
 
3.3.2. How does rMOG-induced AAI mediated by Th2 2D 2 
cells compare to other models of AAI? 
The majority of AAI induction protocols use antigen sensitization to initiate allergic 
responses. However, in this project although sensitization with rMOG was found to 
induce IgE and IgG1 no inflammatory response in the lung was observed. That is 
why a different approach was taken - the adoptive transfer of Th2 polarised    
MOG35-55-reactive (2D2) CD4
+ cells. The use of antigen-reactive Th2 cells to induce 
AAI in response to airway challenge with the antigen has been demonstrated in 
several studies. Cohn et al. used Th2 polarised OVA323-339-reactive CD4
+ cells 
followed by 7 days of daily exposure to aerosolized OVA in BALB/c mice (Cohn et 
al., 1997). In this project a different method of antigen challenge was chosen as it 
was previously determined that intratracheal challenge results in more direct and 
even distribution of the antigen within the lung versus intranasal challenge (Sarah 
Howie, personal communication). Although the experim nts described in this chapter 
involved a similar Th2 polarisation protocol and the same number of transferred 
antigen-reactive Th2 cells as by Cohn et al., most readouts of disease were strikingly 
less severe. As no infiltration scores or total celnumbers in the lung were given in 
that study it is difficult to make a direct comparison in terms of lung pathology. 
However, total cell numbers in BAL and eosinophil counts were approximately 20-
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fold lower in rMOG-induced AAI. Similarly, goblet cell hyperplasia reached ~65% 
in the Cohn study compared to ~12% to 32% observed here. The most obvious 
explanations for these observations would be a different airway challenge protocol 
and a different strain of mouse used.  
 
Interestingly, when the percentages of antigen-reactive Th2 cells were compared, 
OVA323-339-reactive Th2 cells comprised ~8% of all CD4
+ cells in the medLN and 
75% in the lung in the Cohn study versus ~15% of MOG35-55-reactive Th2 cells in 
the medLN and only 9% in the lung in rMOG-induced AAI. Considering the higher 
percentage of Th2 2D2 cells within medLN and much lower in the lung compared to 
OVA323-339-reactive Th2 cells, it is possible that these cells differ in their ability to 
migrate into the lung. The Cohn study demonstrated that IL-4 production by Th2 
polarised OVA323-339-reactive CD4
+ cells was critical to their recruitment into the 
lung (Cohn et al., 1997). Th2 2D2 cells were shown to produce IL-4 upon re-
stimulation in vitro (data not shown). However, low IL-4 concentrations detected in 
BAL fluid of rMOG-challenged mice could suggest that there is insufficient IL-4 
produced by Th2 2D2 cells in vivo for their more efficient recruitment into the lung. 
The lower percentage of Th2 2D2 cells in the lung could in turn correlate with 
decreased disease severity when compared to OVA-induced AAI.  
 
C57BL/6 mouse strain was used in a different AAI study which involved an adoptive 
transfer of 2x106 cells Th2 polarised antigen-reactive CD4+ cells obtained by 
isolating CD4+ cells from the spleens of OVA immunized mice (Hogan et al., 1998). 
The antigen in that study was given via the intranas l route for 8 days, every second 
day. That model was not characterised in detail thoug  and was only done in IL-5-
deficient mice without comparison to WT mice. The two main readouts from that 
study included BAL eosinophilia which was more sever  compared to Th2 2D2 
model used here and a detectable AHR. Previous workithin the laboratory has used 
the same Th2 polarisation and AAI induction protocols and the same strain of mouse 
as in this project but a different antigen, OVA, and OVA323-339-reactive CD4
+ (OT-II) 
cells to drive the disease (Mackenzie, 2011). Comparing the two models, the lung 
pathology was strikingly more severe in Th2 OT-II-driven AAI with the eosinophil 
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contribution in BAL reaching ~80-90% compared to ~30% observed in the Th2 2D2-
driven model. Moreover, the percentage and total number of Th2 OT-II cells in the 
lung upon OVA challenge were ~10-fold higher compared to the percentage and 
number of Th2 2D2 cells upon rMOG challenge. Interestingly, the frequency and 
total numbers of Th2 OT-II and Th2 2D2 cells in medLN were similar. This supports 
the hypothesis that Th2 polarised 2D2 cells may have a disadvantage in their ability 
to traffic into the lung or they are prone to death once they get into the tissue albeit in 
the presence of their cognate antigen. This could be potentially related to the fact that 
MOG is an autoantigen and host self-regulatory mechanisms could limit the 
pathogenicity of 2D2 cells at least in the context of Th2 type of inflammation.  
 
In conclusion, the experiments described in this chapter demonstrated that Th2 
polarised 2D2 CD4+ cells are capable of inducing moderate AAI upon airw y 
challenge with rMOG which is characterized by lung eosinophilia, inflammatory 
infiltration of the lung and goblet cell hyperplasi. Increased production of Th2-
associated cytokines and expression of GATA-3 by Th2 2D2 cells isolated from the 
antigen-challenged lung provide further evidence of Th2-mediated inflammatory 
response and a possible readout of how pathogenic Th2 2D2 cell function/phenotype 
can be modified by regulatory mechanisms.  
 
3.3.3. A role for Foxp3 + cells in the control of lung 
inflammation in AAI 
The importance of Foxp3+ cells in regulating lung inflammation in AAI was 
discussed in section 1.8.2.3. Multiple studies have demonstrated protective effects of 
CD4+ CD25+ cell transfer (Kearley et al., 2005, Leech et al., 2007) and increased 
disease severity upon CD25+ cell depletion prior to antigen challenge (Lewkowich et 
al., 2005, Leech et al., 2007). However, only a limited number of studies have 
investigated how endogenous Foxp3+ cell populations change during AAI and none 
of the studies assessed this in an adoptive transfer model of AAI. Leech et al. showed 
that during acute self-resolving AAI induced by HDM-derived Der p1 the 
percentages of Foxp3+ cells increase within the lung and medLN upon airwy 
challenge (Leech et al., 2007). This increase was detectable four days after the last 
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antigen challenge and corresponded with the peak of disease. This elevated Foxp3+ 
cell frequency then started to decrease and returned to a steady-state level once the 
inflammation was fully resolved. This observation strongly suggested a role for 
Foxp3+ cells in limiting the pathology in that model whic was confirmed by 
depletion studies (Leech et al., 2007). Here, kinetics study of rMOG-induced AAI 
revealed that the peak of lung inflammation occurred two days after the last antigen 
challenge and this corresponded with the highest frquency and absolute numbers of 
Foxp3+ cells in the lung, and with the highest numbers of F xp3+ cells within 
medLN. The percentage of Foxp3+ cells decreased just two days after the peak and 
returned to a steady-state level between days 11 and 16 which also corresponded 
with disease recovery. This similarity in the kinetcs of Foxp3+ cell changes during 
lung inflammation seen in both Der p1- and rMOG-induced models of AAI 
highlights how quickly Foxp3+ cells are able to respond to Th2-mediated 
inflammation and how effectively they can control it by transient changes in their 
proportion. Whether the function of Foxp3+ cells is affected, is as yet undetermined.  
 
The increase in the total numbers of Foxp3+ in the lung tissue following allergen 
exposure has been also demonstrated in OVA-mediated AAI as well (Lu et al., 
2011). However, it was not shown how it correlates with disease severity. Cell 
proliferation measured by BrdU incorporation performed in that study indicated that 
the majority of lung Foxp3+ cells actively proliferated in situ. Interestingly, the 
expansion of Treg within the inflamed CNS during MOG-induced EAE was also 
shown to be associated with rapid proliferation of Treg within the CNS rather than de
novo induction of Foxp3+ cells (Korn et al., 2007, O'Connor et al., 2007). Whether 
elevated levels of Foxp3+ cells observed in the Th2 2D2-driven AAI model could be 
a result of rapidly proliferating nTreg or rather nTreg migration from the periphery or 
de novo induction of iTreg needs to be determined. Moreover, as the antigen-
reactivity of Foxp3+ cells in AAI has never been investigated and it was reported that 
in EAE the CNS-derived Treg are enriched for myelin-reactive Treg (Korn et al., 
2007, O'Connor et al., 2007), it would be valuable to known whether in the Th2 2D2-
driven model of AAI there is an enrichment for antigen-reactive Foxp3+ cells as well.   
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The importance of host Foxp3+ cells in an adoptive Th2 cell transfer model has not 
been addressed before. Having established that Foxp3+ cell population increases in 
size following rMOG challenge in AAI and that this correlates with disease severity, 
it was decided to investigate the effects of depleting hese cells. Most studies have 
previously used α-CD25 antibody to deplete regulatory CD4+ CD25+ cells 
(Lewkowich et al., 2005, Leech et al., 2007). However, as this model involved 
transfer of highly activated CD25+ Th2 2D2 cells, this method of depletion was not 
possible. Hence, Foxp3.LuciDTR-4 mice were used (Suffner et al., 2010). Foxp3+ 
cells were depleted using DTx prior to and during rMOG-induced AAI as it has been 
reported that their numbers do readily recover in the absence of DTx (Suffner et al., 
2010). Ablation of Foxp3+ cells was not found to significantly change total BAL 
counts or eosinophil percentage, however it significantly increased lung infiltration 
scores leaving goblet cell hyperplasia unaffected. Moreover, it resulted in elevated 
percentages of CD4+ cells within the lung and slightly higher percentages of Th2 
2D2 cells within the lung and medLN. These results partially disagree with 
previously published observations from a sensitisaton model of HDM-mediated AAI 
in which an increase in total BAL cells and eosinophilia but no effect on lung 
infiltration were reported upon Foxp3+ cell depletion (Leech et al., 2007). This 
however, could be due to the use of a CD25 depleting a tibody in that study, a 
different model of AAI and the antigen used. Interestingly, in line with results from 
the Th2 2D2-driven AAI model, selective Foxp3+ cell depletion using DTx during 
the sensitization phase was demonstrated to enhance lu g infiltration but did not 
affect goblet cell hyperplasia in OVA-induced AAI model (Baru et al., 2010). The 
elevated production of Th2-associated IL-13 and GM-CSF by Th2 2D2 cells in the 
lung upon Foxp3+ cell depletion which was observed in rMOG-induced AAI was 
also reported in other models (Leech et al., 2007, Lewkowich et al., 2005, Baru et al., 
2010).  
 
An interesting observation made here following Foxp3+ cell depletion was the 
increased frequency of Foxp3+ cells within the transferred Th2 2D2 cell population. 
On the day of transfer, Foxp3+ cells constitute less than 1% of total Th2 2D2 cells. 
This percentage was found to increase to ~18% in the lung and to ~16% in the 
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medLN upon DTx treatment and rMOG challenge. However, it was only found to be 
significantly different in the medLN because of large variability within the groups. It 
is not known whether this increase is associated with expansion of the small 
percentage of Foxp3+ cells transferred within Th2 2D2 cell population or an active 
Foxp3 induction in Th2 2D2 cells. It has been reported previously that in Foxp3-
depleted mice there is a homeostatic proliferation of the remaining Foxp3+ cells to 
ensure rapid recovery of Treg compartment (Suffner et al., 2010). Hence, an 
increased frequency of Foxp3+ cells within Th2 2D2 cell population upon DTx 
treatment could provide an additional compensatory mechanism for the depleted host 
Foxp3+ cells.  
 
3.4. Concluding remarks 
 
• Sensitization and subsequent airway challenge with rMOG does not induce AAI 
in WT or MOG-deficient mice. 
• Adoptive transfer of Th2 polarised 2D2 CD4+ induces moderate lung 
inflammation upon rMOG challenge, characteristic of Th2-mediated AAI. 
• Lung inflammation in rMOG-induced AAI is associated with increased 
frequency of 2D2 Th2 cells within the lung and medLN. 
• The peak of lung inflammation in rMOG-induced AAI correlates with increased 
frequency and total numbers of Foxp3+ cells within the lung. 
• Depletion of host Foxp3+ cell prior to and during AAI induction results in 
increased disease severity.  
 
This rMOG-induced model of AAI provides a critical tool for testing the importance 
of Treg phenotype versus antigen-responsiveness in the r ability to suppress T cell 
responses in different inflammatory conditions. The phenotype of Foxp3+ cells in 
different inflammatory contexts both in vitro and in vivo is discussed in Chapter 4, 
whereas therapeutic activity of Treg is the focus of Chapter 5.  
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4 Treg polarisation in vivo and in vitro 
 
4.1. Introduction 
Different T helper lineages are characterized by the expression of distinct 
transcription factors and chemokine receptors such as expression of T-bet and 
CXCR3 in Th1 cells or expression of GATA-3 and CCR4 in Th2 cells. Although 
Foxp3+ Treg have been shown to differentially express a variety of tissue-specific 
markers and homing molecules (Siewert et al., 2007, Kohm et al., 2002), it is unclear 
whether they can ‘specialize’ like effector CD4+ T cells (Teff) do in particular 
cytokine environments to maximise their suppressive pot ntial towards differentiated 
Teff.   
 
Evidence for Treg ‘specialization’ comes from the studies on the murine models of 
infection. Foxp3+ CD4+ cells have been shown to upregulate expression of T-bet 
during chronic infection with Mycobacterium tuberculosis (Koch et al., 2009). In that 
study T-bet was demonstrated to not only regulate homeostasis of Treg during Th1 
responses in vivo, but also to induce CXCR3 expression in Treg which was important 
for their migration towards the site of inflammation and was associated with more 
effective suppression of Teff both in vitro and in vivo. A different study has shown 
that Foxp3 regulates expression of Th2-associated transcription factor IRF-4 in Treg 
and its ablation leads to an autoimmune lymphoproliferative disorder characterized 
by uncontrollable Th2 responses which can be detected in mice as soon as they reach 
3-4 weeks of age (Zheng et al., 2009). It has therefore been suggested that Treg may 
be capable of utilizing certain components of transcriptional machinery involved in 
promoting the differentiation and function of a particular Teff lineage to efficiently 
control the corresponding type of the immune respone.  
 
Whether Treg can acquire different phenotypes during chronic inflammation 
observed in differentially mediated autoimmune and llergic diseases and how this 
correlates with their suppressive potential is currently unknown. In this project, based 
on evidence from the infection and homeostasis studies, it was hypothesized that 
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Treg derived from the CNS in Th1/Th17-mediated EAE and from the lung in Th2-
mediated AAI will differ in their expression of Th-associated transcription factors 
and chemokine receptors and this will influence their ability to inhibit different types 
of Teff responses. It is important to note that both f these models represent self-
resolving and relatively short inflammation period lasting over days to 2 weeks 
rather than months. Hence, it would be interesting o determine whether relatively 
short inflammation time is sufficient for Treg specialization.  
 
4.1.1. Aims 
The main aims of the experiments described in this c apter were to: 
1) Investigate Foxp3+ CD4+ cell phenotype in the inflamed tissue versus 
peripheral organs in Th1/Th17-mediated EAE and in Th2-mediated AAI. 
2) Assess whether nTreg can be polarised in vitro and hence recapitulate in vivo 
observations, and establish what conditions are most optimal. 
3) Characterize the phenotype of iTreg upon TGF-β-mediated induction and 
how this is affected by polarising conditions i  vitro.  
 
4.1.2. Approach 
Foxp3-GFP mice were used throughout the experiments in this chapter unless 
otherwise stated as they enabled identification of Foxp3+ cells without the need for 
the intracellular Foxp3 staining. Differences in the Foxp3+ cell phenotype in 
differentially mediated inflammatory diseases in vivo were first investigated. EAE 
was used as a model of Th1/Th17-mediated autoimmune inflammation and rMOG-
induced AAI (described in Chapter 3) was used as a model of Th2-mediated allergic 
inflammation. Foxp3+ Treg were characterized in terms of  expression of Th-
associated transcription factors, chemokine receptors and activation markers and the 
phenotype of tissue-derived and peripheral Foxp3+ CD4+ cells was compared in both 
diseases.  
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To establish whether in vivo observations could be recapitulated in vitro, changes in 
nTreg phenotype were assessed upon their stimulation under Th1 or Th2 polarising 
conditions. As the numbers of nTreg available for plarisation were limited and 
significantly diminished after in vitro culture, nTreg expansion with α-CD3/α-CD28 
T cell expander Dynabeads and high IL-2 concentration under polarising conditions 
was utilized. In addition to nTreg, iTreg which provide an easy means of generating 
robust numbers of cells capable of effectively suppressing pathogenic T cell 
responses were also characterized. The phenotype of iTreg was assessed upon TGF-
β-driven Foxp3 induction in vitro, and following their generation and re-stimulation 
under polarising conditions. The stability of Foxp3 expression in Treg manipulated 
in vitro was also addressed.  
 
4.2. Results 
4.2.1. Phenotypic analysis of Foxp3 + cells in vivo 
4.2.1.1. Upregulated expression of T-bet and CXCR3 in Foxp3 + cells 
from inflamed CNS in EAE  
To investigate the phenotype of Treg in a Th1/Th17-mediated inflammation, EAE 
was induced by immunization of Foxp3-GFP mice with MOG35-55 in CFA (Figure 
4.1A). On day 14 to 17 post-immunization as the anim ls were recovering the CNS, 
inguinal lymph nodes (ingLN) draining the site of immunization and spleen were 
harvested for the flow cytometric analysis (Figure 4.1B). Spleen of naïve mice was 
used as a control. The percentage of Foxp3+ CD4+ cells was increased to ~20-30% in 
the CNS compared to ~15% in ingLN and ~10% in the spl en (Figure 4.1C). The 
increase in the percentage of Foxp3+ CD4+ cells during the EAE recovery phase has 
been previously demonstrated and was shown to be driv n by the CNS inflammation 
itself and to be critical for the disease resolution (McGeachy et al., 2005, O'Connor 
et al., 2007). The phenotype of Foxp3+ CD4+ cells isolated from the CNS was 
compared to that of peripheral Treg isolated from the EAE spleen and the naïve 
spleen. The expression of T-bet was found to be specifically upregulated in Treg 
derived from the inflamed CNS, whereas its expression in the EAE spleen and the 
control spleen was absent (Figure 4.1D). It is important to note that expression of T-
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bet in Treg within the CNS was lower compared to its expression in effector CD4+ T 
cells from the same site (data not shown). Low GATA-3 expression was detectable 
Foxp3+ CD4+ cells isolated from the EAE CNS and spleen and the control spleen, 
and no difference in the expression levels was observed (Figure 4.1D).  
 
The expression of the Th1-associated chemokine receptor CXCR3 was the highest on 
Treg isolated from the CNS (Figure 4.2A). CXCR3+ Treg comprised ~50-55% of 
total Treg compared to ~18-20% in the EAE and the naïve spleens. To assess cell 
activation status, expression levels of CD62L and CD44 were compared. All Treg 
isolated from the inflamed CNS were CD62L- compared to ~10% and ~20% of 
CD62L+ Treg observed in the EAE and the naïve spleens, respectively (Figure 4.2B). 
The expression of CD44 was high on all Treg, however th  highest levels were found 
within the CNS. Treg were also characterised in terms of CD73 expression which 
was shown to correlate with their suppressive potential (Kobie et al., 2006, Deaglio 
et al., 2007). CD73 was highly expressed on all Foxp3+ CD4+ cells, but its expression 
was the highest on Treg isolated from the inflamed CNS (Figure 4.2B).  
 
It is important to note that a recently published study by the Vignali group has found 
that Foxp3-GFP mice used in this project have a perturbed Treg function in an 
inflammatory environment (Bettini et al., 2012). This is due to N-terminal GFP-
fusion protein which is s hypomorph that leads to an altered Foxp3-driven epigenetic 
modification of genes in Treg from these mice compared to WT mice. It has been 
shown that this results in accelerated autoimmune diabetes (Bettini et al., 2012). 
Whether this has an effect on Treg phenotype and fuction in EAE is unknown and 
has to be determined.    
 
These data demonstrate that Foxp3+ CD4+ cells derived from the inflamed CNS 
tissue have a distinct phenotype compared to the peripheral Treg and express higher 
levels of Th1-associated T-bet and CXCR3. Moreover, they are CD62L- and 
CD44high indicative of an activated phenotype and CD73high. In order to see if this 
phenotype was associated specifically with a Th1/Th7-mediated response and not 
inflammation itself, the phenotype of Treg in Th2-mediated AAI was investigated.  
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4.2.1.2. Upregulated expression of GATA-3 and lack of T-bet in 
Foxp3 + cells from inflamed lung in AAI  
As demonstrated in Chapter 3, an adoptive transfer of Th2 polarised 2D2 cells and 
airway challenge with rMOG induces Th2-mediated lung i flammation. This was 
shown to be associated with the increased frequency a d total numbers of Foxp3+ 
CD4+ cells within the inflamed lung. The importance of Treg was demonstrated by 
the increased AAI severity when Foxp3+ cells were depleted. The AAI kinetics study 
indicated day 9 as the optimal time point to look at Foxp3+ cells. Following induction 
of AAI either in Foxp3-GFP or C57BL/6 mice, Foxp3+ CD4+ cells from the lung and 
the spleen were analysed by flow cytometry (Figure 4.3A, B). The spleen from PBS-
challenged mice was used as a control.  
 
No T-bet expression was found in the AAI lung, AAI spleen or the control spleen 
(Figure 4.3C). GATA-3 was expressed in Treg isolated from all sites. However, its 
expression was the highest on Foxp3+ cells derived from the inflamed lung (Figure 
4.3C). It is important to note that increased GATA-3 expression in Foxp3+ cells from 
the lung was lower compared to GATA-3 expression in 2D2 Th2 cells isolated from 
the same site (data not shown). Although the MFI of CXCR3 expression of total 
Foxp3+ cells in the lung was increased when compared to the peripheral Foxp3+ 
CD4+ cells (data not shown), the percentage of CXCR3 highly positive Treg was 
~10-12% and was similar to the frequency of CXCR3+ Treg in the AAI and the 
control spleens (Figure 4.4A). CD62L expression in the lung was negative in ~80% 
of Foxp3+ cells and was similar to Treg isolated from the AAI and the naïve spleens 
(Figure 4.4B). The expression of both CD44 and CD73 was high on all Treg but the 
highest expression levels were found on Treg derived from the AAI lung (Figure 
4.4B).   
 
Foxp3+ CD4+ cells isolated from the AAI lung were found to have a distinct 
phenotype from the peripheral Treg and from the CNS-derived Treg in EAE. They 
did not express T-bet and had upregulated expression of GATA-3. Unlike in EAE, 
there was no evidence of increased percentage of CXCR3+ Treg within the lung in 
AAI. In order to verify whether these results could be recapitulated in vitro and 
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establish what conditions were needed for this to occur, Treg stimulation and 
expansion under polarising conditions were next investigated.  
 
4.2.2. Foxp3 + T cell manipulation in vitro 
4.2.2.1. Lack of T-bet and low/intermediate levels of GATA-3 in 
Foxp3 + cells at a steady-state level 
Ex vivo analysis of peripheral CD4+ T cells isolated from naïve Foxp3-GFP mice 
(Figure 4.5A) revealed that there is no T-bet expression in both Foxp3- and Foxp3+ 
cells but low/intermediate levels of GATA-3 (Figure 4.5B). Moreover, GATA-3 
expression was higher in Foxp3+ cells compared to Foxp3- cells (Figure 4.5B).  
 
4.2.2.2. nTreg upregulate T-bet and GATA-3 under Th 1 and Th2 
polarising conditions in vitro, respectively 
Due to the low viability of sorted CD4+ Foxp3+ cells stimulated under polarising 
conditions (data not shown), it was decided to polarise whole splenocytes instead for 
the full phenotypic analysis. Moreover, a higher dose of 100U/ml IL-2 was used 
(compared to standard 10U/ml and 40U/ml IL-2 doses for Th1 and Th2 polarisations, 
respectively) as IL-2 was previously shown to be critical for the Treg survival 
(Sakaguchi et al., 2008). Cells isolated from the Foxp3-GFP mouse were stimulated 
with α-CD3 for 3 days under Th1 (IL-12, IL-18) or Th2 (IL-4, α-IL-12, α-IFN-γ) 
polarising conditions (Figure 4.6A). The percentage of Foxp3+ cells from a starting 
population of ~8-10% of total CD4+ cells decreased to 2-3% after 3-day culture 
reflecting rapid proliferation of Foxp3- cells under polarising and stimulating 
conditions (data not shown). Foxp3- cells were found to have an upregulated 
expression of T-bet when stimulated under Th1 polarising conditions, and 
upregulated expression of GATA-3 when stimulated uner Th2 polarising conditions 
(Figure 4.6B&C). This is in agreement with previously well-established data on 
CD4+ T cell polarisation described in section 1.4. Foxp3+ cells were found to express 
higher levels of T-bet under Th1 conditions and higher levels of GATA-3 under Th2 
conditions in a similar fashion to Foxp3- cells (Figure 4.6B&C). Intermediate T-bet 
expression observed in Th2-polarised cells and GATA-3 expression in Th1-polarised 
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cells might be due to the high activation status of the cells. Overlays of transcription 
factor expression between Foxp3- and Foxp3+ cells revealed that Foxp3- cells 
expressed higher levels of T-bet and GATA-3 under Th1 and Th2 polarising 
conditions, respectively compared to Foxp3+ cells (Figure 4.6B).  
 
It was concluded that IL-12 and IL-18 are sufficient to induce T-bet expression in 
nTreg, whereas IL-4 in the presence of blocking antibodies to IL-12 and IFN-γ is 
sufficient to induce GATA-3 expression. In addition to Th1 and Th2 conditions, 
Foxp3+ cell polarisation under Th17-skewing conditions was lso investigated.  
However, due to the lack of use of exogenous IL-2 in the culture conditions (because 
of its ability to inhibit Th17 differentiation), Foxp3+ cells did not survive the 3-day 
stimulation (data not shown). It has to be noted that CD4+ Foxp3--derived cytokines 
produced upon stimulation such as IFN-γ might be implicated in nTreg polarisation 
as the cell cultures were not sorted.  
 
4.2.2.3. Expanding nTreg under polarising condition s 
In addition to characterizing Foxp3+ cells stimulated under polarising conditions, it 
was investigated whether expansion of Treg under Th1 and Th2 conditions was 
possible, to obtain larger numbers of cells, not only for phenotypic but also 
functional analysis. Cells isolated from Foxp3-GFP mice were FACS sorted for 
CD4+ CD62Lhigh GFP+ cells and expanded in vitro with α-CD3/α-CD28 T cell 
expander Dynabeads in the presence of high IL-2 concentration (1000U/ml) and/or 
Th1 or Th2 polarising conditions for 7 to 10 days (Figure 4.7A). The FACS sort was 
based on CD62L expression as it was shown previously that CD62Lhigh cells retain 
high Foxp3 expression during expansion, whereas CD62Llow/- Treg do not (Stephens 
2009). Although the percentage of viable proliferating cells (judging from the light-
scattering properties of the cells) was lower in nTreg expanded under Th1 or Th2 
polarising conditions versus neutral conditions (Figure 4.7B), no significant 
differences were noted in Foxp3 expression or cell expansion (Figure 4.7C&D).  
 
Phenotypic analysis revealed that Foxp3+ cells expanded under Th1 conditions 
upregulated expression of T-bet, whereas the cells expanded under either neutral or 
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Th2 conditions did not express T-bet (Figure 4.8A). GATA-3 expression was low on 
all expanded nTreg and was not promoted by Th2 polarising conditions (Figure 
4.8A). CXCR3 was high on all cells. However, the highest expression was noted on 
nTreg expanded under Th1 conditions (Figure 4.8B). Such high CXCR3 expression 
observed in nTreg expanded under all conditions could be associated with high cell 
activation status and active cell proliferation.  
 
4.2.2.4. TGF-β-induced Foxp3 + cells have a Th1-like phenotype 
A different Treg subtype, TGF-β induced Foxp3+ cells, can be easily generated in 
vitro in large numbers and have been demonstrated to effectively suppress 
pathogenic responses in various disease models (Chen et al., 2003, Zhang et al., 
2010). Nevertheless, their phenotype upon induction and subsequent re-stimulation 
under different pro-inflammatory conditions has not been well characterized. It is 
unknown whether iTreg and nTreg can be ‘polarised’ in a similar fashion depending 
on the local cytokine environment but it has been established that they respond 
differently to pro-inflammatory cues in terms of the cytokines they produce 
(O'Connor et al., 2010) which may indicate differenc s in their phenotype.  
 
To investigate the possible differences in iTreg phenotype, splenocytes from naïve 
Foxp3-GFP mice were FACS sorted for GFP- CD4+ CD62Lhigh cells and stimulated 
for 5 days with α-CD3/α-CD28 in the presence of IL-2 and TGF-β (Figure 4.9A). 
The induction efficiency of Foxp3 under these conditions varied between 85-95% of 
total cells depending on the experiment (Figure 4.9B). Following induction, iTreg 
were found to express high levels of T-bet which agrees with previously reported 
observations (O'Connor et al., 2010) and contrasts with very low T-bet expression by 
nTreg isolated from naïve mice (Figure 4.9C). GATA-3 was expressed at 
intermediate levels and was similar in iTreg and nTreg (Figure 4.9C). Approximately 
55-60% of iTreg were found to be CXCR3+ compared to ~20% of CXCR3+ nTreg 
(Figure 4.10A). In terms of activation markers, both CD62L- and CD62L+ cells were 
found within iTreg populations compared to the majority of nTreg being CD62L- 
(Figure 4.10B). Both iTreg and nTreg expressed highlevels of CD44, however as the 
cells were stained in separate experiments it is difficult to conclude whether 
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expression of CD44 was higher on iTreg as it appears to be. The expression of CD73 
was high on both iTreg and nTreg (Figure 4.10B). 
 
4.2.2.5. Induction of iTreg under polarising condit ions 
To investigate how the iTreg phenotype in affected by pro-inflammatory cytokines, 
iTreg were first induced in the presence of polarising conditions (Figure 4.11A).    
IL-12 and IL-2 on their own did not induce Foxp3 expression and the simultaneous 
addition of TGF-β was necessary for this to occur (Figure 4.11B&C). Addition of 
titrated concentrations of IL-12 was not found to affect Foxp3 induction nor T-bet 
expression by iTreg on day 5 of culture (Figure 4.11B&C). Experiments with 
simultaneous addition of IL-12 and IL-18 or IFN-γ gave similar results (data not 
shown). Thus T-bet expression is intrinsic to the iTreg program, but cannot be 
elevated by exogenous IL-12 during iTreg induction.  
 
As IL-4 critical for Th2 differentiation was previously reported to inhibit expression 
of Foxp3 (Dardalhon 2008), it was decided to use titrated concentrations of IL-4 to 
establish the dose that would allow for effective iTreg induction. Addition of IL-4,  
α-IL-12 and α-IFN-γ without the presence of TGF-β did not induce Foxp3 expression 
and a dose dependent Foxp3 induction was observed with varying concentrations of 
IL-4 in the presence of TGF-β (Figure 4.12A&B). Expression of GATA-3 in iTreg 
was intermediate and remained unaffected by the presence of IL-4 in iTreg culture 
conditions (Figure 4.12A). Lower than usual GATA-3 expression in the control Th2 
sample might be due to the inefficient induction of Th2 phenotype using sorted CD4+ 
cells without the presence of APC.  
 
Investigation into individual effects of α-IL-12 and α-IFN-γ on IL-4-mediated 
inhibition of Foxp3 induction revealed that α-IFN-γ but not α-IL-12 opposed the 
inhibitory effect of IL-4 (Figure 4.13C). It has been shown that IFN-γ is produced in 
substantial amounts during iTreg induction (O'Connor et al., 2010) and hence 
blocking it may provide an advantage to the Foxp3 expr ssion. Addition of α-IFN-γ 
without IL-4 did not promote Foxp3 induction and this could be due to already very 
efficient Foxp3 induction of ~95%.  
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4.2.2.6. Re-stimulation of iTreg under polarising c onditions  
iTreg have been demonstrated to effectively suppress pathogenic T cell responses in 
vivo when given prior to disease induction (Chen et al., 2003, Zhang et al., 2010). 
Little is known, however, about their ability to suppress on-going inflammation. 
Hence, it was decided to investigate the effects of pr -inflammatory cytokines on 
iTreg phenotype during their re-stimulation under polarising conditions in vitro. 
iTreg were induced in the presence of TGF-β and IL-2 for 5 days followed by FACS 
sorting for pure GFP+ cells and subsequent 3-day re-stimulation under different 
conditions (Figure 4.13A). Re-stimulation of iTreg in the presence of TGF-β +/- IL-2 
resulted in ~90% of iTreg retaining their expression of Foxp3 compared to ~55% in 
the presence of IL-2 only (Figure 4.13B&C). When iTreg were re-stimulated in the 
presence of Th1 or Th2 polarising conditions they maintained ~10-15% of Foxp3 
expression, however simultaneous addition of TGF-β effectively prevented Foxp3 
loss (Figure 4.13B&C). 
   
In terms of iTreg phenotype, re-stimulation under Th1 conditions without the 
presence of TGF-β diminished T-bet expression in Foxp3+ iTreg whereas under Th2 
conditions abrogated it completely (Figure 4.14). The addition of TGF-β did not 
affect T-bet expression which was maintained in iTreg e-stimulated under both Th1 
and Th2 conditions. GATA-3 expression was intermediate in iTreg re-stimulated 
















































































Figure 4.1 Treg der ived from the inflamed CNS in EAE have an upregulated
expression of T-bet.
EAE was induced in Foxp3-GFP mice by immunization with MOG35-55 in CFA and two
consecutive doses of PTX. Mice were harvested during recovery phase on days 14-17.
(A) Induction protocol. (B) Mean clinical scores of EAE. (C) Representative percentages
of Foxp3+ CD4+ cells in the CNS, inguinal lymph nodes and spleen of EAE mice.
(D) Representative histograms showing expression of T-bet and GATA-3 in Treg
isolated fromtheEAE CNSandspleen and froma naïve spleen as a control. Panel on the
right shows overlays. Solid lines mark the staining and the shaded area is an isotype
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Figure 4.2 Treg der ived from the inflamed CNS in EAE express high levels of
CXCR3 and CD73 and havean activated phenotype.
Experimental scheme is shown in Figure 4.1. (A) Representative flow cytometry plots
showing expression of CXCR3 and (B) representative histograms showing expression
CD62L, CD44andCD73 in Treg isolated fromEAE CNS, spleen anda naïve spleen asa
control. Solid lines mark the staining and theshaded area is an isotypecontrol. Data are
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Figure 4.3 Treg der ived from the inflamed lung in AAI do not express T-bet and
havean upregulated expression of GATA-3.
AAI was induced in either Foxp3-GFP or C57BL/6 mice by an adoptive transfer of Th2
polarised 2D2 cells and airway challenges with rMOG. On day 9 the lung, medLN and
spleen were harvested and analysed by flow cytometry. (A) Experimental scheme.
(B) Representative histograms showing expression of T-bet and GATA-3 in Treg
isolated fromtheAAI lungand spleen, and from thePBS-challenged spleen as a control.
Panel on theright shows overlays. Solid lines mark thestainingand theshaded area is an
isotypecontrol. Data are representative of 3 experiments, n=4-5. ** p<0.01as determined
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Figure 4.4 Treg der ived from the inflamed lung in AAI express steady-state levelsof
CXCR3, but areCD73high and havean activated phenotype.
Experimental scheme is shown in Figure 4.3. (A) Representative flow cytometry plots
showing expression of CXCR3 and (B) representative histograms showing expression
CD62L, CD44 and CD73 in Treg isolated from the AAI lung, spleen and a PBS-
challenged spleen as a control. Solid lines mark the staining and the shaded area is an
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Figure 4.5 Foxp3+ CD4+ cells at a steady state are T-bet- but express
low/intermediatelevelsof GATA-3.
Whole splenocytes or FACS sorted GFP+ and GFP- cells from Foxp3-GFP mouse were
analysed by flow cytometry. (A) Representative flow cytometry plots showing thegating
strategy for Foxp3+ and Foxp3- CD4+ cell populations. (B) Representative histograms T-
bet and GATA-3 expression including overlays between Foxp3- and Foxp3+ cells. Red
and blue solid (Foxp3+ cells) and dashed (Foxp3- cells) lines mark the staining and a
shaded area isan isotypecontrol. Dataare representativeof 4 experiments, n=4-6 pooled.
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Figure 4.6 Foxp3+ CD4+ cells stimulated in vitro upregulate T-bet or GATA-3
expression under Th1 or Th2 polarising conditions, respectively.
Splenocytes from Foxp3-GFP mouse were stimulated with α-CD3 under Th1 or Th2
polarisingconditions for 3 days followed by flow cytometry analysis. The gatingstrategy
is shown in Figure 4.5.(A) Experimental scheme. (B) Representative histogramsof T-bet
and GATA-3 expression including overlays between Foxp3+ and Foxp3- cells. (C) Mean
fluorescence intensity (MFI) of T-bet and GATA-3 expression. Dashed lines represent
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Figure4.7Expansion of nTreg under polarising conditions.
Cells from Foxp3-GFP mouse were FACS sorted for GFP+ CD4+ CD62Lhigh cells and
expanded in vitro with Dynabeads in the presence of 1000U/ml IL-2 only (Neutral) or
with theaddition of Th1 or Th2 polarising conditionsfor 7 to 10 days. (A) Experimental
scheme. (B) Representative flow cytometry plots showing forward (FSC) and side light-
scattering properties (SSC) of cells and Foxp3 expression following expansion.
(C) Percentage of Foxp3+ cells and (D) fold expansion of total cells. Data are
representative of 3 experiments (B). Data are pooled from3 experiments (C&D) Data are
shown as mean +/- SEM. ns = not significant as determined by a one-way variance
(ANOVA) usingTukey’smultiplecomparisontest.




































































Figure 4.8 nTreg expanded under Th1 polarising conditions upregulate expression
of T-bet and CXCR3 but maintain GATA-3.
Experimental scheme and gating strategy is shown in Figure 4.7. (A) Representative
histograms of T-bet and GATA-3 expression and (B) CXCR3 expression in nTreg
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Figure4.9Generation and phenotypeof iTreg.
Splenocytes isolated from Foxp3-GFP mouse were sorted for GFP- CD4+ CD62Lhigh
cells using FACS and stimulated in the presence of absence of TGF-β and IL-2 for 5
days. (A) Experimental scheme. (B) Representative flow cytometry plots showing the
gating strategy for Foxp3+ CD4+ cells and the average Foxp3 induction efficiency. IL-2
only was used as a control. (C) Representative histograms showing the expression of
T-bet and GATA-3 in iTreg versus naïve nTreg. nTreg staining was donein a different
experiment. Red linemarks expression of T-bet, blue line marks expression of GATA-3
and the shaded area is an isotype control. Data are representative of at least 3
experiments.
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Figure4.10Phenotypeof in vitro generated iTreg.
Experimental scheme and thegating strategy is shown in Figure 4.9. (A) Representative
flow cytometry plots showing theexpression of CXCR3 in iTreg versusnaïve nTreg. (B)
Representative histograms showing theexpression of CD62L, CD44 and CD73 in iTreg
versus naïve nTreg. nTreg staining was donein a different experiment. Black line marks
the stainingand the shaded area is an isotypecontrol. Data are representative of at least 3
experiments.
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Figure 4.11 IL-12 does not affect Foxp3 induction and T-bet expression in
differentiating iTreg.
Sorted GFP- CD4+ CD62Lhigh cells were stimulated under different polarising conditions
with or without TGF-b for 5 days followed by flow cytometric analysis.
(A) Experimental scheme. (B) Representative flow cytometric plots showing Foxp3
expression and histograms of T-bet expression of cells cultured under different
conditions. (C) Percentages of FoxP3+ cells (of total cells) and MFI of T-bet expression
(gated on Foxp3+ cells or Foxp3- cells for an IL-2 only and Th1-polarised control). Data
are shown as mean +/- SEM. Data are representative of 2 experiments. ns=not significant
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Figure 4.12IL-4 inhibits Foxp3 induction in a dose-dependent manner and does not
upregulateGATA-3 expression in iTreg at the timeof induction.
Experimental approach isshown in Figure 4.11. (A) Representative flow cytometric plots
showingFoxp3expressionand histograms of GATA-3 expression of cells cultured under
different conditions. (B) Percentages of FoxP3 cells of all cells with varying
concentrations of IL-4. (C) Percentages of Foxp3+ cells of all cells with α-IL-12 and
α-IFN-γ added. Data are shown as mean +/- SEM. Data are representative of 2
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Figure 4.13 Re-stimulation of iTreg under polarising conditions leads to rapid loss
of Foxp3 expression which isprevented by exogenousTGF-β.
iTreg were generated as described in Figure 4.9, FACS sorted for GFP+ cells and re-
stimulated with α-CD3/α-CD28 for 3 days under different polarising conditions.
(A) Experimental design. (B) Representative histograms of Foxp3 expression and
(C) percentages of Foxp3+ iTreg re-stimulated under different conditions. Data are (B)
representative of 3 experiments or (C) are pooled from 3 experiments. *p<0.5,
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Figure 4.14 iTreg re-stimulated under Th1 or Th2 polar ising conditions do not
upregulateexpression of T-bet or GATA-3, respectively.
Experimental design is shown in Figure 4.13. Representative histograms of T-bet and
GATA-3 expression in iTreg re-stimulated under different conditions, gated on Foxp3+
cells. Dataare representativeof 2 experiments.
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4.3. Discussion 
4.3.1. Specialization of Treg in Th1- and Th2-media ted 
inflammation 
The suppressive potential of Treg is thought to relay on their ability to accumulate at 
the site of inflammation to adapt to the inflammatory environment in order to 
effectively regulate it (Yuan et al., 2007, Kang et al., 2007, Koch et al., 2009). To 
assess the possibility that Treg may specialize in line with CD4+ T cells driving a 
particular type of inflammation as suggested by other studies, the models of 
Th1/Th17-driven CNS inflammation and Th2-driven lung inflammation were 
investigated. The percentage and total cell number of Foxp3+ cells were found to be 
elevated during the recovery phase in EAE as reportd previously (McGeachy et al., 
2005). Similar observation was made in a new model of rMOG-driven AAI 
described in Chapter 3 where a significant accumulation of Foxp3+ cells was noted 
specifically within the lung upon antigen airway challenge. Phenotypic analysis 
revealed that Treg from the inflamed CNS in EAE hadan upregulated expression of 
the Th1 master regulator T-bet and Th1-associated ch mokine receptor CXCR3. In 
contrast, Treg derived from the inflamed lung in AAI had an increased expression of 
the Th2 master regulator GATA-3, lacked expression of T-bet and displayed 
decreased levels of CXCR3 compared to the CNS-derived Treg. Importantly, this 
“specialization” of Treg was only found in those sampled from the sites of 
inflammation and peripheral Treg displayed the same ph notype as Treg isolated 
from naïve mice. Foxp3+ and effector CD4+ cells sourced from EAE CNS and spleen 
and naïve spleen were also phenotyped by whole genom  analysis using Affymetrix 
and preliminary analysis supports the increased expression of T-bet and CXCR3 in 
the CNS-derived Treg (data not shown).  
 
The first evidence that Treg might be able to express T-bet came from a study which 
used a repetitive antigenic stimulation to induce IL-10-secreting CD4+ cells (Tr1) in 
a model of peptide-induced tolerance (Anderson et al., 2006). Gene expression 
profiling performed in that study indicated T-bet as one of the upregulated genes in 
the peptide-induced (PI)-Treg which was linked to the suppression of IL-2 
transcription thereby contributing to the tolerogenic rather than pathogenic potential 
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of these cells. Tr1 cells however do not express Foxp3 and hence it was unclear 
whether T-bet expression within the Treg compartment could also apply to Foxp3+ 
Treg. T-bet expression in Foxp3+ cells was reported later in Treg during Th1 type 
inflammation and, as already mentioned, it was demonstrated to be critical for Treg 
homeostasis, function and CXCR3-mediated migration o the site of inflammation 
(Koch et al., 2009). Interestingly, T-bet expression was found to be higher in Foxp3- 
cells compared to Foxp3+ cells in that study which is similar to the observation made 
in this project, namely that CNS-derived effector T cells have higher T-bet 
expression compared to Foxp3+ cells. This would support the idea that a low T-bet 
transcription in Treg is needed to switch on gene expression important for the control 
of Th1 response, whereas high T-bet expression, as found in Th1 cells, is associated 
with a pathogenic potential.  
 
Pathogenic T-bet expression in Treg was reported in a study involving a lethal 
infection with Toxoplasma gondii (Oldenhove et al., 2009). The highly Th1-
polarised environment in this infection model was suggested to disrupt Treg 
homeostasis, induce high T-bet and IFN-γ expression and contribute to Treg 
instability and hence inability to suppress CD4+ T cell responses. It is unclear 
however what level of T-bet expression in Treg confers more efficient suppressive 
phenotype and what level disrupts basic Treg functio s.   
 
In addition to the already mentioned expression of the Th2-associated transcription 
factor IRF4 in Treg (Zheng et al., 2009), an increased GATA-3 expression in Foxp3+ 
cells has been reported at mucosal sites in the gastrointestinal tract and the skin but 
not in the lung under steady-state conditions (Wohlfert et al., 2011). That study 
indicated that GATA-3 expression was not required to maintain Treg homeostasis 
and function at steady state. However, during inflammation it was required for Treg 
migration to the site of inflammation, for the mainte ance of Foxp3 expression 
stability and for resistance to the acquisition of effector functions (Wohlfert et al., 
2011). Interestingly, GATA-3-deficient Treg failed to protect in a model of 
Th1/Th17-mediated colitis indicating that in this case the site of inflammation rather 
than the type of immune response dictated Treg phenotype. Utilizing the method of 
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systemic activation and expansion of Treg with rIL-2 coupled with α-IL-2 antibody 
that study also demonstrated systemic GATA-3 upregulation in Foxp3+ cells and 
suggested that GATA-3 upregulation observed in Treg related to their activation 
status and was not a result of adaptation to the cytokine milieu. However, it was also 
shown that GATA-3 expression can be modified by polarising cytokines in vitro 
which poses a question whether the same modification happens under inflammatory 
conditions in vivo. The results from this project show that Foxp3+ cells derived from 
Th1/Th17 environment express lower levels of GATA-3 versus those derived from 
Th2 environment when compared to peripheral Treg which would indicate that such 
modification in vivo exists.  
 
It is important to note that although EAE is considered to be mediated by Th1/Th17 
cells, this project did not investigate the expression of Th17-associated transcription 
factors in Treg derived from the CNS due to insufficient cell numbers available for 
analysis. It has, however, been published that Foxp3+ cells can under certain 
conditions express STAT3, a transcription factor critical for Th17 differentiation 
which enables them to control pathogenic Th17 respon es (Chaudhry et al., 2009).    
 
There is evidence that this phenotypic diversity within the Treg compartment 
associated with specialization towards the corresponding types of CD4+ cell 
responses which is observed in murine models of inflammation is also relevant to 
human. Duhen et al. have reported that human peripheral blood contains multiple 
subsets of Treg characterised by distinct expression of chemokine receptors, 
transcription factors and cytokine responses (Duhen et al., 2012). Th1-, Th2-, Th17- 
and Th22-like Treg were differentiated on the basis of chemokine receptor 
expression including expression of CXCR3 in Th1-like Treg and CCR4 in Th2-like 
Treg. Moreover, mRNA expression showed higher levels of T-bet in Th1-like Treg 
as well as elevated ROR-γt in Th17-like Treg. Increased GATA-3 expression in Th2-
like Treg was less conclusive (Duhen et al., 2012). This highlights important 
differences to the murine model where peripheral Treg do not seem to be specialized, 
but acquire a distinct phenotype during inflammation specifically within the tissue. It 
would be of interest to know whether human Treg types distinguished in the 
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periphery of healthy individuals are more evident during inflammation in the affected 
tissue itself.  
 
4.3.2. Homing / activation status – tissue-derived versus 
peripheral Treg 
High expression of CD62L in conventional CD4+ T cells is associated with a naïve 
cell phenotype and ability of T cells to recirculate between the blood and the lymph 
nodes. In Treg, expression of CD62L differentiates s veral subsets. CD62L+/high Treg 
have been shown to migrate to lymphoid tissues and suppress activation of T cells 
within them, whereas CD62L-/low Treg have the ability to enter inflamed tissues and
suppress on-going inflammation (Huehn et al., 2004, Stephens et al., 2007). This is 
consistent with the CD62L- phenotype of tissue-derived Treg observed in this 
project. Interestingly, both CD62L- and CD62L+ Treg populations were isolated from 
the inflamed lung which may indicate that a subset of lung-derived Treg maintained 
the capacity to recirculate, whereas the CD62L- Treg from the CNS did not.  
 
Treg isolated from the CNS and the lung tissue had highly upregulated expression of 
CD44 compared to peripheral steady-state Treg. CD44 is a hyaluronic acid receptor 
and is commonly used as a T cell activation/memory marker. CD44 is upregulated on 
Treg upon activation and its high expression positively correlates with their 
suppressive capacity both in vitro and in vivo in a model of graft versus host disease 
(Firan et al., 2006, Bollyky et al., 2007). This suggests that Foxp3+ cells derived 
from the inflamed tissues in both EAE and AAI are activated and may have 
increased suppressive capacity which could contribute to their ability to effectively 
resolve inflammation observed in both disease models.    
 
A different cell surface marker that has been also a sociated with suppressive 
capacity of Treg is CD73 which was highly elevated on Treg specifically from the 
inflamed CNS and the lung. CD73 is a surface enzyme that converts local 5’AMP to 
adenosine which was shown to suppress proliferation and cytokine secretion of Th1 
and Th2 cells (Kobie et al., 2006, Deaglio et al., 2007). 5’AMP was suggested to be 
released by neutrophils or dying cells and hence to contribute to the resolution of 
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inflammation by dampening excessive damage to the tissue (Kobie et al., 2006). 
Therefore, higher expression of CD73 on Treg may play an important role in 
mediating the control and resolution of inflammation n the EAE and AAI models.  
 
4.3.3. Cytokine control of Treg polarisation in vitro 
Ex vivo CD4+ Foxp3- cells isolated from the spleen of non-manipulated mice did not 
express T-bet and had intermediate levels of GATA-3, which is consistent with 
previous reports (Lighvani et al., 2001, Zhang et al., 1997). nTreg shared the same 
phenotype, but their expression of GATA-3 was consistently higher compared to 
naïve Foxp3- cells. Elevated GATA-3 within the Treg compartment versus the CD4+ 
Foxp3- cell compartment at a steady-state level was report d previously and the most 
pronounced differences were shown to occur mainly at the site of mucosal barriers 
(Wohlfert et al., 2011). Interestingly, upregulation of GATA-3 in Treg was 
demonstrated to occur upon TCR engagement (Wohlfert et al., 2011) and hence 
could reflect a higher activation status of peripheral Treg, either as a whole 
population or within a specific Treg subset, compared to Foxp3- cells. Another study 
which also reported that nTreg at a steady-state lev l have a higher expression of 
GATA-3 compared to conventional CD4+ cells, suggested that this intrinsic property 
of nTreg predisposes them towards conversion to Th2cells contributing to the 
greater potential plasticity of Treg (Wang et al., 2010).  
 
It has been well established from in vitro studies that IL-12 induces differentiation of 
CD4+ cells to Th1 cells (Hsieh et al., 1993, Seder et al., 1993), whereas IL-18 acts as 
an enhancer (Yoshimoto et al., 1998). IL-12 signalli g results in activation of T-bet 
which controls expression of Th1-characterstic genes such as ifnγ and cxcr3 (Kaplan 
et al., 1996, Szabo et al., 2000). Consistent with these observations, polyclonal 
stimulation of splenocytes isolated from naïve mice in the presence of IL-12 and IL-
18 resulted in upregulation of T-bet in CD4+ Foxp3- cells. Relatively high GATA-3 
expression in these conditions could be a transient effect of a high activation status. 
Interestingly, it was demonstrated that IL-12 and IL-18 also upregulated T-bet 
expression within the Foxp3+ cell population. Similar results were obtained by Wei 
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at al. who showed that Foxp3+ cell stimulation in the presence of IL-12 only is 
sufficient for the induction of T-bet (Wei et al., 2009). Lower expression of T-bet in 
nTreg versus Th1 cells under polarising conditions is consistent with the in vivo data.  
 
A key cytokine driving the differentiation of Th2 cells is IL-4 which activates 
GATA-3 expression and hence programmes the Th2 cell lin age (Zheng and Flavell, 
1997). Stimulation in the presence of IL-4 and blocking antibodies to IL-12 and IFN-
γ was found to upregulate expression of GATA-3 in nTreg similarly to conventional 
CD4+ Foxp3- cells indicating that the cytokine driving Th2 cell development also 
mediates similar transcriptional changes in nTreg. Interestingly, the expression 
pattern of GATA-3 in nTreg and Foxp3- CD4+ cells was very different. Foxp3- CD4+ 
cells uniformly upregulated GATA-3, whereas nTreg semed to express GATA-3 in 
a bimodal fashion suggesting that only a subset of Treg was capable of expressing 
GATA-3 at the same level as conventional CD4+ cells. Upregulation of GATA-3 in 
the presence of IL-4 was also reported by Wohlfert et al and moreover IL-2 was 
demonstrated in that study to contribute to this (Wohlfert et al., 2011).  
 
It is important to note that although IL-12 and IL-18, and IL-4 were determined to be 
sufficient for the polarisation of nTreg towards a Th1- or a Th2-like phenotype, 
respectively, cytokines derived from CD4+ Foxp3- cells such as IFN-γ might be 
implicated as well. However, in order to test this, sorted nTreg would have to be 
stimulated under polarising conditions and this wasfound to result in substantial cell 
death of nTreg over 3-day period.  
 
An interesting observation was made during nTreg expansion under polarising 
conditions. Whereas, IL-12 and IL-18 were able to induce T-bet and high CXCR3 
expression in expanding nTreg, IL-4 was did not promote GATA-3 upregulation. It 
has been previously demonstrated that Foxp3 can bind to and inhibit GATA-3 
expression repressing Th2 cell development and, vice ersa, IL-4 was shown to 
inhibit Foxp3 expression (Wei et al., 2007, Mantel et al., 2007). Therefore, it is 
possible that upregulation of GATA-3 does not happen in actively proliferating 
nTreg or it requires additional factors in vitro. This would be consistent with the 
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observed GATA-3 upregulation in nTreg stimulated uner Th2 conditions but not in 
proliferating nTreg during their expansion under the same Th2 conditions.  
 
Although the cytokine production by nTreg under polarising conditions was decided 
not to be investigated in this project, previous repo ts have indicated that whereas 
nTreg stimulated under Th1 polarising conditions can produce small amounts of 
IFN-γ (Wei et al., 2009), nTreg stimulated in the presence of IL-4 did not acquire an 
ability to produce Th2-associated cytokines (Wohlfert t al., 2011). This poses 
interesting questions of the extent to which T-bet and GATA-3 affect the 
transcriptional machinery in Treg such as the expression of chemokine receptors and 
cytokines and how this is controlled to maintain a on-pathogenic phenotype.    
 
4.3.4. How do pro-inflammatory cytokines affect in vitro 
generated iTreg? 
Phenotypic analysis of steady-state nTreg and in vitro TGF-β-induced iTreg revealed 
substantial differences between the two types of Foxp3+ cells. iTreg were found to 
express intermediate levels of GATA-3, similarly to nTreg. However, they had 
highly upregulated expression of T-bet and CXCR3. High T-bet expression in iTreg 
was demonstrated previously and it was shown to be expressed at a similar level 
compared to IL-12 conditioned Foxp3- cells (O'Connor et al., 2010). iTreg were also 
characterized by elevated expression of CD44 and CD73, like nTreg. However, they 
had a higher proportion of CD62Lhigh cells. Due to these differences, it was of 
interest to know whether the effect of polarising cytokines on the cell phenotype was 
similar in nTreg and iTreg.  
 
The presence of IL-12 did not affect TGF-β-induced conversion of CD4+ CD62Lhigh 
cells into iTreg in vitro, which is consistent with previous studies (Neufert et al., 
2007). High expression of T-bet in iTreg also remained unaffected by IL-12. 
However, as the phenotypic analysis was done on day 5 of induction, and the kinetics 
of T-bet expression in iTreg was demonstrated to be the highest on day 2 and then 
decrease (O'Connor et al., 2010), it is possible that IL-12 could exert its effects 
earlier during the induction process. The presence of IL-4 during the iTreg 
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generation was observed to inhibit Foxp3 induction in a dose-dependent manner. 
This is consistent with the already mentioned report that IL-4 has a capacity to 
suppress Foxp3 expression (Mantel et al., 2007). Interestingly, α-IFN-γ but not        
α-IL-12, present in Th2-polarising conditions, was able to effectively oppose the 
inhibitory effects of IL-4 on Foxp3 expression. iTreg are known to produce IFN-γ 
during their induction (O'Connor et al., 2010) and, hence, this may indicate that its 
neutralization promotes iTreg conversion under suboptimal conditions when IL-4 is 
present. Addition of α-IFN-γ on its own did not promote Foxp3 induction and could 
be explained by highly efficient Foxp3 induction conditions used in this project. An 
enhancing effect α-IFN-γ on iTreg induction was also reported in vivo in tumour-
bearing mice (Cao et al., 2009). No GATA-3 upregulation was detected in iTreg 
generated under Th2 polarising conditions as reportd previously (Dardalhon et al., 
2008). This could be explained by the reciprocal regulation of Foxp3 and GATA-3 
expression (Wei et al., 2007, Mantel et al., 2007) and also by the fact that TGF-β 
together with IL-4 was demonstrated to result in the generation of a new cell subset 
called IL-9+ IL-10+ Foxp3- cells, described as Th9 cells (Dardalhon et al., 2008). 
However, the production of IL-9 and IL-10 was not investigated in here, hence it is 
not known whether the cells generated were Th9 cells.    
 
The influence of cytokines on already induced iTreg was also investigated. It was 
found that iTreg re-stimulated under either Th1 or Th2 polarising conditions rapidly 
lose Foxp3 expression which was prevented by the addition of TGF-β to the cultures. 
The instability of Foxp3 in iTreg upon re-stimulation in vitro was described 
previously and is thought to be a result of an incomplete demethylation of the foxp3 
promoter region (Floess et al., 2007, Huehn et al., 2009, Chen et al., 2011). This is in 
contrast to nTreg which have a fully demethylated foxp3 promoter region and hence 
seem to be stable under stimulatory conditions. The presence of IL-12 or IL-4 did not 
promote upregulation of T-bet or GATA-3 in iTreg, but interestingly, the presence of 
TGF-β was critical for the maintenance of high T-bet expr ssion and intermediate 
GATA-3 expression in iTreg upon re-stimulation. This suggests the importance of 
TGF-β in maintaining not only the Foxp3 stability upon re-stimulation as shown 
before (Chen et al., 2011) but also the characteristic iTreg phenotype.   
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The default Th1-like phenotype of iTreg and the inab lity to modulate it in vitro 
poses a question whether iTreg can be ‘polarised’ in vivo in the same way as nTreg. 
Stock et al. have reported on T helper type 1-like regulatory T cells that developed in 
vivo from CD4+ CD25- T cells during a strong Th1 response (Stock et al., 2004). 
These expressed both T-bet and Foxp3 and effectively inhibited Th2-induced airway 
hyperactivity. They argued that Th1-like iTreg might counter a Th2-mediated 
response by secreting IL-10 and IFN-γ. Whether Th2-like iTreg can be generated in 
vivo as well is unknown.  
 
4.4. Concluding synopsis  
• Peripheral Foxp3+ CD4+ cells from naïve mice do not express T-bet and have 
low/intermediate levels of GATA-3. 
• Foxp3+ CD4+ cells upregulate expression of T-bet and CXCR3 (but not GATA-
3) specifically within the inflamed CNS in Th1/Th17-mediated EAE. 
• Foxp3+ CD4+ cells upregulate expression of GATA-3 (but not T-bet and 
CXCR3) within the inflamed lung in Th2-mediated AAI. 
• In vitro experiments suggest that IL-12 and IL-18 are respon ible for 
upregulation of T-bet in stimulated nTreg, whereas IL-4 is responsible for 
upregulation of GATA-3.  
• TGF-β-induced iTreg have a substantially different phenotype to steady-state 
nTreg and display a default Th1-like phenotype with h gh T-bet and CXCR3 
expression. 
• The phenotype of iTreg cannot be modified by polarising cytokines during their 
generation in vitro which seem to mainly affect the induction of Foxp3 
expression. 
• iTreg re-stimulated under Th1 or Th2 polarising conditions in vitro do not 
upregulate T-bet or GATA-3, respectively.  
• TGF-β is critical to the maintenance of Foxp3 expression and Th1-like iTreg 
phenotype upon re-stimulation. 
 
The functional consequences of Treg polarisation and the importance of Treg 
phenotype versus antigen reactivity are discussed in Chapter 5.  
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The importance of Treg phenotype for their effective suppressive capacity was 
suggested by several studies. T-bet expression was demonstrated to be critical for 
Treg-mediated inhibition of CD4+ T cell responses in a model of Th1-mediated 
infection by affecting Treg function, homeostasis and migration (Koch et al., 2009). 
Expression of Th2-associated IRF-4 was shown to be important for the control of 
Th2 responses (Zheng et al., 2009). However, it has been never addressed whether 
polarised Treg phenotype makes them ineffective at mediating suppression driven by 
non-corresponding CD4+ T cells, or whether the Treg phenotype is plastic and can 
adapt to a different inflammatory environment.   
 
The marked difference between nTreg and i  vitro generated iTreg that has been 
noted and described in Chapter 4 is that the default Th1-like iTreg phenotype, in 
contrast to nTreg, could not be skewed towards being more Th1-like (with higher T-
bet expression) or Th2-like (with upregulated GATA-3) by polarising cytokines, 
unless iTreg stability was compromised. Whether this observation has functional 
consequences needs to be investigated. Interestingly, it has been demonstrated that 
iTreg induced in vivo during a strong Th1-response can effectively suppress Th2-
driven inflammation (Stock et al., 2004) suggesting that iTreg, in contract to nTreg, 
may not need to adapt to the inflammatory environmet in order to effectively 
regulate it.  
  
It is still unclear whether antigen reactivity is criti al to iTreg-mediated suppression. 
Multiple studies on autoimmune disease models such as diabetes, gastritis and EAE 
have demonstrated protective effects of antigen-reactive iTreg only (Tang et al., 
2004, Huter et al., 2008, Zhang et al., 2010), however some showed suppressive 
potential of polyclonal iTreg as well (Selvaraj and Geiger, 2008). Interestingly, the 
majority of investigations into Th2-mediated sensitization models of asthma show 
                                                                                            CHAPTER 5 RESULTS 
 158
inhibitory effects of polyclonal iTreg (Chen et al., 2003, Xu et al., 2012), however no 
comparison to antigen-reactive iTreg has been made.  
 
5.1.1. Aims 
The aims of the experiments described in this chapter were to: 
1) Assess the importance of polarised nTreg phenotype in vitro and in vivo in 
models of Th1/Th17-mediated EAE and Th2-mediated AAI. 
2) Establish the suppressive capacity of T-bet+ CXCR3+ iTreg towards pre-
activated polarised CD4+ T cells in vitro. 
3) Investigate the prophylactic and therapeutic potential of iTreg in EAE and 
AAI and determine how important iTreg antigen reactivity is. 




To investigate the effect of a polarised nTreg phenotype on their suppressive 
capacity in vitro, a standard suppression assay previously described by the Shevach 
group was used (Thornton and Shevach, 1998, Thornton and Shevach, 2000). It 
consisted of an unchanged number of CD4+ conventional T responder cells (Tresp), 
either naïve or pre-activated, and APC incubated with serially diluted nTreg in the 
presence of a TCR stimulus. For functional assessment in vivo, T-bet+ CXCR3high 
Treg were isolated from the CNS of EAE mice and transferred into an AAI model 
prior to allergen challenge. As Treg derived from the inflamed CNS in EAE were 
demonstrated to be enriched for MOG-reactive Treg (O'Connor et al., 2007, Korn et 
al., 2007), and rMOG-induced AAI is driven by MOG-reactive CD4+ cells, this 
model was used to distinguish between the effects of polarised Treg phenotype and 
their antigen reactivity. To isolate and sort for nTreg, Foxp3-GFP mice were used in 
these experiments.  
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For the investigation of functional consequences of the default Th1-like iTreg 
phenotype, in vitro suppression assays and models of EAE and AAI were utilized. In 
EAE, the ability of iTreg to inhibit disease induction at the priming stage and to 
suppress on-going CNS inflammation was investigated. In AAI, the prophylactic 
potential of iTreg to suppress pre-activated polarised Th2 cells prior to the 
establishment of lung inflammation was tested. The eff ct of iTreg on on-going lung 
inflammation could not be tested due to the acute nature of rMOG-induced AAI. 
Antigen-reactive and polyclonal iTreg, generated in vitro from 
2D2xFoxp3.LuciDTR4 and Foxp3.LuciDTR4 mice respectively, were compared.  
 
5.2. Results 
5.2.1. Regulation by nTreg 
5.2.1.1. nTreg suppress naïve CD4 + T cells in vitro 
To verify the effective use of an in vitro suppression assay in this project and 
establish the baseline efficiency of nTreg suppression, unchanged numbers of naïve 
conventional CD4+ T responder cells (Tresp) were incubated with serially diluted 
freshly isolated nTreg in the presence of irradiate APC and were stimulated with α-
CD3 (Figure 5.1A). Proliferation of Tresp was measured on day 4 by 3H thymidine 
incorporation. nTreg effectively suppressed polyclona  proliferation of naïve CD4+ 
cells and suppression of more than 50% of proliferation was achieved until the nTreg 
to Tresp ratio reached 1:16 (Figure 5.1B).  
     
5.2.1.2. Suppression by nTreg expanded under polari sing 
conditions 
In order to investigate the functional consequences of polarised Treg phenotype, 
nTreg expanded under different polarising conditions were tested for their 
suppressive capacity in vitro. Polyclonal nTreg expanded in vitro under neutral, Th1 
or Th2 polarising conditions were first incubated with naïve Tresp in the presence of 
APC and were stimulated with α-CD3 (Figure 5.2A). All nTreg populations achieved 
50% suppression at approximately 1:16 ratio (Figure 5.2B&C).  
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Neutral, Th1- and Th2-conditioned nTreg were then tsted for their ability to 
suppress polyclonal proliferation of pre-activated Th1 and Th2 cells. All nTreg 
populations suppressed Th1 and Th2 cells with similar efficacy (Figure 5.3A&B). 
Higher nTreg to Tresp ratios were required to achieve 50% suppression of pre-
activated T cells compared to naïve CD4+ cells. Moreover, Th1 cells were found to 
be more resistant to suppression than Th2 cells even though Th2 cells had a higher 
proliferation rate (data not shown).  
 
5.2.1.3. T-bet+ CNS-derived Treg do not suppress rMOG-induced 
AAI 
To assess the functional importance of the polarised Treg phenotype (T-bet+ 
CXCR3high) that was observed in Th1/Th17-mediated EAE, Treg w re isolated from 
the inflamed CNS in EAE and tested in the AAI model by transfer (Figure 5.4A). To 
ensure sufficient cell numbers obtained from the CNS, cells were harvested 3 days 
after Foxp3-GFP mice reached peak of disease and not uring resolution (Figure 
5.4B). These CNS-derived Treg had similar expression levels of T-bet and CXCR3 
as those isolated during resolution of EAE (Figure 4.1D). Treg from the CNS and the 
control Treg from naïve spleen were FACS sorted for GFP+CD4+ cells and over 99% 
purity was achieved (Figure 5.4C). All transferred c ll populations were traceable.    
 
Lower than average inflammatory response was achieved in this experiment. Total 
cell numbers in BAL were unaffected by CNS-derived Treg (Figure 5.4D) as were 
the percentages of BAL eosinophils (Figure 5.4E). Lung infiltration scores in the 
peri-vascular and peri-bronchiolar areas were similar in all groups (Figure 5.5A&B), 
and the percentages of goblet cells in small and large irways remained unchanged in 
the group that received CNS-Treg (Figure 5.5A&C). The percentages of goblet cells 
in large airways of mice that received naïve nTreg were significantly increased 
compared to rMOG only control (Figure 5.5C).  
 
The total cell number in the lung seemed lower in the CNS-Treg group however it 
was not significantly different (Figure 5.6A). The total cell numbers in medLN and 
spleen were unaffected (Figure 5.6B). The percentags of CD4+ cells in the lung, 
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medLN and spleen were similar in all groups (Figure 5.6C). Percentages and total 
numbers of transferred 2D2 Th2 cells in the lung, medLN and spleen were 
unchanged by CNS-Treg or naïve Treg transfer (Figure 5.6B). Percentages and 
absolute numbers of total Foxp3+ cells were increased in the lung irrespective of 
CNS or naïve Treg transfer in all rMOG challenged groups (data not shown) which is 
characteristic of lung inflammation as described in Chapter 3. No transferred Treg 
were detectable in any of the groups (data not shown). 
 
The lack of a protective effect of CNS-derived Treg on the lung inflammation in AAI 
could suggest that T-bet+ CXCR3high Treg were unable to effectively suppress pre-
activated Th2 cells. Due to the complicated design of this experiment it was decided 
to take an alternative approach to verify this result. It involved an induction of Th1-
mediated AAI by Th1-polarised 2D2 cells and an asses ment of Treg phenotype in 
this model. If the Treg were found to have a Th1-like phenotype, they would then be 
transferred into Th2-mediated AAI model to test their suppressive capacity.  
 
5.2.1.4. Treg in Th1-mediated AAI do not acquire ex pression of     
T-bet 
A model of Th1-mediated AAI was previously described involving an adoptive 
transfer of Th1-polarised OVA323-339-reactive CD4
+ cells followed by OVA airway 
challenge (Hansen et al., 1999). It was shown in that model that Th1 cells were 
capable of inducing severe lung inflammation characterized by predominant 
lymphocyte infiltrates in the lung instead of eosinophils, and a smaller degree of 
goblet cell hyperplasia compared to the Th2-mediate AAI. Th2- and Th1-mediated 
AAI were compared here by polarisation of 2D2 cells towards either a Th2 or a Th1 
phenotype for transfer into WT hosts followed by airw y challenges with rMOG 
(Figure 5.7A). Total cell numbers in BAL were increas d after transfer of either Th1 
or Th2 cells, and rMOG challenge (Figure 5.7B). Th2 cells induced BAL 
eosinophilia as described previously, whereas the transfer of Th1 cells resulted in 
very few eosinophils and increased percentages of neutrophils and lymphocytes 
(Figure 5.7C). Lung infiltration scores in rMOG challenged mice that received Th1 
or Th2 cells were increased (Figure 5.7D). The percentages of goblet cells in small 
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and large airways were increased in rMOG-challenged mice that received Th2 cells, 
and negligible in mice that received Th1 cells (Figure 5.7E) which is consistent with 
previously published observations (Hansen et al., 1999).  
 
The percentages and total numbers of transferred Th1 and Th2 2D2 cells in the lung 
were increased by rMOG challenge (data not shown, Figure 5.8A) as were the total 
numbers of Foxp3+ cells (Figure 5.8B). The stability of Th1 or Th2 phenotype was 
confirmed by overnight re-stimulation of cells isolated from the lung with MOG35-55 
followed by intracellular staining for cytokines. Approximately 8-10% of Th2 2D2 
cells produced IL-13 and fewer than 3% produced IFN-γ, whereas 20-25% of Th1 
2D2 cells secreted IFN-γ and fewer than 2% produced IL-13 (Figure 5.8C). Staining 
for transcription factors revealed that although both lung-derived Th2 2D2 cells and 
Foxp3+ cells from the Th2-mediated AAI had an upregulated GATA-3 expression, 
Th1 2D2 cells and the corresponding Foxp3+ cells did not express T-bet, as was 
expected (Figure 5.8D). Lack of T-bet expression by Foxp3+ cells in Th1-mediated 
AAI meant that this model could not be used for testing the importance of the Treg 
phenotype in different inflammatory contexts.  
 
5.2.2. Regulation by iTreg 
In addition to nTreg which are present in the periphery at a relatively low frequency, 
in vitro induced Treg (iTreg) provide an easy means of generati g robust numbers of 
cells capable of effectively suppressing pathogenic T ell responses. Moreover, as 
iTreg display a Th1-like phenotype, this provides an opportunity to test whether high 
expression of T-bet and CXCR3 is implicated in the failure of CNS-derived Treg to 
suppress Th2-mediated AAI.  
 
5.2.2.1. 2D2 iTreg suppress proliferation of naïve 2D2 CD4+ T cells 
in vitro more effectively than polyclonal iTreg  
The importance of iTreg antigen reactivity for effective suppression of CD4+ cells 
was first tested in vitro. 2D2 iTreg and polyclonal (poly) iTreg were induced in vitro 
in the presence of TGF-β and IL-2 as described previously. The average Foxp3 
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induction efficiency from both 2D2 and WT mice was >85-95% of total CD4+ cells 
on day 5. iTreg were sorted for GFP+ cells using FACS prior to culture set up. 
Unchanged numbers of naïve 2D2 CD4+ cells (Tresp) were incubated with serially 
diluted 2D2 iTreg or poly iTreg in the presence of irradiated APC and were 
stimulated with MOG35-55 (Figure 5.9A). 2D2 iTreg were found to suppress antige -
driven proliferation of naïve 2D2 CD4+ cells more effectively than poly iTreg 
(Figure 5.9B). 50% suppression was achievable using 2D2 iTreg at iTreg to Tresp 
ratios of 1:32 and above whereas this was lost withpoly iTreg below a ratio of 1:4 
(Figure 5.9B).  
 
5.2.2.2. 2D2 iTreg proliferate in vivo in response to antigen but 
partially lose Foxp3 expression 
To determine the potential of 2D2 iTreg to suppress naïve CD4+ T cell activation / 
proliferation in vivo, their ability to migrate and proliferate in the dLN in response to 
immunization was first assessed. CD90.1+ CD90.2+ 2D2 iTreg were transferred into 
WT mice without prior FACS sort for GFP+ cells as the 2D2 mouse used was not on 
a Foxp3-GFP reporter background. This was followed by immunization of WT mice 
with MOG35-55 in CFA (Figure 5.10A). Unimmunized mice were used as a control.  
On day 4 post-immunization, dLN and spleen were harvested. On the day of transfer, 
the iTreg population was ~85% Foxp3+ and the cells expressed high levels of Ki-67, 
known to be expressed by actively proliferating cells (Figure 5.10B).  
 
Four days after immunization, the total number of 2D2 iTreg in the dLN was 
significantly higher compared to the unimmunized contr l (Figure 5.10C). Ki-67 
staining revealed that ~60% of total 2D2 iTreg (Figure 5.10C) and ~50% of Foxp3+ 
iTreg (data not shown) were actively proliferating  response to antigen i vivo. This 
was associated with the loss of Foxp3 expression observed in ~50% of iTreg from 
~85% Foxp3+ iTreg on the day of transfer (Figure 5.10C). However, since the 
transferred 2D2 iTreg population was unsorted, it is possible that the Foxp3- cells 
expanded more than Foxp3+ cells upon immunization and this could partially account 
for the observed decrease in Foxp3 expression. 2D2 iTreg that did not see an antigen 
in vivo, stopped proliferating but retained their expression of Foxp3 (Figure 5.10C). 
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A similar pattern of results was seen in the spleen with the exception that 2D2 iTreg 
in the presence of an antigen retained higher levels of Foxp3 ranging from 40-50% 
(Figure 5.10D). These results suggest that 2D2 iTreg ar  able to migrate to dLN and 
proliferate in response to their cognate antigen in vivo. 
 
5.2.2.3. 2D2 iTreg limit the survival of naïve 2D2 cells and effector 
cytokine production in vivo  
To test the in vivo suppressive potential of 2D2 iTreg, these were generated from a 
2D2 mouse and transferred into WT host together with traceable naïve 2D2 CD4+ 
cells (Tresp) at a 1 to 1 ratio followed by immunizat on with MOG35-55 in CFA 
(Figure 5.11A). Mice that received Tresp or 2D2 iTreg only and unimmunized mice 
that received both Tresp and 2D2 iTreg were used as controls. Analysis of dLN 4 
days after immunization showed that the total number of Tresp was significantly 
reduced upon co-transfer of 2D2 iTreg (Figure 5.11B). Interestingly, the vast 
majority of Tresp were still Ki-67+ (Figure 5.11B) which indicates that 2D2 iTreg 
did not inhibit Tresp proliferation but rather limited their survival in vivo. The same 
pattern of results was obtained in a separate experiment where Tresp were labelled 
with CFSE proliferation dye (data not shown). Similar reduction in the total numbers 
of Tresp was observed in the spleen, however smaller suppression of Tresp 
proliferation was noted (Figure 5.11C) and this was most likely due to the lower 
percentage of iTreg present in the spleen versus the dLN (data not shown). Although 
the percentages of 2D2 iTreg in dLN were similar in the immunized groups with or 
without Tresp, the total numbers of iTreg were higher when Tresp were co-
transferred (data not shown) which suggests that 2D2 iTreg migrated to the dLN 
more effectively in response to inflammatory reaction driven by Tresp. The loss of 
Foxp3 expression by 2D2 iTreg (~70% in dLN and ~40-50% in the spleen) was 
similar irrespective of Tresp co-transfer (data not shown).  
 
To investigate the effects of 2D2 iTreg on effector cytokines produced in response to 
immunization, cells isolated from the dLN and spleen were re-stimulated with 
increasing concentrations of MOG35-55 for 3 days followed by cytokine assay. 2D2 
iTreg were found to significantly reduce the production of IFN-γ, IL-17A and GM-
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CSF in dLN (Figure 5.12A) and of IL-17A in the spleen (Figure 5.12B). This 
reduction in effector cytokines is most likely due to the reduced percentages of Tresp 
when co-transferred with 2D2 iTreg (data not shown).  
 
5.2.2.4. 2D2 iTreg increase Foxp3 expression within  transferred 
2D2 cells 
In addition to limiting the survival of Tresp in vivo and the levels of effector 
cytokines, 2D2 iTreg were also found to increase the percentages and total numbers 
of Foxp3+ Tresp within the dLN and spleen upon immunization (Figure 5.13A, 
B&C). The percentage of Foxp3+ cells within 2D2 naïve CD4+ cells prior to transfer 
varied between 2-4% (data not shown) and it was found to increase to ~ 20-25% in 
unimmunized control (Figure 5.13A&B). This could bedue to better survival of 
Foxp3+ cells versus Foxp3- cells in the absence of an antigen in vivo. The percentage 
of Foxp3+ Tresp decreased to less than 1% upon immunization (Figure 5.13B) which 
was due to the rapid expansion of Foxp3- cells, as the total numbers of Foxp3+ Tresp 
remained unaffected in the unimmunized control and in the Tresp only group (Figure 
5.13C). 2D2 iTreg were observed to significantly increase the percentages of Foxp3+ 
Tresp to ~11-12% in dLN and ~20% in the spleen, and increase the total numbers of 
Foxp3+ Tresp (Figure 5.13A, B&C). Whether this increase i due to the iTreg-
mediated expansion of pre-existing Foxp3+ cells within the transferred Tresp in the 
presence of an antigen, or true Foxp3 induction in aïve 2D2 upon activation needs 
further investigation.   
 
5.2.2.5. 2D2 iTreg but not polyclonal iTreg suppres s induction of 
EAE 
Previously published reports demonstrated that antige -reactive iTreg but not 
polyclonal iTreg are capable of suppressing EAE induction in a model of PLP139-151 
driven active EAE (Zhang et al., 2010). They suggested that iTreg suppress induction 
of EAE in an antigen-depended fashion similarly to nTreg. Contrasting results were 
shown by an earlier paper which reported that in a model of MOG35-55-driven EAE 
polyclonal iTreg are effective at suppressing disease severity (Selvaraj and Geiger, 
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2008). However, no comparison was made between the suppressive potential of 
antigen-reactive and polyclonal iTreg in that study. Results from the experiments 
described in this Chapter suggest that 2D2 iTreg suppress naïve cell activation / 
proliferation more efficiently than polyclonal iTreg, and moreover they expand in 
vivo in response to the antigen and effectively inhibit CD4+ T cell responses. In order 
to establish whether these results reflect what happens during EAE induction, 
traceable 2D2 iTreg and polyclonal iTreg were transferred into WT mice prior to 
immunization with MOG35-55 in CFA for the induction of EAE (Figure 5.14A). PBS-
treated mice were used as a control.  
 
It was found that 2D2 iTreg but not polyclonal iTreg suppressed EAE induction. The 
lower dose of 2D2 iTreg, namely 2x105 cells was able to significantly reduce disease 
severity whereas the same dose of polyclonal iTreg had no effect on a disease course 
(Figure 5.14B). The mice that received a higher dose f 2D2 iTreg, namely 1x106 
cells remained 100% disease-free (Figure 5.14B). Total cell numbers and numbers of 
CD4+ cells were significantly reduced in the CNS of mice that received 1x106 of 2D2 
iTreg (Figure 5.14C&D). However, the cellularity and total numbers of CD4+ cells 
within dLN were significantly higher in these mice and in mice that received a lower 
dose of 2D2 iTreg compared to the groups treated with poly iTreg or PBS (Figure 
5.14C&D). In the spleen, the total cellularity and total numbers of CD4+ cells were 
significantly reduced in sick mice treated with PBS or poly iTreg which is consistent 
with the observed leukopenia in EAE (Figure 5.14C&D). This was prevented by 2D2 
iTreg treatment (Figure 5.14C&D). These observations suggest that the protective 
effect of 2D2 iTreg could be due to reduced mobilization of cells, including effector 
CD4+ cells, from the dLN (and the spleen) into the CNS.  
 
To test whether 2D2 iTreg affected effector functions of CD4+ cells, the cells from 
the CNS, dLN and spleen were re-stimulated overnight with MOG35-55 followed by 
intracellular cytokine staining. Within the CNS, mice that received 1x106 2D2 iTreg 
had significantly lower percentages of IFN-γ+, TNF-α+ and GM-CSF+ CD4+ cells 
(Figure 5.15A&B). Interestingly, the percentages of IL-17A+ CD4+ cells were 
unaffected by 2D2 iTreg. The percentages of IFN-γ+, TNF-α+ , GM-CSF+ and IL-
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17A+ CD4+ cells were reduced in dLN, and remained unchanged in the spleen 
(Figure 5.16A&B).   
 
5.2.2.6. 2D2 iTreg accumulate in dLN when transferr ed prior to EAE 
induction 
iTreg transferred into WT host were traceable which enabled identification of the 
potential site at which they accumulated and exerted their suppressive effect. 
Numbers of poly iTreg and 2D2 iTreg at both doses wre very low or negligible in 
the CNS itself (Figure 5.17A). This suggests that 2D2 iTreg either migrated to the 
CNS at an earlier time point and quickly died off after effector CD4+ cells had been 
effectively suppressed, or that the CNS was not the main site at which they exerted 
their suppressive function. Analysis of dLN and spleen revealed that 2D2 iTreg 
numbers in the dLN were elevated compared to poly iTreg numbers, and moreover 
they were higher compared to their numbers in the spl en (Figure 5.17A). This 
confirms antigen-driven migration/accumulation of 2D2 iTreg in the dLN as 
previously shown 4 days post-immunization (Figure 5.10). iTreg stability could not 
be assessed due to the low cell numbers which did not allow for reliable analysis of 
Foxp3 expression.  
 
When Foxp3 expression by total CD4+ cells was compared, it was found that the 
percentages of Foxp3+ CD4+ cells in the CNS were unaffected by 2D2 iTreg 
treatment, but their total numbers were significantly reduced in the group that 
received 1x106 2D2 iTreg (Figure 5.17B). This can be explained by the fact that the 
animals were disease-free and had no inflammation in the CNS that would drive the 
accumulation of Foxp3+ cells. The mice that received 1x106 2D2 iTreg had, however, 
higher percentages and total numbers of Foxp3+ CD4+ cells within dLN and spleen 
compared to PBS and poly iTreg-treated groups (Figure 5.17A&B). Whereas the 
total numbers of Foxp3+ cells within spleen of 2D2 iTreg-treated mice were within 
normal range found in naïve mice, the numbers within dLN were elevated (Figure 
5.17B). The elevated numbers of Foxp3+ cells in dLN corresponded to the increased 
total cellularity of dLN.    
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5.2.2.7. iTreg suppress proliferation and cytokine production by 
activated effector T cells in vitro in an antigen-dependent 
manner 
Having established that 2D2 iTreg effectively suppress naïve cells in vitro and in 
vivo, it was decided to determine their suppressive capa ity against activated and 
polarised cells. A standard suppression assay was used as described previously and 
pre-activated polarised cells were obtained by stimulation of 2D2 splenocytes under 
Th1, Th2, Th17 or GM-CSF-polarising conditions for 3 days in vitro followed by 3 
to 4 day rest in IL-2. Polarised cells were sorted for CD4+ cells (Tresp) prior to co-
culture with iTreg and irradiated APC in the presence of MOG35-55 (Figure 5.18A). 
2D2 iTreg were able to suppress proliferation of all polarised Tresp and they were 
more effective than poly iTreg (Figure 5.18B). The 50% suppression of proliferation 
of activated cells mediated by 2D2 iTreg was effectiv  o an iTreg to Tresp of 1:16 
for Th1 cells, 1:2 for Th2 cells, 1:8 for Th17 cells and 1:2 for GM-CSF+ cells. These 
ratios were variable among experiments, however, thy were always the highest for 
GM-CSF+ cells suggesting that these cells are the most resistant to iTreg-mediated 
suppression.   
 
In terms of effector functions of polarised Tresp, 2D2 iTreg effectively inhibited 
IFN-γ production by Th1 cells, IL-4 and IL-13 by Th2 cells and IL-17A by Th17 
cells (Figure 5.19). Interestingly, although polyclonal iTreg were found to suppress 
some IFN-γ secretion they failed to suppress Th2-associated cytokines and IL-17A. 
GM-CSF secretion by GM-CSF polarised cells was not suppressed efficiently by 
either 2D2 iTreg or poly iTreg (Figure 5.20A). However, it was partially inhibited by 
2D2 iTreg when GM-CSF was produced by Th1 or Th2 cells (Figure 5.20B).  
 
5.2.2.8. 2D2 iTreg accumulate in CNS during EAE but  are unable to 
suppress on-going inflammation 
In order to determine whether iTreg would be able to suppress activated CD4+ cells 
in vivo in a disease context, 1x106 2D2 iTreg or poly iTreg were transferred into WT 
mice post EAE induction when animals showed first clinical signs of disease (Figure 
5.21A). PBS-treated mice were used as a control. 2D2 iTreg and polyclonal iTreg 
were induced from 2D2xFoxp3.LuciDTR4 and Foxp3.LuciDTR4 mice, respectively, 
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and the purity of Foxp3+ cells prior to transfer was >99% (Figure 5.21B). 2D2 iTreg 
and poly iTreg were not found to suppress disease sev rity or lead to an earlier 
disease resolution (Figure 5.21C). Tissues were harvested close to the peak of EAE, 
on day 13, and as the animals were recovering, on day 23. 
 
The total cell numbers and numbers of CD4+ cells in the CNS and dLN on day 13 
were unaffected by 2D2 iTreg or poly iTreg transfer (data not shown). Similarly, the 
production of pro-inflammatory cytokines within the CNS and dLN was unchanged 
which corresponds with the unaffected disease course pon iTreg transfer (data not 
shown). 2D2 iTreg were detectable in the CNS and their percentage and total number 
seemed higher compared to poly iTreg, however this difference was not significant 
(Figure 5.21A). The total number of 2D2 iTreg was 70-fold higher in the dLN (and 
in the spleen) compared to the CNS, and their numbers were not significantly 
different to poly iTreg numbers. On day 23, the disease readouts such as total cell 
numbers in the CNS and dLN, and cytokine production were similar in all three 
groups (data not shown). Interestingly, the percentage of 2D2 iTreg was significantly 
increased specifically within the CNS compared to the percentage of poly iTreg, and 
the total cell number of 2D2 iTreg was ~10-fold higher compared to day 13 (Figure 
5.22A&B). The total number of 2D2 iTreg in dLN was 60-fold lower compared to 
day 13 and comparable to the number of poly iTreg (Fi ure 5.22A).  
 
These results suggest that 2D2 iTreg accumulated spcifically within the CNS as the 
disease progressed, however they were unable to suppress on-going inflammation. In 
terms of iTreg stability, ~60% of 2D2 iTreg from the CNS and ~30% in the dLN and 
spleen had lost their expression of Foxp3 (Figure 5.22C). Polyclonal iTreg stability 
within CNS could not be analysed due to low cell numbers. Polyclonal iTreg from 
the dLN and spleen had a similar percentage loss of Foxp3 as 2D2 iTreg (Figure 
5.22C) suggesting that the loss of Foxp3 expression was due to inflammation and not 
due to antigen-driven re-activation of iTreg in vivo.     
 
In conclusion, iTreg were demonstrated to be capable of suppressing Th1/Th17-
mediated EAE induction in an antigen-dependent manner but not an on-going 
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disease. Whether this is due to their inability to suppress on-going inflammation 
itself or an inability to control activated Th1 and Th17 cells needs to be investigated. 
It was next decided to test whether iTreg would able to inhibit pre-activated Th2 
cells in a model of rMOG-induced AAI and whether this would be antigen-
dependent was well.  
 
5.2.2.9. 2D2 iTreg migrate to the lung and medLN up on rMOG 
airway challenge 
Polyclonal iTreg can suppress the Th2-driven sensitization model of AAI when 
transferred prior to antigen challenge or after the first challenge (Xu et al., 2012) 
suggesting that iTreg can effectively control CD4+ cell responses once the memory 
Th2 cells have developed but before the inflammation is established. It is not known, 
however, whether antigen-reactive iTreg would be more effective or whether iTreg 
will be able to suppress pre-activated Th2 cells in vivo. In order to answer these 
questions, it had to be first determined whether 2D2 iTreg could migrate specifically 
into the medLN and the lung upon airway challenge with rMOG. WT hosts received 
2x106 of traceable 2D2 iTreg followed by a single intratracheal injection with rMOG 
or PBS as a control (Figure 5.23A). The tissues were harvested two days after the 
challenge. The percentages and total cell numbers of 2D2 iTreg were increased 
specifically within the lung and medLN upon rMOG challenge compared to PBS 
challenged mice, whereas in the spleen they were similar (Figure 5.23B&C). 
Nevertheless, the total number of 2D2 iTreg in the c allenged spleen itself was 
higher compared to the lung and medLN suggesting that more antigen challenges and 
time is needed for iTreg to be mobilized into the lung.  
 
5.2.2.10. iTreg suppress rMOG-induced AAI driven by  pre-activated 
Th2 cells in antigen-dependent fashion 
In order to test the potential of iTreg to suppress pre-activated Th2 cells in vivo, WT 
hosts received 5x106 2D2 iTreg or polyclonal iTreg followed by AAI induction via 
an adoptive transfer of activated Th2 2D2 cells and rMOG airway challenges (Figure 
5.24A). All cell populations were traceable. Although no significant changes in the 
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total numbers of cells in BAL were detected (Figure 5.24B), 2D2 iTreg but not 
polyclonal iTreg suppressed the percentage and total number of BAL eosinophils 
(Figure 5.24C&D). The total numbers of macrophages w re similar in all groups 
(Figure 5.24E). Lung infiltration scores were reduced upon 2D2 iTreg treatment 
(Figure 5.25A&B). Moreover, in mice that received 2D2 iTreg (but not polyclonal 
iTreg) goblet cells were not evident in either the small or large airways (Figure 
25A&B).  
 
The total cell numbers and percentages of CD4+ cells in the lung and medLN 
between groups did not differ significantly (Figure 5.26A). However, the percentages 
and total numbers of transferred Th2 2D2 cells were significantly lower within the 
lung of 2D2 iTreg-treated mice (Figure 5.26B). The total numbers of Th2 2D2 cells 
were also significantly lower in the medLN in the same group (Figure 5.26B). In the 
spleen, the percentages of Th2 2D2 cells were significa tly lower in all the groups 
when compared to the PBS control. However, the absolute numbers were unchanged 
(Figure 5.26B).  
 
To assess whether effector function of the transferred Th2 2D2 cells was affected, 
cells from the lung, medLN and the spleen were re-stimulated overnight in the 
presence or absence of MOG35-55 followed by intracellular cytokine staining. The 
percentage of IL-13+ Th2 2D2 cells in the lung was reduced from 10% in the PBS-
treated group to 4% in the 2D2 iTreg-treated group (Figure 5.27A). The lungs from 
the group treated with polyclonal iTreg were not analysed in this experiment. The 
percentages of IL-13+ Th2 2D2 cells within medLN were significantly lower in both 
2D2 iTreg- and poly iTreg-treated groups and the percentage of IL-5+ 2D2 cells was 
reduced upon 2D2 iTreg transfer only (Figure 5.27B). Similar pattern of results was 
observed in the spleen (Figure 5.27C).  
 
Interestingly, it was observed that only in mice that received 2D2 iTreg, the 
percentages of IFN-γ+ 2D2 cells were significantly increased from 1-2% to 7% in 
medLN and from 2-4% to 15% in the spleen (Figure 5.27B&C). The absolute 
numbers of IFN-γ+ 2D2 cells cannot be reliably calculated after overnight re-
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stimulation. Hence, it is not known whether this increase in the percentage 
corresponds to elevated total numbers of IFN-γ+ 2D2 cells or is a result of a 
decreased expansion of IL-13 and IL-5-producing 2D2 cells in the 2D2 iTreg-treated 
group.    
 
5.2.2.11. Highest iTreg to Th2 cell ratio is found in the lung 
No significant differences in the percentages or total numbers of 2D2 iTreg and poly 
iTreg within the lung were found although 2D2 iTreg seemed to be elevated (Figure 
5.28A). Interestingly, the percentage of 2D2 iTreg was significantly higher in the 
medLN compared to polyclonal iTreg (Figure 5.28A). The percentages and numbers 
of 2D2 iTreg and polyclonal iTreg in the spleen were similar (Figure 5.28A). The 
ratio of 2D2 iTreg to Th2 2D2 cells was the highest in the lung and was ~2 compared 
to below 1 in the medLN and the spleen (Figure 5.28B). Moreover, it was 
significantly higher than the ratio of polyclonal iTreg to Th2 2D2 cells in the lung 
(Figure 5.28B).   
 
Approximately ~65% of 2D2 iTreg and ~ 50% of polyclonal iTreg retained their 
Foxp3 expression within the lung compared to ~80% in the medLN and spleen in 
both groups (Figure 5.28C). This suggests that Foxp3 loss is due to inflammation 
rather than antigen re-stimulation of iTreg in vivo.   
  
5.2.2.12. Induction of Foxp3 expression in Th2 2D2 cells by 2D2 
iTreg 
When Th2 2D2 cells were analysed for Foxp3 expression, it was observed that the 
frequency of Foxp3+ cells upon rMOG challenge increased to 10% specifically 
within the lung compared to less than 1% in the PBS-challenged group (Figure 
5.29A&B). 2D2 iTreg but not polyclonal iTreg were found to promote this effect in 
the lung in terms of the frequency of Foxp3+ Th2 2D2 cells but not the total cell 
numbers (Figure 5.29A&B). Interestingly, the percentages but not total cell numbers 
of Foxp3+ Th2 2D2 cells seemed higher in the medLN and spleen upon 2D2 iTreg 
but not polyclonal iTreg treatment as well. In order to determine whether this 
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increase was due to the iTreg-mediated expansion of Foxp3+ cells within transferred 
Th2 2D2 cell population in the presence of an antige  or true Foxp3 induction in Th2 
2D2 cells, it was decided to deplete 2D2 Th2 cells of resident Foxp3+ cells prior to 
transfer for the induction of AAI (Figure 5.30A).   
 
Splenocytes from 2D2xFoxp3.LuciDTR4 mouse were used to polarise cells towards 
Th2 phenotype. Following stimulation under Th2 polarising conditions the frequency 
of Foxp3+ cells within Th2 2D2 cells was 0.8% and was reduce to 0.12% by sorting 
out GFP+ cells using FACS (Figure 5.30B). It was found that the percentage and total 
numbers of Foxp3+ Th2 2D2 cells were significantly increased in the m dLN and the 
spleen in the group that received 2D2 iTreg but not polyclonal iTreg  (Figure 5.30C). 
The percentage of Foxp3+ Th2 2D2 cells increased from ~1.5-2% in the rMOG only 
and polyclonal iTreg groups to ~12% in the 2D2 iTreg group within the medLN and 
~5.5% in the spleen. Interestingly, in mice that were challenged with rMOG and did 
not receive any iTreg, the percentages and numbers of Th2 2D2 Foxp3+ cells seemed 
higher compared to the PBS control. The lung could not be analyzed due to 
insufficient cell numbers obtained. These results indicate that iTreg are capable of 
inducing Foxp3 expression within pre-activated Th2 cells in an antigen-dependent 
fashion and this could contribute to their protective effect seen in AAI. 
 
5.2.2.13. 2D2 iTreg do not suppress AAI driven by a  different antigen 
Treg have been suggested to be capable of mediating suppression using a variety of 
mechanisms one of them being a bystander suppression, whereby they can inhibit 
CD4+ cells reactive to a different antigen via, for example, local production of anti-
inflammatory IL-10 and TGF-β (Groux, 2003, Roncarolo et al., 2006). This 
phenomenon has been reported to occur in vivo in a model of arthritis (Zonneveld-
Huijssoon et al., 2011). However, in EAE it has been shown that PLP-reactive iTreg 
are unable to suppress EAE induced by a different antigen to the one that iTreg are 
reactive to even when iTreg cognate antigen is present (Zhang et al., 2010). It is 
unknown whether transferred iTreg can suppress lung inflammation in AAI which is 
driven by CD4+ cells of different antigen reactivity. In order to test this, iTreg and 
Th2 cells responsive to different unrelated antigens were used and suppression was 
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determined in the presence of both cognate antigens and Th2 cognate antigen only. 
WT hosts received 5x106 2D2 iTreg prior to AAI induction with 2.5x106 Th2 CD4+ 
cells responsive to OVA323-339 (OT-II cells) and airway challenges with PBS, OVA or 
OVA/rMOG (Figure 5.31A). A lower dose of Th2 OT-II cells was used as these 
were shown to induce significantly more severe inflammation compared to Th2 2D2 
cells (Mackenzie, 2011). The capacity of 2D2 iTreg to suppress Th2 2D2 cells was 
tested and confirmed in the same experiment, however it is not shown in this section 
(data not shown).  
 
2D2 iTreg did not reduce the total cell numbers in BAL in the AAI model driven by 
Th2 OT-II cells even when iTreg cognate antigen waspresent (Figure 5.31B). The 
percentages of eosinophils and lymphocytes in BAL were unaffected by 2D2 iTreg 
treatment as well (Figure 5.31C). However, the total number of eosinophils was 
significantly reduced by 2D2 iTreg and this required the presence of their cognate 
antigen (Figure 5.31D). The total numbers of macrophages were similar in all groups 
(Figure 5.31E). Peri-vascular and peri-bronchiolar infiltration scores were 
unchanged, as were the percentages of goblet cells in small and large airways (Figure 
5.32A&B).  
 
Analysis of total cell numbers and percentages of CD4+ cells in the lung, medLN and 
spleen revealed that these were unaffected by the 2D2 iTreg treatment in the 
presence or absence of their cognate antigen (data not shown). The percentages and 
total cell numbers of 2D2 iTreg were found to be signif cantly increased in mice 
challenged with rMOG/OVA (Figure 5.33A) indicating that the presence of iTreg 
cognate antigen is critical for their migration to the medLN and the lung and/or 
survival. The ratio of 2D2 iTreg to Th2 OT-II cells within the lung was very low 
compared to that observed with Th2 2D2 cells (Figure 5.33B) and although it seemed 
higher it was not significantly affected by the presence of iTreg cognate antigen. The 
2D2 iTreg to Th2 OT-II cell ratios in the medLN and spleen were similar to the one 
in the lung and significantly higher in the rMOG/OVA-challenged group compared 
to the OVA only group (Figure 5.33B). 
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It is important to note that no increase in the percentage of total Foxp3+ CD4+ cells or 
Foxp3+ Th2 OT-II cells was observed in any of the groups (data not shown).  
 
5.2.2.14. 2D2 iTreg suppress Th2-associated cytokin es in a 
bystander fashion in AAI 
Effector functions of Th2 OT-II cells were investigated by overnight re-stimulation 
of the cells isolated from medLN and the spleen with OVA323-339 and MOG35-55 
followed by intracellular cytokine staining. 2D2 iTreg significantly reduced the 
percentages of IL-13+ and IL-5+ Th2 OT-II cells within the medLN upon 
OVA/rMOG challenge (Figure 5.34A). The frequency of IFN-γ+ Th2 OT-II cells was 
unaffected. Similar pattern of results was observed in the spleen (Figure 5.34B). 
Interestingly, in the spleen the percentages of IL-13+ and IL-5+ Th2 OT-II cells were 
also suppressed by 2D2 iTreg in the absence of their cognate antigen. Insufficient 





























































Figure 5.1 Naïve nTreg suppress polyclonal proliferation of naïve CD4+ cells in
vitro.
Freshly isolated nTreg from Foxp3-GFP mouse were mixed with increasing numbers of
sorted naïve CD4+ cells (Tresp) and stimulated with α-CD3 in the presence of irradiated
APC. Proliferation of naïve CD4+ cells was measured by 3H thymidineincorporation on
day 4. (A) Experimental scheme. (B) Suppression assay showing proliferation of Tresp.
Medium only (no α-CD3), Tresp only and nTreg only were used as controls. Dashed line
marks 50% of maximum proliferation noted in Tresp only sample. Data are from one
experiment, using triplicate wells.**p<0.01, ***p< 0.001 as determined by a one way
























































Figure 5.2 nTreg expanded under Th1- and Th2-polar ising conditions effectively
suppresspolyclonal proliferation of naïveCD4+ cells in vitro.
Sorted GFP+ CD4+ CD62Lhi nTreg from Foxp3-GFP mice were expanded under neutral,
Th1 (Il-12. IL-18) or Th2 (IL-4, α-IL-12, α-IFN-γ) conditions for 7 days. They were
mixed with increasing numbers of sorted naïve CD4+ cells (Tresp) and stimulated with
α-CD3 in the presence of irradiated APC. Proliferation of Tresp was measured by 3H
thymidine incorporation on day 4. (A) Experimental scheme. (B) Suppression mediated
by nTreg expanded under neutral conditions and (C) by nTreg expanded under Th1 and
Th2 polarising conditions. Medium only (no α-CD3), Tresp only and nTreg only were
used as controls. Dashed lines marks 50% of maximum proliferation noted in Tresp only
sample. Data are from one experiment, using triplicate wells.*p<0.05, ** p<0.01,
***p< 0.001as determined by a one way variance (ANOVA) using Dunnett’s multiple
comparisontest andTresp sampleasareference.
































































nTreg : Tresp ratio
Figure 5.3 nTreg expanded under neutral or polar ising conditions do not differ in
their ability to suppresspre-activated Th1 and Th2 cells.
Experimental scheme is shown in Figure 5.2. Tresp cells were obtained by polyclonal
stimulation of whole splenocytes under Th1 or Th2 polarising conditions followed by 3-
day rest in IL-2 and CD4+ cell sort. (A) Percentages of suppression of Th1 cell
proliferation and (B) Th2 cell proliferation. Dashed line marks 50% of suppression. Data
are from one experiment, using duplicate cells with Th1 cells and triplicate wells with
Th2 cells. ns=not significant as determined by a one-way variance (ANOVA) using
Tukey’smultiplecomparisontest.
nTreg : Tresp ratio
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Figure 5.4 CNS-der ived Treg do not suppress BAL eosinophilia in rMOG-induced
AAI .
EAE was induced in Foxp3-GFP (CD90.2+ CD45.2+) mice by immunization with
MOG35-55 in CFA. CNS was harvested on day 16, GFP+ Treg were sorted and 1.25x105
cells were transferred into WT (CD90.2+ CD45.1+) mice. Treg from naïve Foxp3-GFP
spleen were used as a control. The following day, Th2 polarised 2D2 CD4+ cells
(CD90.1+ CD45.2+) were transferred followed by three intratracheal challenges with
rMOG. (A) Experimental scheme. (B) Mean clinical scores of EAE, n=27. Red arrow
indicates harvest. (C) Purity of GFP+ cells pre- and post-sort using FACS. (D) Total cell
numbers in BAL. (E) Percentages of cells in BAL. Data are from oneexperiment, n=4.









































Figure 5.5 CNS-der ived Treg do not suppress lung infiltration and goblet cell
hyperplasia in rMOG-induced AAI .
Experimental scheme is shown in Figure 5.4. (A) H&E and PAS staining. (B) Infiltration
scores and (C) percentages of goblet cells in the lung. Black line represents 100µm. Data






































































































Figure 5.6 Total cell numbers and percentages of Th2 2D2 cells in the lung and
medLN areunaffected by CNS-der ived Treg.
Experimental scheme is shown in Figure 5.4.(A) Total cell numbers and percentages (%)
of CD4+ T cells of all cells. (B) Percentages of Th2 2D2 cells of all CD4+ cells and total
numbers of Th2 2D2 cells. Data are from one experiment, n=4. ns=not significant as
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Figure 5.7 Adoptive transfer of Th1 2D2 cells followed by rMOG challenge induces
neutrophils in BAL and lung infiltration but not goblet cell hyperplasia.
CD90.1+ 2D2 splenocytes were stimulated with MOG35-55 under Th1 or Th2 polarising
conditions, sorted for CD4+ cells and 5x106 cells were transferred into WT (CD90.2+)
mice followed by three intratracheal challenges with rMOG. (A) Experimental scheme.
(B) Total cell numbers in BAL. (C) Percentages of cells in BAL. (D) Infiltration scores
and (C) percentages of goblet cells in thelung. Data are representative of 2 experiments,
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Figure 5.8 Transfer of Th1 2D2 cells induces an increase in the number of Foxp3+
cellswithin the lung however thesedo not expressT-bet.
Experimental scheme is shown in Figure 5.7.(A) Total numbers of transferred 2D2 cells
and (B) Foxp3+ cells within the lung. (C) Representative flow cytometry plots showing
production of IFN-γ and IL-13 by Th1 and Th2 2D2 cells isolated from rMOG-
challenged groups and re-stimulated overnight with MOG35-55. (D) Representative
histograms showing expression of GATA-3 and T-bet in transferred 2D2 cells and in
Foxp3+ cells. Red lines mark Th1 cells, blue lines mark Th2 cells and a shaded area is an




















































































Figure 5.9 2D2 iTreg suppress proliferation of naïve 2D2 CD4+ cells in vitro more
effectively than polyclonal iTreg.
2D2 iTreg and polyclonal iTreg were generated in vitro from2D2xFoxp3.LuciDTR4 and
Foxp3.LuciDTR4 mice, respectively, in the presence of TGF-β and IL-2 for 5 days and
sorted for GFP+ cells usingFACS. GFP+ cells were mixed with naïve CD4+ cells (Tresp)
at different ratios and stimulated with MOG35-55 in the presence of irradiated APC.
Proliferation of naïve CD4+ cells was measured by 3H thymidineincorporation on day 4.
(A) Experimental scheme. (B) Suppression assay showing proliferation of Tresp.
Medium only (no MOG35-55), Tresp only and iTreg only were used as controls. Dashed
line marks 50% of maximum proliferation noted in Tresp only sample. Representative of
4 experiments, using triplicate wells. **p< 0.01, ***p< 0.001 as determined by an
unpaired t-test.
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Figure 5.10 2D2 iTreg proliferate in vivo in response to antigen and partially lose
Foxp3 expression.
2D2 iTreg (CD90.1+CD90.2+) were induced fromnaïve 2D2 CD4+ CD62Lhigh cells in the
presence of TGF-β and IL-2 for 5 days. On day -1, 2x106 2D2 iTreg were injected into
WT (CD90.2+) host followed by immunization with MOG35-55/CFA. Unimmunized host
was used as a control. On day 4, draining LN (dLN) and spleen were harvested.
(A) Experimental scheme. (B) Profile of 2D2 iTreg prior to transfer. Naïve CD4+ cells
are shown in filled histogram. (C) Total numbers of 2D2 iTreg, their expression profile
of Ki-67 (gated on all iTreg) and percentages (%) of Foxp3+ iTreg of total iTreg in dLN
and D) spleen. Unimmunized control is shown in filled histogram. Data are from one










































































































Figure 5.112D2 iTreg limit survival but not proliferation of naïve 2D2 CD4+ cells in
vivo upon immunization.
Naïve 2D2 (CD90.1+) CD4+ cells (Tresp; 2x106) were transferred with or without 2D2
iTreg (CD90.1+ CD90.2+) into WT (CD90.2+) host followed by MOG35-55/CFA
immunization. Unimmunized host that received both naïve 2D2 CD4+ cells and 2D2
iTreg was used as a control. On day 4, dLN andspleen were harvested. (A) Experimental
scheme. (B) Total cell numbers and Ki-67 staining of Tresp in dLN and (C) in spleen.
Black line marks Tresp + iTreg, filled histogram denotes Tresp only. Data represent 2
























































































































Figure 5.12 2D2 iTreg reduce levels of effector cytokines produced in response to
recall stimulation with antigen.
Experimental scheme is shown in Figure 5.11. Cells isolated from dLN and spleen were
cultured in vitro with increasing concentrations of MOG35-55; IFN-γ, IL-17A and GM-
CSF production was measured from the cell supernatants using ELISA on day 3 of re-
stimulation. Dotted lines represent un-stimulated controls. Data are from oneexperiment.
**p< 0.01,** *p<0.001asdetermined by a two way variance(ANOVA) usingBonferroni
multiplecomparisontest.
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Figure 5.13 2D2 iTreg increase Foxp3 expression within transfer red naïve 2D2
CD4+ cell population upon immunization.
Experimental scheme is shown in Figure 5.11. (A) Representative histograms showing
Foxp3 expression in Tresp. Numbers indicate percentages of gated cells within Tresp
population. Control denotes unimmunized host that received both naïve 2D2 CD4+ cells
and 2D2 iTreg. (B) Percentages (from all Tresp) and C) total numbers of Foxp3+ Tresp.
Data are from oneexperiment. *p<0.05,**p< 0.01, ** *p<0.001as determined by a one-
way variance(ANOVA) usingTukey’smultiplecomparisontest.
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Figure5.142D2 iTreg but not polyclonal iTreg suppress induction of EAE.
FACS sorted GFP+ 2D2 or polyclonal iTreg (CD90.1+) were transferred into WT
(CD90.2+) host followed by MOG35-55/CFA immunization for EAE induction and
monitored for clinical signsof disease. Mice were harvested onday 14.(A) Experimental
scheme. B) Clinical course of EAE. Results are from 2 pooled experiments n=8-16.
(C) Total cell numbers. (D) Total numbers of CD4+ cells. Results are representative of 2
experiments, n=8. ***p< 0.001, **p< 0.01 as determined by (B) a Fisher’s exact test,
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Figure 5.15 2D2 iTreg transferred pr ior to immunization suppress production of
pro-inflammatory cytokineswithin theCNS.
Experimental scheme is shown in Figure 5.14.Cells isolated fromtheCNS were cultured
overnight in the presence or absence of MOG35-55 followed by ICS cytokine staining.
(A) Gating strategy and representative histograms showing cytokinestaining in theCNS
of mice that were treated either with PBS or 1x106 2D2 iTreg. Numbers indicate
percentages of gated cells within CD4+ cell population. B) Percentages of CD4+ cells
expressing IFN-γ, IL-17A, TNF-α or GM-CSF of total CD4+ cells in theCNS. Data are
representative of 2 experiments, n=8 with each data point representing 2 pooled mice.





























































































Figure 5.16 2D2 iTreg transfer red pr ior to immunization reduce cytokine
production within thedLN but not in thespleen.
Experimental scheme is shown in Figure 5.14.Cells isolated from the dLN and spleen
were cultured overnight in the presence or absence of MOG35-55 followed by ICS
cytokine staining. A) Percentages of CD4+ cells expressing IFN-γ, IL-17A, TNF-α or
GM-CSF of total CD4+ cells in dLN and B) in spleen. Dashed lines mark unstimulated






















































Figure 5.17 2D2 iTreg accumulated within dLN and this corresponded with
increased total cell numbersof CD4+ Foxp3+ cells.
Experimental scheme is shown in Figure 5.14. (A) Total numbers of iTreg.
(B) Percentages and absolute numbers of total Foxp3+ CD4+ cells. Data are
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Figure 5.18 2D2 iTreg suppress proliferation of pre-activated polarised CD4+ cells
in vitro moreeffectively than polyclonal iTreg.
2D2 iTreg and polyclonal iTreg were induced in the presence of TGF-β and IL-2 for 5
days and sorted for GFP+ cells using FACS. These were mixed with sorted pre-activated
CD4+ cells (Tresp) at different ratios and stimulated with MOG35-55 in the presence of
irradiated APC. Proliferation of Tresp was measured by 3H thymidine incorporation on
day 4. (A) Experimental scheme. (B) Suppression assay showing proliferation of Tresp.
Medium only (no MOG35-55), Tresp only and iTreg only were used as controls. Dashed
lines mark 50% of maximum proliferation noted in Tresp only sample. Data are
representative of 4 experiments, using triplicate wells. *p<0.05,**p<0.01as determined
by an unpaired t-test.
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Figure 5.19 2D2 iTreg suppress cytokine production by pre-activated polar ised
CD4+ cells in vitro moreeffectively than polyclonal iTreg.
Experimental scheme is shown in Figure 5.18. Cytokine production by Tresp was
measured by ELISA on day 3. Dashed lines mark 50% of maximum cytokine
concentration noted in Tresp only sample. Data are representative of 4 experiments,
using triplicate wells. *p<0.05, **p< 0.01, ** *p<0.001 as determined by an unpaired t-
test.
iTreg : Tresp ratio iTreg : Tresp ratio
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Figure 5.20 2D2 iTreg suppress GM-CSF production by Th1- and Th2-polar ised
cellsbut lesseffectively by GM-CSF-polarised cells.
Experimental scheme is shown in Figure 5.18. Cytokine production by Tresp was
measured by ELISA on day 3. (A) GM-CSF production by GM-CSF-polarised cells and
by (B) Th1- and Th2-polarised cells. Dashed lines mark 50% of maximum cytokine
concentration noted in Tresp only sample. Data are representative of 2 experiments,
using triplicate wells. *p<0.05, **p< 0.01, ** *p<0.001 as determined by an unpaired t-
test.
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Figure 5.21 2D2 iTreg do not protect from EAE when transferred after the onset of
thedisease.
WT (CD90.2+) hosts were immunized with MOG35-55/CFA for theinduction of EAE and
monitored for clinical signs of disease. Upon approaching grade 1-2, mice received
intravenous injection of 1x106 CD90.1+ polyclonal iTreg (poly iTreg) or 2D2 iTreg
which were FACS sorted for GFP+ cells prior to transfer. PBS was used as a control.
Tissuewas harvested 4 days and 14 days after iTreg transfer. (A) Experimental scheme.
(B) Flow cytometry plots showing percentages of Foxp3+ (GFP+) cells from all cells pre-


































































































Figure 5.22 2D2 iTreg accumulate in CNS during EAE but are unable to suppress
on-going inflammation.
Experimental scheme is shown in Figure 5.21.(A) Total numbers of iTreg on day 13 and
day 23. (B) Representative flow cytometry plots showing percentages of iTreg within
CD4+ cell population on day 23. (C) Foxp3 expression by poly iTreg and 2D2 iTreg on
day 23. Foxp3expression by poly iTreg in the CNS is not shown due to insufficient cell
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Figure 5.23 2D2 iTreg migrate to the medLN and the lung upon airway challenge
with rMOG.
2D2 iTreg (CD90.1+) were transferred into WT (CD90.2+) host followed by a single
airway challenge with rMOG. Tissue was harvested 2 days after the challenge.
(A) Experimental scheme. (B) Percentages and (C) total numbers of 2D2 iTreg in the
lung, medLN andspleen.Dataare fromoneexperiment, n=1-3.
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Figure 5.24 2D2 iTreg but not polyclonal iTreg reduce BAL eosinophilia dr iven by
Th2 2D2 cells in rMOG-induced AAI .
FACS sorted GFP+ 2D2 or poly iTreg (CD90.1+ CD90.2+) were injected into WT
(CD90.2+) host followed by transfer of Th2-polarised 2D2 (CD90.1+) cells and 3
consecutive airway challenges with rMOG. Tissuewas harvested 2 days after last airway
challenge. (A) Experimental scheme. (B) Total cell number in BAL. (C) Percentages of
cells in BAL. (D) Total numbers of eosinophils and (E) macrophages. Data are
representative of 2-4 experiments, n=4-6. Data are shown as mean +/- SEM. *p<0.05,













































Figure 5.252D2 iTreg reduce lung infiltration and goblet cell hyperplasia in rMOG-
induced AAI .
Experimental scheme is shown in Figure 5.24.A) H&E and PAS staining (B) Infiltration
scores and (C) percentages of goblet cells in the lung. Black line represents 100µm. Data





























































































































Figure 5.26 2D2 iTreg reduce the numbers of Th2 2D2 cells within the lung and
medLN.
Experimental scheme is shown in Figure 5.24.A) Total cell numbers and percentages of
CD4+ cells. B) Total percentages and numbers of 2D2 Th2 cells. Data are representative




























































Figure 5.27 2D2 iTreg suppress the production of Th2-assciated cytokines and
increasetheproduction of IFN-γ.
Experimental scheme is shown in Figure 5.24. Cells from the lung, medLN and spleen
were cultured overnight with or without MOG35-55 followed by ICS staining for
cytokines. A) Percentage of IL-13+ Th2 2D2 cells (of all Th2 2D2 cells) in the lung, poly
iTreg not included, data pooled from 4 mice due to insufficient cell numbers.
B) Percentages of IL-13+, IL-5+ and IFN-γ+ Th2 2D2 cells (of all Th2 2D2 cells) in the
medLN and spleen. Dashed lines mark unstimulated control. Data are from (A) one
experiment or (B) are representative of 2 experiments. *p<0.05,**p< 0.01, *** p<0.001
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Figure5.28The ratio of 2D2 iTreg to Th2 cells is thehighest in the lung.
Experimental scheme is shown in Figure 5.24. (A) Percentages and total numbers of
iTreg of all CD4+ cells. (B) iTreg to Th2 2D2 cell ratio. (C) Percentages of Foxp3+
iTreg (of all iTreg). Data are representative of 2-4 experiments. *p<0.05, ** p<0.01 as
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Figure 5.29 2D2 iTreg but not polyclonal iTreg increase the percentages of Foxp3+
cellswithin transfer red Th2 2D2 cells.
Experimental scheme is shown in Figure 5.24.(A) Representative flow cytometry plots
showing Foxp3 expression in Th2 2D2 cells. (B) Percentages and total numbers of
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Figure 5.30 2D2 iTreg but not polyclonal iTreg induce expression of Foxp3 in
transfer red Th2 2D2 cells.
Splenocytes from 2D2xFoxp3.LuciDTR4 (CD90.1+ CD90.2+) mice were stimulated with
MOG35-55 under Th2 polarising conditions, and FACS sorted for CD4+ GFP- cells prior
to transfer into WT (CD90.2+) mice. FACS-sorted GFP+ 2D2 iTreg or polyclonal iTreg
(CD90.1+) were transferred the day before. AAI was induced by three intratracheal
challenges with rMOG. (A) Experimental scheme. (B) Flow cytometry plots showing
Foxp3expression in Th2 2D2 cells pre- and post-sort. (C) Percentages and total numbers
of Foxp3+ Th2 2D2 cells (from all Th2 2D2 cells). *p<0.05, **p< 0.01, ***p< 0.001 as
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Figure 5.312D2 iTreg reduce BAL eosinophilia dr iven by OVA-reactive Th2 CD4+
cellswhen iTreg cognateantigen ispresent.
2D2 iTreg (5x106) generated from 2D2 (CD90.1+ CD45.2+) mouse were injected into
WT host (CD90.2+ CD45.2+) followed by transfer of 2.5x106 Th2-polarised OT-II CD4+
(CD90.2+ CD45.1+) cells and 3 consecutive airway challenges with OVA, OVA/rMOG
or PBS as a control. Tissue was harvested 2 days after last airway challenge.
(A) Experimental scheme. (B) Total cell numbers in BAL. (C) Percentages of cells in
BAL. (D) Total numbers of eosinophils and (E) macrophages. Data are from one







































Figure 5.322D2 iTreg do not suppress lung infiltration and goblet cell hyperplasia
dr iven by Th2 OT-I I cells.
Experimental scheme is shown in Figure 5.31.(A) Infiltration scores and (B) percentages
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Figure 5.33 The presence of the cognate antigen is cr itical for 2D2 iTreg migration
into the lung and medLN.
Experimental scheme is shown in Figure 5.31. (A) Percentages and total numbers of
iTreg. (B) Ratios of iTreg to Th2 OT-II cells. Data are from one experiment, n=5-7.





















































































Figure 5.34 2D2 iTreg suppress the production of Th2 OT-I I -der ived IL-5 and
IL-13.
Experimental scheme is shown in Figure 5.31.Cells from the medLN and spleen were
cultured overnight with or without OVA223-239 and MOG35-55 followed by ICS staining
for cytokines. (A) Percentages of IL-13+, IL-5+ and IFN-γ+ Th2OT-II cells in themedLN
and (B) spleen. PBS control for medLN was pooled. Dashed lines mark unstimulated
control. Data are from oneexperiment. *p<0.05, **p <0.01, ***p< 0.001 as determined
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5.3. Discussion 
5.3.1. Effect of Treg phenotype on suppression 
It has been suggested that nTreg may be capable of utilizing certain components of 
Th-associated transcriptional machinery to efficiently control the corresponding type 
of the immune response (Koch et al., 2009, Zheng et al., 2009). However, the 
efficiency of polarised nTreg has not been tested against different inflammatory 
contexts. Due to their poor survival giving insufficient cell numbers, the functional 
consequences of T-bet and GATA-3 upregulation in nTreg stimulated under Th-
polarising conditions in vitro could not be tested here. An alternative approach 
involved expanding naïve nTreg under Th1 or Th2 polarising conditions in vitro, as 
described in Chapter 3, which enabled obtaining sufficient cell numbers for 
functional analysis. Increased levels of T-bet and CXCR3 in nTreg expanded under 
Th1 conditions did not affect nTreg ability to suppress Th1 or Th2 cell responses. 
This suggests that nTreg polarisation may not be important for direct suppressive 
function in vitro but it could be crucial for Treg migration and homeostasis under 
inflammatory conditions in vivo. This is supported by the data that T-bet-deficient 
Treg retain their suppressive function in vitro (Bettelli et al., 2004). However, it has 
to be noted that that study used naïve CD4+ Tresp and not pre-activated Th1 cells. 
This data also indicates that the expression of T-bet by nTreg does not compromise 
their suppressive capacity which is consistent with previous reports (Koch et al., 
2009). Whether upregulation of GATA-3 under Th2 polarising conditions influences 
the suppressive function of nTreg in vitro needs to be established.    
 
In order to test whether nTreg derived from Th1/Th17 inflammation can suppress 
Th2-driven inflammation in vivo, T-bet+ CXCR3high nTreg were isolated from EAE 
CNS and transferred into WT host prior to AAI induction with the same antigen. 
These nTreg, previously shown to suppress EAE (McGea hy et al., 2005), were not 
capable of inhibiting lung inflammation driven by pre-activated Th2 cells even 
though their numbers were 6-fold higher compared to these used in the EAE study 
done by McGeachy et al. However, a solid conclusion c uld not be reached, given 
alternative possibilities such as poor survival of transferred CNS-derived nTreg or 
insufficient cell numbers needed for effective suppression of pre-activated Th2 cells. 
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In the EAE study done by McGeachy et al. CNS-derived nTreg were used to inhibit 
EAE induction (McGeachy et al., 2005) and there is limited evidence that Treg can 
inhibit a passive model of EAE driven by a transfer of pre-activated Th1 cells. 
Moreover, in vitro suppression assays presented here showed that pre-ctivated Th-
polarised cells are more resistant to nTreg-mediate suppression compared to naïve 
cells. Taking into account that the ratio of transferred CNS-derived Treg to Th2 cells 
was 1:40, and that the frequency of MOG-reactive Treg isolated from the CNS at the 
peak of EAE is ~7.6% of total Treg (Korn et al., 2007), it is possible that the number 
of transferred antigen-reactive Treg was too low to observe effective suppression. 
Due to technical difficulties of this experimental design, a different approach has to 
be taken to establish how important nTreg phenotype is in suppression of different 
forms of inflammation and whether it is adaptable. This is further discussed in 
Chapter 6.  
 
The low numbers of nTreg available for in vivo transfer experiments prompted the 
investigation of the suppressive function of iTreg which can be generated in vitro in 
robust numbers. The default Th1-like iTreg phenotype, in contrast to nTreg, could 
not be skewed towards being more Th1-like (with higher T-bet expression) or Th2-
like (with upregulated GATA-3) by polarising cytokines, unless iTreg stability was 
compromised. This could mean that a certain level of T-bet and CXCR3 expression 
could be important for iTreg induction and maintenance of Foxp3 expression.  
 
T-bet+ CXCR3+ iTreg effectively suppressed both the proliferation and cytokine 
production by Th1, Th17 and Th2 cells, but were less ffective against highly 
polarised GM-CSF+ cells in vitro. High expression of T-bet and CXCR3 was also not 
disadvantageous to iTreg during in vivo suppression where they effectively 
suppressed both Th1/Th17- and Th2-mediated tissue inflammation. The ability of 
iTreg to inhibit a range of CD4+ T cell responses was demonstrated previously in a 
variety of mouse inflammation models (Huter et al.,2008, Zhang et al., 2010, Xu et 
al., 2012). This may indicate that nTreg and iTreg use different components of 
transcriptional machinery to control their suppressive function. Stock et al. 
demonstrated that iTreg that were induced in vivo during a Th1 type of inflammation 
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expressed T-bet and effectively suppressed Th2-driven inflammation in a 
sensitization model of AAI (Stock et al., 2004). However, it is unknown whether 
Th2-like iTreg can be induced in vivo from CD4+ CD25- cells during Th2 type of 
inflammation and how effective they are in suppressing Th1 responses. Nevertheless, 
the Th1-like phenotype of in vitro generated iTreg and their ability to suppress a 
range of CD4+ cell responses suggests that iTreg may not have to adapt to the 
inflammatory environment to effectively regulate the associated Th cell function. 
Whether iTreg phenotype is modified in vivo by inflammation needs to be 
determined.  
 
5.3.2. Effect of iTreg antigen reactivity on suppre ssion 
Suppression of inflammation in EAE and AAI mediated by iTreg was found to be 
antigen-dependent. 2D2 iTreg effectively suppressed EAE induction whereas 
polyclonal iTreg failed to exert any effect. This observation is consistent with 
previous reports showing that only PLP-reactive iTreg suppressed PLP-induced EAE 
(Zhang et al., 2010) and reflects the data on the importance of antigen-reactivity in 
nTreg-mediated suppression (Stephens et al., 2009). Since both 2D2 iTreg and 
polyclonal iTreg were found to suppress naïve CD4+ cells in vitro but with different 
efficiencies, it is possible that antigen-driven migration of iTreg to the site of 
inflammation or the dLN was critical to ensure that sufficient numbers of iTreg 
accumulated at appropriate site in order to effectiv ly suppress pathogenic CD4+ T 
cell responses. This result disagrees with the previously published efficiency of 
polyclonal iTreg to inhibit induction of MOG-induced model of EAE (Selvaraj and 
Geiger, 2008). However, in that study 6x106 of polyclonal iTreg were transferred 
which is 30 times more than the dose of 2D2 iTreg (2x105 cells) demonstrated to 
effectively suppress disease severity in this project. Collectively, antigen-reactive 
iTreg are more effective than polyclonal iTreg and hence can be used at much lower 
doses.  
 
Although in vitro data showed that 2D2 iTreg can inhibit Th1, Th17 and to a lesser 
extent GM-CSF+ cell proliferation and cytokine production, the transfer of 2D2 iTreg 
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after EAE induction, when the mice showed first clini al signs of a disease, failed to 
suppress disease severity or to lead to an earlier resolution. 2D2 iTreg were shown to 
accumulate within the inflamed CNS as the disease progressed and started to resolve. 
However, they were unable to control on-going inflammation. As GM-CSF produced 
by effector CD4+ cells has been shown to be necessary to drive EAE (Codarri et al., 
2011), it is possible that substantial amounts of GM-CSF within the CNS, combined 
with a poor ability of iTreg to reduce GM-CSF production (as shown by in vitro 
suppression assays) could contribute to the lack of disease control. Moreover, data on 
iTreg re-stimulation under strong Th1 polarising conditions in vitro showed that they 
rapidly lose Foxp3 and this could contribute to the lack of iTreg-mediated 
suppression during on-going inflammation. Nevertheless, it has been shown 
previously that IL-12-conditioned ex-iTreg can still provide protection against EAE 
if given before immunization (O'Connor et al., 2010).   
 
No previous study has directly compared the efficien y of antigen-reactive versus 
polyclonal iTreg in a model of Th2-driven AAI. Studies using standard sensitisation / 
challenge models of AAI have indicated that polyclonal iTreg can effectively 
suppress disease when transferred prior to sensitization, antigen challenge or after the 
first antigen challenge but before the disease is established (Chen et al., 2003, Xu et 
al., 2012). The data from this project, however, indicate that polyclonal iTreg fail to 
suppress Th2-mediated AAI and only 2D2 iTreg are abl to regulate eosinophilia and 
lung infiltration. The in vitro data which showed that polyclonal iTreg do not 
suppress Th2-associated IL-4 and IL-13 support the in vivo observations. Of note, 
polyclonal iTreg did reduce the levels of IL-13 in vivo within the medLN but had no 
effect on disease severity. The discrepancy between published observations and 
results from this project is most likely due to the different modes of AAI induction 
and the timing and dosage of iTreg transfers. Chen et al. injected iTreg twice, 1x106 
cells during sensitization phase and 5x105 cells prior to airway challenge and so it is 
likely that those iTreg exerted most of their effect by inhibiting the development of 
the Th2 response (Chen et al., 2003). Xu et al. used 5x106 polyclonal iTreg prior to 
and after the first antigen challenge (Xu et al., 2012). However, the cells that had to 
be suppressed were most likely memory Th2 cells, rathe  than freshly activated Th2 
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cells as used in this project. This suggests that suppression of activation of memory 
Th2 cells can be mediated by large numbers of polyclonal iTreg, however 
suppression of proliferation and cytokine production by already activated Th2 cells 
can only be effectively mediated by antigen-reactive iTreg. Whether these are able to 
ameliorate AAI once the lung inflammation has been established needs to be 
determined, requiring a model with greater chronicity.  
 
5.3.3. How do iTreg suppress? 
5.3.3.1. Antigen-specific suppression of EAE induct ion 
Transferred antigen-reactive 2D2 iTreg were demonstrated to proliferate in vivo in 
response to antigen and to migrate to the lymph node draining the site of 
immunization. When co-transferred with naïve 2D2 responder cells, on day 4 post-
immunization they limited 2D2 cell survival and cytokine production but not cell 
proliferation. In EAE, 2D2 iTreg transferred prior to disease induction significantly 
reduced CD4+ T cell infiltrate within the CNS. Moreover, they also prevented splenic 
lymphopenia normally observed in EAE mice as a result of cell mobilisation due to 
on-going inflammation. Interestingly, total cell numbers and numbers of CD4+ cells 
were significantly increased in dLN of mice treated with 2D2 iTreg (at both doses) 
compared to poly iTreg- and PBS-treated groups. This suggests that the protective 
effect of 2D2 iTreg could be due to retention of CD4+ effector T cells in dLN and 
hence limited Teff mobilization into the CNS. This is supported by the finding that 
2D2 iTreg accumulated within dLN, and indicates that dLN is the main site of 2D2 
iTreg action. Similar observations were made in studies by the Shevach group who 
used 1x106 polyclonal nTreg and iTreg to suppress MOG35-55-driven induction of 
EAE (Davidson and Shevach, 2011). They reported that reduced EAE severity 
corresponded with reduced percentages of Teff within e CNS. Moreover, using 
polyclonal nTreg and TCR transgenic Foxp3- T cell transfer prior to EAE induction, 
they showed that nTreg did not limit Foxp3- T cell proliferation but rather retained 
Teff in lymph nodes draining the site of immunization. Although in this study 
proliferation of Teff was not measured, increased prcentages and total cell numbers 
of Teff in dLN suggest that a similar phenomenon occurred. The Shevach group also 
                                                                                            CHAPTER 5 RESULTS 
 215
demonstrated that the higher number of Teff in dLN was associated with the lower 
Teff numbers in the blood suggesting that nTreg were able to restrain Teff from 
entering the circulation from the dLN and hence prevent them from migrating to the 
target organ (Davidson and Shevach, 2011). The unaffected Teff proliferation but 
reduced migration of Teff into the target organ mediated by antigen-reactive iTreg 
was also reported in a model of autoimmune gastritis (Nguyen et al., 2011). As the 
potential mechanisms the Shevach group suggested nTreg-mediated downregulation 
in CXCR4, Syndecan-4 and S1P1 which are implicated in cell mobility (Longley et 
al., 1999, Thangada et al., 2010). It would be interesting to know whether the levels 
of these proteins were affected by antigen-reactive iTr g in this study. Moreover, it 
would be of great value to determine whether 2D2 iTreg are able to produce 
chemokines that could affect Teff mobilization and hence contribute to their 
protective function. Antigen-reactive iTreg were shown to secrete a number of 
chemokines such as CCL3 and CCL4 (in a model of autoimmune gastritis) when 
activated in inflammatory environment and these were found to be distinct from 
chemokines produced by nTreg and Teff (Nguyen et al., 2011). These chemokines 
were found to preferentially induce migration of iTreg themselves into the target 
organ and reduce the migration of Teff.  
 
Even though negligible numbers of 2D2 iTreg were prsent in the CNS itself on day 
14 of the EAE, this may be associated with a late time point of the harvest. It is 
possible that 2D2 iTreg migrated into the CNS early fter injection and prevented 
activated CD4+ cells from entering the CNS or reducing their effector function 
and/or survival within the CNS itself. 2D2 iTreg can efficiently migrate to the target 
organ in response to their cognate antigen even in the absence of inflammation as 
shown in the lung with a single intratracheal antigen challenge. As the BBB is 
impermeable to solutes and cells in healthy mice, th  migration into the CNS could 
be facilitated by PTx which was shown to increase permeability of the BBB 
(Linthicum et al., 1982) and induce leukocyte recruitment into the CNS (Kerfoot et 
al., 2004). In order to determine the migratory potential of 2D2 iTreg, early time-
points after cell transfer would have to be investigated.  
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In addition to decreased CD4+ effector cell numbers within the CNS in 2D2 iTreg-
treated mice, the production of pro-inflammatory IFN-γ, TNF-α and GM-CSF, but 
not IL-17A, was significantly reduced as well. This is consistent with the lack of 
inflammatory reaction in the CNS and demonstrates that 2D2 iTreg were able to 
affect not only the total numbers of Teff within target organs but also their effector 
functions. Similar observations were made with antigen-reactive iTreg in a model of 
autoimmune gastritis where they were shown to reduc levels of IFN-γ and IL-17 but 
increase anti-inflammatory IL-10 (Nguyen et al., 2011). Interestingly, the Shevach 
group did not find evidence of decreased IFN-γ and IL-17 in their study upon 
polyclonal nTreg/iTreg treatment in EAE and attributed Treg protective effects to 
suppressed Teff migration only (Davidson and Shevach, 2011). It is possible that 
iTreg have to be antigen-reactive in order to effectiv ly suppress effector functions 
of Teff. The production of IFN-γ, TNF-α and GM-CSF was also lower in dLN of 
2D2 iTreg-treated mice but unchanged in the spleen and this could be due to the 
lower percentage of 2D2 iTreg in the spleen versus dLN.  
 
To conclude, the significantly diminished Teff function within the CNS of 2D2 
iTreg-treated mice could be due to 2D2 iTreg suppressing the development of 
inflammatory reaction within the target organ, or inhibiting CD4+ cell effector 
function and migratory capacity in dLN. The 2D2 iTreg accumulation within dLN is 
in favour of the latter explanation, however this would have to be determined. Of 
note, the resistance of IL-17 production to Treg-mediated suppression in EAE was 
reported before and was shown to occur during in vitro suppression assay of CNS-
derived nTreg and CD4+ effector cells (O'Connor et al., 2007). Although 2D2 iTreg 
effectively suppressed EAE induction, they failed to control on-going CNS 
inflammation when transferred after disease onset. This could be due to their 
inability to either regulate already established inflammation itself or to suppress 
activated Th1/Th17 cells driving the response. Interestingly, 2D2 iTreg were 
demonstrated to effectively inhibit pre-activated Th2 cells in a model of AAI.   
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5.3.3.2. Antigen-specific suppression of Th2-driven  AAI 
2D2 iTreg effectively migrated into the lung and medLN upon antigen airway 
challenge and suppressed eosinophilia, goblet cell hyperplasia and lung infiltration in 
a model of AAI driven by pre-activated Th2 cells. This was associated with a 
significantly decreased representation of transferred Th2 2D2 effector cells within 
the lung and medLN. Their effector function (production of IL-13 and IL-5) was also 
reduced within the lung, medLN and spleen. As IL-13 is implicated in the induction 
of goblet cell hyperplasia (Yang et al., 2001) and IL-5 in the recruitment of 
eosinophils (Foster et al., 1996), their suppressed levels correlate with the improved 
disease. Interestingly, 2D2 iTreg increased the percentage of IFN-γ+ Th2 2D2 cells. 
However, it is not known whether this corresponds to increased overall levels of 
IFN-γ within the lung/medLN and hence could contribute to the protective effect of 
iTreg. IFN-γ inhibits proliferation of Th2 cells (Oriss et al., 1997) and its elevated 
levels were detected (together with IL-10 and TGF-β) in BAL upon iTreg treatment 
in a model of cockroach-induced AAI (McGee and Agrawal, 2009). The levels of 
IFN-γ would have to be tested in the lung tissue/dLN or in BALF in this model.  
 
Although the percentages and absolute numbers of 2D2 iTreg were higher in medLN 
compared to the lung, the highest iTreg to Th2 2D2 cell ratio (~2) was found in the 
lung tissue itself. As the total numbers of Th2 2D2 effector cells and their cytokine 
production was suppressed in both the lung and medLN, this suggests that 2D2 iTreg 
may exert their suppressive capacity at both sites. I  also suggests that 2D2 iTreg 
may induce cell death of Th2 2D2 effector cells in the lung and medLN but may also 
limit the migration of Th2 2D2 cells into the lung. The regulation of Teff/iTreg 
migration mediated by 2D2 iTreg could be due to the production of chemokines as 
shown in a model of autoimmune gastritis (Nguyen et al., 2011) or due to 
downregulated expression of molecules implicated in cell mobility as suggested by 
the Shevach group (Davidson and Shevach, 2011). However, this needs further 
investigation. It would be also interesting to know whether the mechanisms of 
suppression mediated by 2D2 iTreg differ not only in Th1/Th17- versus Th2-
mediated inflammation but also in regulation of naïve T cells upon activation (as in 
EAE induction) versus pre-formed Th2 polarised cells.   
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5.3.3.3. ‘Infectious tolerance’ as a mode of iTreg- mediated 
suppression? 
2D2 iTreg were found to increase the percentages and total numbers of Foxp3+ cells 
within the transferred naïve 2D2 cells in the dLN and spleen upon immunization. 
This indicated that 2D2 iTreg were able to either expand the Foxp3+ cell population 
transferred within 2D2 cells or to induce Foxp3 expr ssion in Foxp3- 2D2 cells. One 
of the first studies describing a phenomenon of ‘inectious tolerance’ whereby a 
tolerance-inducing state is transferred from one cell population onto another was 
reported by the Waldmann lab (Qin et al., 1993). This finding was later expanded by 
the same group who showed that this ‘infectious tolerance’ was dependent on Foxp3+ 
Treg induced de novo in mice tolerized to transplants (Cobbold et al., 2004). The 
observation that the generation of these Foxp3+ Treg from naïve cells was mediated 
by Foxp3+ nTreg and was TGF-β dependent was first reported by the Shevach group 
(Andersson et al., 2008). In EAE it was previously shown that the cells isolated from 
the dLN of MOG35-55 immunized, iTreg-treated mice and subsequently deplet d of 
these iTreg could protect from EAE induction (Selvaraj and Geiger, 2008). This 
suggested that iTreg were capable of inducing a protective cell population.  
 
In this project the transfer of 2D2 iTreg prior to EAE induction led to the increased 
number of Foxp3+ CD4+ cells within dLN compared to PBS- and poly iTreg-treated 
mice which corresponded with the increased total cellularity of dLN.  This could be 
due to the 2D2 iTreg-mediated retention of total CD4+ cells within dLN. However, a 
possibility of the 2D2 iTreg-mediated accumulation of nTreg within dLN or Foxp3 
induction in Foxp3- CD4+ cells cannot be excluded. Since ‘infectious tolerance’ was 
shown to be mediated by TGF-β expression, it would be of interest to determine 
whether its levels are affected by 2D2 iTreg treatment in dLN. No changes in the 
level of Foxp3 expression in poly nTreg- and PBS-treated groups were found by the 
Shevach group in their EAE study (Davidson and Shevach, 2011) which suggests 
that such changes may only occur in the presence of antigen-reactive Treg.   
 
Interestingly, 2D2 iTreg but not polyclonal iTreg were found to induce Foxp3 
expression in transferred pre-activated Th2 2D2 cells within medLN and spleen in a 
model of AAI. This phenomenon might also occur in the lung. However, low cell 
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numbers obtained did not permit a full analysis. Induction of Foxp3 expression in 
effector cells was previously demonstrated to occur in vitro in memory Th2 cells 
(Kim et al., 2010). Those cells were shown to trans-differentiate into Foxp3+ cells 
when stimulated in the presence of TGF-β, all-trans retinoic acid and rapamycin. The 
converted Th2 memory Treg downregulated expression of GATA-3, produced very 
low levels of IL-4, IL-5 and IL-13 and effectively suppressed memory Th2 cells in 
vitro, and AHR and eosinophilia upon transfer in a model of AAI in an antigen-
dependent fashion (Kim et al., 2010). Moreover, these cells were very stable and 
capable of suppressing certain disease parameters in already established AAI. The 
converted Foxp3+ Th2 2D2 cells described here which were induced in vivo by 2D2 
iTreg via ‘infectious tolerance’ could play a role in iTreg-mediated suppression of 
AAI. The phenotype and functional importance of these converted cells would have 
to be established.   
 
5.3.3.4. Bystander suppression in a model of AAI 
Treg were reported to be able to suppress CD4+ cells reactive to a different antigen in 
vitro once they become activated (Thornton and Shevach, 2000). The so-called 
bystander suppression was also demonstrated in vivo in a model of arthritis 
(Zonneveld-Huijssoon et al., 2011). However, Zhang et al was unable to replicate 
this observation in a model of PLP-driven EAE (Zhang et al., 2010) posing a 
question whether phenomenon of Treg-mediated bystander suppression applies to 
different forms/models of inflammation. A new model of rMOG-induced AAI 
established in this project and an already established model of Th2 OT-II-driven AAI 
enabled testing whether 2D2 iTreg were capable of bystander suppression in a Th2 
inflammatory context. 2D2 iTreg suppressed Th2 OT-II-driven BAL eosinophilia 
and Th2-associated cytokines but did not reduce lung infiltration or goblet cell 
hyperplasia. Moreover, in order to mediate suppression, 2D2 iTreg required the 
presence of their cognate antigen. One of the reasons for this could be antigen-driven 
migration of iTreg to the lung and medLN as in its absence negligible numbers of 
2D2 iTreg were detected. Another reason could be that iTreg had to be re-activated 
in vivo by their antigen. Suppression of certain but not all disease parameters may be 
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due to local production of anti-inflammatory cytokines by iTreg upon re-stimulation. 
IL-10 was suggested by previous studies to mediate protective effects of iTreg 
(McGee and Agrawal, 2009, Xu et al., 2012). However, in this project in vitro re-
stimulated iTreg were found to secrete very low leve s of IL-10 and high levels of 
IFN-γ, GM-CSF and IL-2 (Richard O’Connor, personal communication, unpublished 
data). It is possible that TGF-β is implicated and its production by 2D2 iTreg would 
have to be assessed.  
 
The lack of inhibition of lung infiltration and goblet cell hyperplasia could be due to 
a large difference in disease severity between the rMOG-induced and the OVA-
induced AAI models. 2D2 iTreg might be able to effectively suppress a moderate 
degree of inflammation in the rMOG model but not the substantial inflammation in 
the OVA model. An alternative explanation would be the that effective iTreg-
mediated suppression i vivo is contact-dependent and this requires iTreg and CD4+ 
T effector cells to be of the same antigen-reactivity. This could also explain the lack 
of suppression mediated by polyclonal iTreg in addition to their reduced antigen-
driven migratory capacity.  
 
5.3.4. Stability of iTreg in inflamed environment 
Rapid loss of Foxp3 in re-stimulated iTreg in the absence of TGF-β (Floess et al., 
2007) led to the concerns over their potential to convert into effector T cells and 
hence contribute to the inflammation when used in a therapeutic setting. Moreover, a 
number of studies reported on Treg instability under inflammatory conditions 
rendering them either ineffective or even pathogenic (Peng et al., 2005, Zhou et al., 
2009b, Beres et al., 2011). It is unclear what exactly drives the loss of Foxp3 
expression in iTreg in vivo and under what conditions this compromises their 
regulatory function in different disease settings.  
 
In this study, iTreg were demonstrated to limit survival and cytokine production of 
the co-transferred TCR transgenic CD4+ cells (Tresp) upon immunization. This was 
achieved irrespective of the loss of Foxp3 expression in ~70% of iTreg in dLN and 
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~40-50% of iTreg in the spleen from a starting population of ~85% Foxp3+ iTreg. 
Interestingly, the loss of Foxp3 was similar irrespctive of Tresp co-transfer 
indicating that in this case it is the antigen-driven iTreg re-stimulation in vivo rather 
than inflammation that leads to the Foxp3 expression instability in iTreg. In EAE, the 
Foxp3 stability of the protective iTreg transfer prior to disease induction could not be 
determined due to insufficient cell numbers on the day of harvest. However, when 
iTreg were transferred after disease induction and alysed 14 days after, ~40% of 
2D2 iTreg within the CNS and ~70% in the dLN/spleen retained their Foxp3 
expression. Moreover, the similar loss of Foxp3 expr ssion by polyclonal iTreg 
within dLN/spleen suggested that, in the EAE setting, the loss of Foxp3 in iTreg in 
secondary lymphoid organs is driven by inflammation and not by the presence of 
iTreg cognate antigen. However, it is important to highlight the fact that 2D2 iTreg 
were ineffective in this setting even though they rtained their Foxp3. Possible 
reasons for this and implications are further discus ed in Chapter 6.   
 
In AAI mediated by pre-activated Th2 cells, the Foxp3 expression was retained by 
~65% of 2D2 iTreg and ~ 50% of polyclonal iTreg within the lung compared to 
~80% in the medLN and spleen in both groups. The Foxp3 stability of 2D2 iTreg and 
polyclonal iTreg could be analyzed in the inflamed target organs in this disease 
setting, and it revealed that 2D2 iTreg were more stable than polyclonal iTreg. This 
suggested that iTreg cognate antigen may be important for maintaining their Foxp3 
expression. Similarly to EAE, no difference between 2D2 iTreg and polyclonal iTreg 
was noted in the medLN/spleen in AAI, and the highest Foxp3 loss was noted in the 
target organs itself.   
 
How inflammation could affect Foxp3 stability in iTreg in vivo could be due to a 
number of ways. It has been reported that pro-inflamm tory cytokines such as IL-1β 
and TNF can downregulate Foxp3 expression in human Treg (Deknuydt et al., 2009, 
Valencia et al., 2006). Moreover, in this project it has been shown that in vitro re-
activation of iTreg in the presence of IL-12, IL-18 or IL-4 leads to the rapid loss of 
Foxp3 unless exogenous TGF-β is present. In addition to this, rapidly proliferating 
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pathogenic T cells need IL-2 for their survival and may compete for it with iTreg 
which require IL-2 to maintain their expression of F xp3 (Chen et al., 2011).  
These data collectively indicate that the Foxp3 instability in iTreg in a disease setting 
is due to inflammation rather than antigen-driven r-stimulation in vivo. Importantly, 
even though iTreg partially lose their Foxp3 in vivo, they remain suppressive. 
However, it has to be remembered that this is achieved prior to the establishment of 
inflammation. Retention of Foxp3 in majority of iTreg (~75%) during on-going 
inflammation was reported by Nguyen et al. suggesting that iTreg have a potential to 
be stable under already established inflammatory conditi ns as well (Nguyen et al., 
2011).    
 
5.4. Concluding synopsis 
• Upregulation of T-bet and CXCR3 expression by nTreg expanded under Th1 
conditions did not affect their ability to suppress Th1 or Th2 responses in vitro. 
• CNS-derived nTreg (T-bet+ CXCR3high) did not suppress Th2-driven lung 
inflammation in a model of AAI (this needs further verification). 
• 2D2 iTreg suppressed naïve cell proliferation in vitro more effectively than 
polyclonal iTreg.  
• 2D2 iTreg but not polyclonal iTreg effectively inhibited induction of EAE. 
• iTreg accumulated within dLN and reduced the total number of effector cells and 
cytokine production within the CNS.  
• 2D2 iTreg but not polyclonal iTreg suppressed proliferation and cytokine 
production by pre-activated 2D2 CD4+ effector cells in vitro. 
• 2D2 iTreg were unable to suppress ongoing CNS inflamm tion in EAE even 
though they accumulated within the CNS. 
• 2D2 iTreg but not polyclonal iTreg effectively suppressed AAI driven by pre-
activated 2D2 Th2 cells. 
• In AAI, iTreg reduced total numbers of effector cells and effector cytokines 
within the lung and medLN. 
• 2D2 iTreg induced Foxp3 expression in Th2 2D2 effector ells in AAI.  
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• 2D2 iTreg mediated bystander suppression of BAL eosinophilia and Th2-
associated cytokines in the presence of their cognate antigen in a model of Th2 
OT-II-driven AAI. 
• Foxp3 expression instability in iTreg is associated with inflammation rather than 
antigen-driven re-stimulation of iTreg in vivo. Moreover, the presence of iTreg 
cognate antigen is associated with better maintenance of Foxp3 expression and/or 
survival of iTreg in vivo.   
 
In a summary, Th1-like iTreg effectively suppressed in uction of Th1/Th17-
mediated inflammation in EAE and the development of AAI driven by pre-activated 
Th2 cells in an antigen-dependent manner. In terms of nTreg specialization, more 
experimental evidence in needed to establish the importance of Treg phenotype for 
their effective suppressive function.  
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6 General discussion 
 
Foxp3+ regulatory T cells have been shown to be crucial in preventing inflammation 
in autoimmunity and allergic diseases (McGeachy et al., 2005, Kearley et al., 2005, 
Kim et al., 2007). Previous reports have suggested that Treg may specialize in 
different types of inflammation by using Th-associated transcriptional machinery to 
effectively control the corresponding types of Th cells (Koch et al., 2009, Zheng et 
al., 2009). This thesis tested the hypothesis that Treg acquire different phenotypes in 
Th1- versus Th2-mediated inflammatory diseases in-line with their effector CD4+ T 
cell (Teff) counterparts and can therefore optimally specialize to control such Teff 
responses.  
 
The results can be summarised as follows: 
• Treg acquire a Th1-like phenotype (T-bet+ GATA-3low CXCR3high) specifically 
within the inflamed CNS in Th1/Th17-mediated EAE and a Th2-like phenotype 
(T-bet- GATA3+) within the inflamed lung in Th2-mediated AAI. 
• IL-12 and IL-18, or IL-4 are sufficient to polarise nTreg in vitro towards a Th1- 
or Th2-like phenotype, respectively.  
• CNS-derived Treg from a model of EAE appear to be incapable of suppressing 
lung inflammation in Th2-driven AAI (this needs verification). 
• In vitro generated iTreg have a default Th1-like phenotype (T-bet+ CXCR3high) 
which cannot be modified in vitro during induction/re-stimulation of iTreg 
without compromising Foxp3 expression.  
• Th1-like iTreg effectively suppress inflammation in a model of Th1/Th17-
mediated EAE and in a model of Th2-mediated AAI in an antigen-dependent 
manner. 
• iTreg cognate antigen is critical to their survival/migration to the site of 
inflammation.  
• 2D2 iTreg suppress EAE induction but are unable to control on-going 
inflammation despite their accumulation within the CNS.  
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• 2D2 iTreg inhibit rMOG-induced AAI driven by an adoptive transfer of pre-
activated Th2 2D2 cells.  
• iTreg partially lose Foxp3 expression in the inflamed tissue irrespective of 
antigen presence. However, they retain Foxp3 expression in secondary lymphoid 
organs. 
• Antigen-reactive but not polyclonal iTreg reduce numbers of Teff and pro-
inflammatory cytokines within target organs in EAE and AAI. 
• iTreg promote Foxp3 induction and/or migration of Fxp3+ cells in EAE 
specifically within/into dLN and induce Foxp3 expression in transferred Th2 2D2 
cells in AAI within secondary lymph organs in an antigen-dependent manner. 
• iTreg suppress eosinophilia and production of Th2-associated cytokines in AAI 
in a bystander fashion. However, they do not limit lung infiltration or goblet cell 
hyperplasia. 
 
These results demonstrate substantial differences in the phenotype of nTreg and in 
vitro generated iTreg which may reflect how these cells adapt to the inflammatory 
environment to effectively regulate it. Moreover, they highlight the importance of 
antigen-reactivity in effective iTreg-mediated suppression.  
 
6.1. The importance of Treg phenotype and antigen 
reactivity in the control of inflammation 
Treg have been suggested to be able to specialize in different types of inflammation 
to better control the corresponding type of CD4+ cells driving the inflammatory 
response (Koch et al., 2009, Zheng et al., 2009). However, how this specialization 
affects Treg suppression in different inflammatory settings has not been addressed. A 
new model of rMOG-induced AAI established in this project enabled testing the 
importance of Treg phenotype in the suppression of Th1/Th17- versus Th2-mediated 
inflammatory diseases. Treg derived from the inflamed CNS tissue in EAE expressed 
T-bet and low levels of GATA-3, whereas Treg from the inflamed lung in AAI 
lacked T-bet expression and had an upregulated GATA-3 expression. Moreover, they 
also differentially expressed the Th1-associated chemokine receptor CXCR3 with 
CNS-derived Treg expressing it at higher level compared to the lung-derived Treg. 
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As the inflammatory response in both disease models wa  driven by the same 
antigen, and it has been showed that antigen-reactiv  Treg accumulate within 
inflamed tissue (O'Connor et al., 2007), the transfer of CNS-derived Treg prior to 
induction of AAI would allow for assessment of the functional consequences of their 
polarised phenotype. CNS-derived Treg did not suppress Th2-driven inflammation in 
AAI. However, the result from this technically complicated experiment could not be 
verified using alternative method.  
 
Nevertheless, the possibility that Treg may need to specialize for their most optimal 
control of inflammation and may not be easily adaptable towards suppression of 
different forms of inflammation in vivo can have potentially important implications 
in their use in immunotherapy. First of all, it could mean that naïve Treg currently 
used in clinical trials (Di Ianni et al., 2011, Brunstein et al., 2011) are not the most 
efficient suppressive cells and hence therapy may requi e very large numbers and 
frequent transfusions of Treg to exert their optimal immunosuppressive effects. 
Second, it can offer a possibility to instruct Treg phenotype to specifically inhibit 
certain types of immune responses by targeting highly specialized cells directly into 
the inflamed tissue. 
 
Interestingly, in vitro generated iTreg were found to have a default Th1-like 
phenotype (T-bet+ CXCR3high) and this did not prevent them from effectively 
suppressing both Th1/Th17-mediated inflammation in EAE and Th2-mediated 
inflammation in AAI. This suggests that high expression of T-bet itself cannot 
account for the failure of CNS-derived Treg to inhibit Th2-driven inflammation. It 
could also mean that nTreg and iTreg may use different intrinsic mechanisms to 
suppress effector CD4+ cell responses with iTreg being effective without the need to 
adapt to the corresponding type of Teff driving the inflammation.  
 
An important consideration in the efficacious use of iTreg is their antigen reactivity. 
Multiple studies have suggested that in autoimmune inflammation antigen-reactive 
iTreg, similarly to nTreg, have superior suppressive abilities when compared to 
polyclonal iTreg (Stephens et al., 2009, Zhang et al., 2010). In allergic inflammation 
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this has not been investigated before, but polyclonal nTreg and iTreg were shown to 
improve the disease (Kearley et al., 2005, Xu et al., 2012). This study has 
demonstrated that only antigen-reactive iTreg could effectively suppress tissue 
inflammation in EAE and AAI. iTreg cognate antigen was found to be critical for 
iTreg survival in vivo and their migration to the inflamed tissue. Interestingly, 
antigen-reactive iTreg in the presence of their cognate antigen suppressed 
eosinophilia and production of Th2-associated cytokines in AAI driven by Th2 cells 
responsive to a different antigen. Treg-mediated bystander suppression was 
previously suggested to be mediated by local IL-10 and TGF-β production (Groux et 
al., 1997, Roncarolo et al., 2006, Andersson et al., 2008). In this study the observed 
bystander suppression could be attributed to TGF-β expression as no iTreg-derived 
IL-10 was detected by ELISA and a cytokine bead array analysis (Richard 
O’Connor, personal communication, unpublished data). Nevertheless, the lung 
infiltration scores and goblet cell hyperplasia were unaffected despite the presence of 
iTreg cognate antigen, suggesting that effective iTr g-mediated suppression i  vivo 
may be contact-dependent and this would require iTrg and CD4+ T effector cells to 
be of the same antigen-reactivity. This may have substantial implications in the 
choice of Treg used for cellular immunotherapy as discussed in the next section.   
 
6.2. Therapeutic application of iTreg in MS and ast hma 
The question whether suppressive function of Treg can be harnessed for the use in 
immunotherapy has been addressed by several clinical trials investigating therapeutic 
potential of naïve or in vitro expanded nTreg in graft versus host disease (Di Ianni et 
al., 2011, Brunstein et al., 2011). However, in chronic inflammatory diseases such as 
MS and asthma there is evidence that the patient’s Treg are defective not only in 
numbers but also in function (Viglietta et al., 2004, Haas et al., 2005, Hartl et al., 
2007). Therefore, expansion of these impaired cells in vitro and transfusion into 
patients, or expansion in vivo using low antigen doses as shown in animal models 
(Apostolou and von Boehmer, 2004, Kretschmer et al., 2005) might prove ineffective 
in combating inflammation.  
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In vitro generated iTreg provide an easy means of generating robust numbers of cells 
from patients naïve CD4+ cells and protocols for efficient induction of human iTreg 
have been described (Lu et al., 2010). However, instability of Foxp3 expression in 
iTreg and potential conversion into pathogenic cells question the effective use of 
iTreg in therapy. Nevertheless, multiple studies have indicated that iTreg effectively 
suppress inflammation in a wide variety of animal models of disease including MS 
and asthma (Zhang et al., 2010, Xu et al., 2012). Moreover, iTreg re-stimulated 
under pro-inflammatory conditions were found to lack pathogenic potential and were 
still able to suppress CNS inflammation in EAE (O'Connor et al., 2010).   
 
The data presented here and previously shown by other s udies indicate that antigen-
reactive iTreg are much more effective at suppressing inflammation compared to 
polyclonal iTreg and can be used at low numbers (Stephens et al., 2009, Zhang et al., 
2010). This seems to be related to better iTreg survival in the presence of their 
cognate antigen, efficient migration to the site of inflammation and possible cell 
contact-dependent interactions between iTreg and Teff. Although in MS, CD4+ cells 
reactive to MBP and PLP have been identified in the peripheral blood and CSF of 
patients (Illes et al., 1999, Burns et al., 1999, Bielekova et al., 2004), the antigen 
driving the disease remains elusive and more likely a number of antigens are 
involved due to epitope spreading as the disease progresses. Epitope spreading is a 
phenomenon whereby an inflammatory reaction directed at a particular antigen 
enhances antigen presentation and co-stimulatory abilities of APC and this can result 
in activation of bystander T cells recognizing different epitopes of the same or a 
distinct antigen (Vanderlugt and Miller, 2002). This was described to occur in an 
MBP-induced model of EAE (Lehmann et al., 1993, Perry t al., 1991). Although it 
is unknown how well CD4+ cells derived from peripheral blood and CSF of patients 
represent pathogenic CD4+ cells found within CNS, it is possible that identification 
of key epitopes driving the immune response in MS will allow generation of a panel 
of iTreg reactive to different myelin-derived antigens to maximise their efficiency. 
The issue of antigen-reactivity is easier to overcome in asthma and allergic disease 
where an allergen is usually well-specified providing a more straightforward 
approach in generating antigen-reactive iTreg.  
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Bystander suppression, which is implicated in Treg-mediated suppression of 
inflammation, describes a phenomenon whereby activated Treg can suppress T cells 
reactive to different antigens (Groux et al., 1997, Roncarolo et al., 2006, Andersson 
et al., 2008). This offers a promising tool in therapy when a disease-driving antigen 
is unknown or multiple antigens could be implicated such as in MS and in patients 
allergic to multiple antigens. However, the results from this project indicate that 
iTreg cognate antigen is critical to their survival nd migration to the site of 
inflammation. Moreover, even in the presence of their cognate antigen, iTreg in AAI 
were able to suppress some Teff responses, but did not improve lung infiltration and 
goblet cell hyperplasia. This indicates that, to be eff ctively used in therapy, iTreg 
have to be antigen reactive and in diseases mediated by several antigens a panel of 
antigen-reactive iTreg has a better chance to suppress inflammation rather than 
relying on the effect of bystander suppression.  
 
Another important issue raised by other studies is that Treg may not function 
optimally in an inflamed environment (Korn et al., 2007). However, it has been 
shown that Treg drive resolution in models of inflammation such as EAE and AAI 
(O'Connor et al., 2007, Leech et al., 2007). Sub-optimal function in inflammatory 
environment, however, may apply to iTreg as they failed to suppress on-going CNS 
inflammation in EAE. Previous studies have shown that although nTreg can suppress 
Th1 responses, they are unable to control Th17 responses (O'Connor et al., 2007). In 
addition to this, here it was observed that 2D2 iTreg effectively suppressed Th1 
responses in vitro and Th2 responses both in vitro and in vivo, but they seemed to be 
unable to regulate highly polarised GM-CSF+ cells. As GM-CSF was found to be 
essential in driving EAE (Codarri et al., 2011), this might explain the lack of control 
during on-going inflammation when high levels of GM-CSF were detected. These 
observations suggest that effective cellular therapy involving Treg might have to be 
combined with additional pharmacological treatment that will reduce on-going 
inflammation. An example of such treatment could be rapamycin which was shown 
to inhibit T cells responses to IL-2 simultaneously promoting survival of Treg 
(Battaglia et al., 2006) and is currently used in organ transplantation.   
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What also needs to be addressed when considering iTre as an immunotherapy is the 
persistence of iTreg in vivo and longevity of their suppressive effects. In a model of 
AAI used in this project, the lung inflammation was short and self-resolving hence 
iTreg did not need to persist for long and one dose of iTreg was sufficient. 2D2 iTreg 
were detectable 10 days after the transfer in AAI and pproximately 2 weeks after 
EAE induction. It is unknown how long they would persist in the absence of 
inflammation and whether they would be able to prevent re-induction of disease in 
both models. As both MS and asthma are chronic diseases it seems likely that 
multiple and/or regular treatment would be required.   
 
6.3. Future work 
The primary issue that has to be addressed in the future work is the verification 
whether Th1-like Treg adapted to Th1/Th17-mediated inflammation are truly unable 
to effectively control Th2-mediated inflammation as indicated in this study. As the 
alternative approach of using Th1-mediated AAI failed to provide a source of Th1-
like Treg, CNS-derived Treg could be perhaps further expanded in vitro to increase 
their numbers for the transfer into AAI model. As alre dy mentioned, it is possible 
that the frequency of MOG-reactive nTreg within transferred total CNS-derived Treg 
was insufficient to suppress 5x106 of pre-activated 2D2 Th2 effector cells. However, 
in this case it may be simply unfeasible to sufficiently increase the numbers of Th1-
like nTreg from the CNS to inhibit inflammation driven by pre-activated Th2 cells. 
Different models of inflammation that would provide larger numbers of antigen-
reactive Th1-like Treg may have to be considered.    
 
Moreover, in addition to CXCR3, changes in other Th1-associated chemokine 
receptors such as CCR5 and Th2-associated CCR4 and CCR8 should be tested in 
nTreg derived from EAE and AAI. It would be of interest to know whether changes 
in tissue-derived Treg phenotype in EAE and AAI are reflected in epigenetic 
modifications in the genes that encode upregulated/downregulated transcription 
factors and chemokine receptors. As epigenetic modifications were shown to be 
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associated with the stability of gene expression, this would provide additional 
information on the stability/adaptability of Treg phenotype.  
 
Antigen-reactive iTreg suppressed induction of EAE. However, they were unable to 
control on-going CNS inflammation. As the regulation f on-going disease and not 
disease induction is relevant to immunotherapy, it would of great value to know 
whether iTreg failure to control on-going EAE is associated with their inability to 
control any form of established inflammation, or an inability to control effector 
functions of activated T cells (such as GM-CSF production as suggested by in vitro 
studies). This could be determined by an assessment of iTreg protective effect in a 
passive model of EAE induced by a transfer of lymphocytes polarised under Th1, 
Th17 or GM-CSF conditions. Since antigen-reactive iTreg effectively suppressed 
AAI driven by pre-activated Th2 cells it would be interesting to know whether they 
can regulate an already established Th2-driven inflammation. This would require a 
chronic model of AAI.   
 
It is also important to determine how long iTreg persist in the target organ and 
secondary lymphoid organs in EAE and AAI and whether y are able to prevent 
disease re-induction. The exact mechanism of how 2D2 iTreg are able to restrict Teff 
access into the CNS in EAE, and how they suppress Teff numbers and effector 
function in the lung/medLN in AAI should be deciphered, for example, by looking at 
the expression of chemokines and migratory molecules on Teff/iTreg. 
 
 
6.4. Closing statement 
In a summary, this thesis provides data that indicate substantial phenotypic 
differences between nTreg and in vitro generated iTreg, which may reflect how they 
are able to control pathogenic CD4+ T cells and the resulting inflammatory reaction. 
Moreover, antigen-reactivity of iTreg was demonstrated to be critical for their 
effective suppression of autoimmune and allergic inflammation which may have 
important implications in their use in immunotherapy.   
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Appendix 1 Kineticsof rMOG-induced Th2 2D2-dr iven mediated AAI .
Traceable Th2-polarised CD4+ 2D2 cells were transferred into C57BL/6 mice followed
by three intratracheal challenges with rMOG. (A) Experimental scheme. (B) Total cell
numbers in BAL. (C) Percentages of cells in BAL. (D) Total numbers of eosinophils, (E)
macrophages and (F) lymphocytes in BAL. Data are from one experiment. Data are
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Appendix 2 The highest percentage and total numbers of Foxp3+ CD4+ cells is
found on day 9.
Experimental approach is shown in Appendix 1. (A) Total cell numbers. (B) Percentages
of CD4+ cells of all cells in the lung. (C) Percentages of Th2 2D2 cells of all CD4+ cells
and total cell numbers of Th2 2D2 cells in the lung. (D) Percentages of total CD4+
Foxp3+ cells of all CD4+ cells and total cell numbers of Foxp3+ CD4+ cells in the lung.
Data are from oneexperiment. *p<0.05 as determined by a one-way variance (ANOVA)
usingTukey’smultiplecomparisontest.
*
*
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* *
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